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Summary 
 
Most eukaryotic proteins form complexes, but how these complexes are assembled in the cell often 
remains unknown. A prominent eukaryotic protein complex is RNA polymerase II (Pol II), a 12-subunit, 
520-kDa enzyme that carries out transcription of protein-coding genes. The structure and function of 
Pol II has been studied extensively, but little is known about its biogenesis. Assembly of Pol II apparently 
occurs in the cytoplasm prior to its nuclear import. Pol II biogenesis requires all three members of the 
recently discovered GPN-loop GTPases, but the function of these enzymes is unknown. The family is 
characterized by two protein insertions and a highly conserved motif consisting of the amino acids Gly-
Pro-Asn (single letter code: GPN) that is suggested to function in GTP hydrolysis. Depletion or mutation 
in the nucleotide binding site or GPN motif of human GPN1 (also called RPAP4, XAB1, MBDin) or its 
yeast homolog Npa3 leads to cytoplasmic accumulation of Pol II, but it is unknown whether these 
enzymes are involved in nuclear import and/or assembly. Lack of structural data for any eukaryotic GPN-
loop GTPase so far prevented detailed molecular understanding of these essential enzymes. 
In this thesis we report crystal structures of the GPN-loop GTPase Npa3 from the yeast 
S. cerevisiae. The enzyme was trapped in a GDP-bound, closed conformation, that shows eukaryote-
specific features in both insertion regions at 2.3 Å resolution. Further we show a GTP analog-bound 
structure at 2.2 Å resolution that reveals a novel, open conformation displaying a conserved 
hydrophobic pocket distant from the active site. We show that both insertion regions rearrange upon 
transition from the closed to the open state and provide atomic details of how Npa3 binds the 
nucleotides. Using site-directed mutagenesis, enzymatic activity assays and molecular modelling we 
elucidate the molecular mechanism of Npa3 hydrolysis from GTP to GDP that involves the GPN motif.  
We further show that Npa3 has chaperone activity and interacts with hydrophobic regions of 
Pol II subunits that form interfaces in the assembled Pol II complex. Consistent with a function as Pol II 
assembly chaperone, we show that Npa3 does not interact with mature, assembled Pol II. Biochemical 
results are in agreement with a model that the hydrophobic pocket binds peptides, and that this can 
allosterically stimulate GTPase activity and subsequent peptide release.  
Thus, our results indicate that GPN-loop GTPases form a new family of assembly chaperones for 
Pol II and maybe other protein complexes. 
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1. Introduction 
1.1. Transcription 
1.1.1. DNA-dependent RNA-Polymerases 
Gene transcription by DNA-dependent RNA polymerases is one of the most fundamental processes in all 
living organisms. Whereas bacteria and archaea rely on a single RNA polymerase, eukaryotes have 
evolved at least three specialized RNA polymerases (Pol I, II and III) that synthesize distinct subsets of 
RNA molecules. (Cramer et al., 2008; Werner & Grohmann, 2011). Pol I is located in the nucleoli and 
produces most ribosomal RNAs (rRNA). In the nucleoplasm, Pol II transcribes messenger RNAs (mRNA) 
and other small RNAs and Pol III synthesizes transfer RNAs (tRNA), 5S rRNAs and other small RNAs. In 
plants, two additional polymerases called Pol IV and Pol V transcribe non-coding RNAs required for gene 
silencing (Matzke et al., 2009). Further, chloroplasts and mitochondria contain their own, phage-related, 
single-subunit RNA polymerases that specifically transcribe the DNA of these organelles (Cheetham & 
Steitz, 1999).  
Eukaryotic Pol I, II and III consist of 14, 12 and 17 subunits, respectively (Table 1). Five core 
subunits are shared among all eukaryotic enzymes and two between Pol I and Pol III (Vannini & Cramer, 
2012). The crystal structure of the 10 subunit Pol II core (Cramer et al., 2000) provided first structural 
insights and was later extended to a complete 12 subunit model that also shows the so-called stalk 
(Armache, et al., 2005). Structural data derived from homology modeling is also available for Pol III 
(Jasiak et al., 2006) and the crystal structure of Pol I was solved recently (Engel et al., 2013). Even 
though the multi-subunit RNA polymerases synthesize distinct RNAs, they show great structural 
conservation (Vannini & Cramer, 2012). The two largest subunits that form the active center cleft are 
related to those of the bacterial polymerase and two subunits of the eukaryotic enzymes contain the 
bacterial α motif, respectively (Werner & Grohmann, 2011). Consistent with the structural conservation, 
eukaryotic Pol I, II and III share common features including a conserved mechanism of transcription 
initiation that requires interaction with transcription factors. 
Although the structure and function of eukaryotic RNA polymerases has been studied 
extensively during the last decades (Cramer, et al., 2008), only little is known about biogenesis of these 
essential molecular machines (Wild & Cramer, 2012). 
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Table 1| Subunit composition of RNA polymerases. 
Adapted from (Werner & Grohmann, 2011; Vannini & Cramer, 2012) 
1.1.2. Transcription cycle and regulation of RNA polymerase II 
The transcription cycle of Pol II comprises five steps: pre-initiation, initiation, elongation, termination 
and recycling (Svejstrup, 2004). During pre-initiation Pol II and general transcription factors (GTFs; Table 
2) are recruited to the promoter to form the pre-initiation complex (PIC), DNA is melted and the 
template strand is inserted into the polymerase active site (Sainsbury et al., 2015). Initiation starts with 
the incorporation of the first RNA nucleotides till the nascent chain reaches a length of 12-13 
nucleotides leading to an exchange of initiation to elongation factors and transition to the productive 
elongation phase. When Pol II reaches the 3’ end of the gene termination occurs with the help of 
termination factors, the newly synthesized RNA and Pol II are released and the enzyme can be recycled 
for another round of transcription (Svejstrup, 2004). 
Transcription regulation is coordinated by the Carboxy-terminal domain (CTD) of Rpb1 which is 
composed of heptapeptide repeats comprising the amino acids Y1S2P3T4S5P6S7. Hereby, specific and 
reversible posttranslational modifications of the hydroxy-groups and proline isomerizations provide a 
unique ‘CTD-code’ that forms a binding platform for transcription factors only at specific stages of the 
cycle to modulate transcription (Kim et al., 2010; Mayer et al., 2010; Kubicek et al., 2012; D. W. Zhang et 
al., 2012; M. Zhang et al., 2012; Eick & Geyer, 2013; Jasnovidova & Stefl, 2013). Additional regulation is 
obtained by particular secondary structures of nucleic acids (Allen et al., 2004; Lehmann et al., 2007; 
Aguilera & Garcia-Muse, 2012) and binding of accessory proteins to the DNA, nascent RNA and the Pol II 
core (Svejstrup, 2004). 
  Pol I Pol II Pol III Bacteria 
Polymerase core     
- large subunits A190 Rpb1 C160 β’ 
 A135 Rpb2 C128 β 
- partially shared/α-motif containing AC40 Rpb3 AC40 α 
 AC19 Rpb11 AC19 α 
- specific A12.2 Rpb9 C11 - 
- shared Rpb5 Rpb5 Rpb5 - 
 Rpb6 Rpb6 Rpb6 ω 
 Rpb8 Rpb8 Rpb8 - 
 Rpb10 Rpb10 Rpb10 - 
 Rpb12 Rpb12 Rpb12 - 
Polymerase stalk  A14 Rpb4 C17 - 
 A43 Rpb7 C25 - 
TFIIF-like  A49 Tfg1 C37 - 
 A34.5 Tfg2 C53 - 
Pol III specific  - - C82 - 
 - - C34 - 
 - - C31 - 
Number of subunits 14 12 17 5 
M [kDa] 589 514 693 ~400 
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1.1.3. General transcription factors in yeast 
Pol II transcription initiation requires the general transcription factors TFIIA, -B, -D, -E, -F and -H 
(Sainsbury, et al., 2015) (Table 2). In the canonical model, initiation starts with binding of the TFIID 
subunit TATA-binding protein (TBP) to promoter DNA were it induces an up to 90° kink of the DNA (J. L. 
Kim et al., 1993; Y. Kim et al., 1993). Then TFIIA and TFIIB bind the binary complex and TFIIB bridges 
between the TBP-DNA complex and Pol II (Bushnell et al., 2004; Kostrewa et al., 2009; X. Liu et al., 2010; 
Sainsbury et al., 2013), which is recruited to the promoter in complex with TFIIF to form the core PIC. 
The PIC is completed upon binding of TFIIE and TFIIH leading to an ATP-dependent DNA opening, the 
formation of a transcription bubble and initial RNA synthesis (Sainsbury, et al., 2015). Once RNA reaches 
12-13 nucleotides it clashes with TFIIB, triggering TFIIB displacement and formation of the elongation 
complex (Sainsbury, et al., 2013). 
 
Table 2| General transcription factors in yeast. 
Adapted from (Sainsbury, et al., 2015) 
Factor Subunits Functions 
TFIIA 2 Stabilizes TFIID-DNA complex, counteracts repressive effects of negative co-factors; 
stimulates constitutive and activated transcription.  
TFIIB 1 Required for Pol II recruitment to the promoter, stabilizes TFIID-DNA complex, assists in 
transcription start site (TSS) selection and stimulates initial RNA synthesis; may aids in 
DNA-RNA strand separation and is critical for initiation-to-elongation transition. 
TFIID 14-15 Nucleates Pol II recruitment and PIC assembly via binding of TBP to TATA-box promoters 
or TBP associated factors (TAFs) to TATA-less promoters. Further involved in chromatin 
remodeling and activator binding. 
TFIIE 2 Facilitates recruitment of TFIIH to promoters and stimulates ATPase and kinase activities 
of TFIIH. Functions in promoter opening and stabilization of open DNA by binding to 
ssDNA. 
TFIIF 2-3 Tightly associates with Pol II and stabilizes the PIC. Stimulates early RNA synthesis and aids 
in TSS selection.  
TFIIH 10 Consists of a core that functions in promoter opening as an ATP-dependent translocase 
and DNA repair, and a kinase module that phosphorylates the CTD to facilitate 
initiation-to-elongation transition.  
1.2. Life cycle of RNA polymerase II 
Although the structure and function of Pol II has been studied extensively over the last decades 
(Cramer, et al., 2008), only little is known about the life cycle of Pol II that comprises assembly, nuclear 
import and degradation or recycling of the subunits. During the last years a rising number of studies 
investigated these processes, leading to the identification of required proteins and novel insights into 
these essential cellular mechanisms. Here, a detailed summary about the current knowledge of the RNA 
polymerase II life cycle is provided. 
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1.2.1. Assembly 
Biogenesis of Pol II apparently starts in the cytoplasm with the synthesis of its 12 subunits Rpb1-Rpb12, 
but how they assemble remains poorly understood.  
Initial insights into subunit assembly derived from the bacterial RNA polymerase (Ishihama & 
Ito, 1972) because the eukaryotic Pol II core subunits Rpb1, Rpb2, Rpb3/11 and Rpb6 are homologous to 
the bacterial subunits β’, β, α and ω, respectively (Zhang et al., 1999; Cramer et al., 2001; Vassylyev et 
al., 2002). Urea-induced complete dissociation of bacterial polymerase subunits followed by stepwise in 
vitro reconstitution of the enzyme and analysis of the assembly intermediates led to the first model of 
bacterial RNA polymerase assembly (Ishihama & Ito, 1972). The postulated pathway starts with the 
association of two α-subunits to a αα-dimer which is then bound by the β-subunit to form a α2β 
assembly intermediate (Figure 1C). The functional polymerase arises from binding of subunit β’. The 
remaining ω subunit is not essential but is thought to be involved in folding and stabilization of β’, 
possibly joins the α2β intermediate in complex with subunit β’ and promotes assembly of both 
subcomplexes. (Ghosh et al., 2001; Minakhin et al., 2001). Recent NMR data indicates, that β’ω 
association is restricted to an early stage where the subunits are not completely folded yet (Drogemuller 
et al., 2015). The postulated in vitro assembly pathway was confirmed in vivo (Ishihama, 1981).  
Assuming a similar pathway for eukaryotic Pol II, the two subunits Rpb3 and Rpb11, that both 
contain the bacterial α motif (Werner & Grohmann, 2011), would form a complex that subsequently 
binds to Rpb2. Indeed, dissociation experiments with yeast Pol II revealed a Rpb2/3/11 subcomplex 
Figure 1| RNA polymerase subunit composition and assemblies. 
(A) Crystal structure of Pol II (pdb-code: 1WCM)(Armache, et al., 2005). Potential subassemblies are indicated. Eight zinc ions 
and the magnesium ion are shown as cyan and pink spheres, respectively. (B) Scheme of eukaryotic RNA polymerase subunit 
composition. Shared or homologous subunits are depicted in the same color. (C) Assembly of bacterial RNA polymerase. 
Subunit are colored according to their eukaryotic homologs as in (B). (D) Putative pathway for assembly of the Pol II core. 
Subunits shown in light grey (with broken outlines) have no homologs in bacterial RNA polymerases. Adapted from (Wild & 
Cramer, 2012). 
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 that was stable at 6M urea (Kimura et al., 1997). Additionally, Rpb10 was more weakly bound to this 
complex to form a Rpb2/3/11/10 subassembly at 4M urea. This is consistent with genetic studies, 
suggesting that Rpb10 association with the Rpb3 and Rpb11 homologs of Pol I and III (AC40 and AC19) 
has an important role in assembly and also indicates a conserved assembly pathway of the three 
polymerases (Lalo et al., 1993).  For in vivo assembly, the abundance of the individual subunits may also 
play an important role. Quantitative western blot analysis of all Pol II subunits in S. pombe revealed that 
Rpb3 is least abundant, thus limiting for complex formation, followed by Rpb1, Rpb2 and Rpb7 (2 fold 
more abundant) whereas the other subunits were 4-15 fold more abundant (Kimura et al., 2001). 
Further the smaller subunits Rpb4-Rpb12 also existed, at least temporarily, in unassembled form. A 
critical function has been proposed for the common subunit Rpb12 (Rubbi et al., 1999). The structure of 
the assembled Pol II core shows that Rpb12 interacts with both, Rpb3 and Rpb2, thus supporting a 
fundamental role of Rpb12 in biogenesis of all three polymerases as it bridges between the conserved 
second largest and α motif containing subunits (Rubbi, et al., 1999; Cramer, et al., 2000). It is thought 
that Rpb12 first binds to the Rpb3/11/10 subassembly to form a Rpb3/11/10/12 subcomplex that is 
then bound by a Rpb2/9 subcomplex (Wild & Cramer, 2012). In the last step of bacterial polymerase 
assembly the Rpb1 homolog β’ binds the corresponding assembly intermediate and the Rpb6 homolog 
ω was implicated in assembly and stability of the largest subunit (Minakhin, et al., 2001; Drogemuller, et 
al., 2015). In yeast, temperature-sensitive Rpb1 mutant cells, characterized by transcriptional shutdown, 
can be rescued by overexpression of Rpb6 (Nonet et al., 1987) underpinning the important role of this 
subunit in Rpb1 stability. In line with this, mutation of the Rpb6-interacting foot domain of Rpb1 leads to 
Pol II instability and assembly defects which can also be rescued by overexpression of Rpb6 (Garrido-
Godino et al., 2013). Additionally, substoichometric levels of Rpb8 were bound to Rpb1 in dissociation 
experiments using 4 M urea (Kimura, et al., 1997). Thus, Rpb1 likely binds the other two subassemblies 
as Rpb1/5/6/8 complex to build the 10 subunit Pol II core (Wild & Cramer, 2012). The whole assembly 
pathway is further supported by pulse labeling experiments with temperature sensitive subunits Rpb1, 
Rpb2 and Rpb3 that showed an Rpb2/3 subcomplex that forms early after subunit synthesis and 
subsequently interacts with Rpb1 (Kolodziej & Young, 1991). The additional, peripheral subunits, such as 
the stalk, are likely added to the core afterwards as preassembled complexes (Wild & Cramer, 2012). 
Consistent with this, dissociation from the core has been reported for Rpb4/7 (Pol II) in solution 
(Edwards et al., 1991), and C25/C17 (Pol III) during native mass spectrometry (Lorenzen et al., 2007). 
Further the TFIIF-like subcomplex of Pol I (A49/A34.5) can be dissociated with urea (Huet et al., 1975) 
and native mass spectrometry also revealed dissociation of its Pol III counterpart (C37/C53) as well as 
the Pol III-specific subunits C82/C34 (Lorenzen, et al., 2007). 
Taken together, the current model suggests the formation of an initial subcomplex, comprising 
subunits Rpb3/11/10/12 that subsequently binds to an Rpb2/9 subassembly (Wild & Cramer, 2012). This 
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large assembly intermediate is then bound by a third, Rpb1/5/6/8 subcomplex. Finally, the stalk 
comprising subunits Rpb4 and Rpb7 joins the Pol II core to form the complete functional 12 subunit 
Pol II complex (Armache, et al., 2005) (Figure 1). 
RNA polymerase II assembly factors 
In contrast to bacterial RNA polymerase, the eukaryotic enzymes could so far never be reconstituted 
from individual subunits in vitro, indicating that their assembly in vivo depends on the help of several 
factors. Systemic affinity purification screens identified a number of factors that interact with eukaryotic 
RNA polymerases, both in yeast (Gavin et al., 2002; Krogan et al., 2006) and in human (Jeronimo et al., 
2007). However, their cellular function often remains enigmatic and involvement in a wide range of 
processes like polymerase assembly, cellular transport, transcription, disassembly or degradation is 
possible. To more specifically screen for putative Pol II assembly factors (Table 3), two recent studies 
purified human Pol II from conditions that enrich for partially assembled enzymes (Boulon et al., 2010; 
Forget et al., 2010). Mass spectrometry analysis identified proteins bound to Pol II complexes, including 
components of the R2TP-prefoldin-like chaperone complex, the large CCT chaperonin complex and all 
three members of a recently discovered subfamily of GPN-loop GTPases, called GPN1, GPN2 and GPN3 
in human (Forget, et al., 2010). In the second study cells were treated with α-amanitin, a transcription 
inhibitor that leads to degradation of Rpb1 (Nguyen et al., 1996) and Rpb3 accumulation in the 
cytoplasm, thus allowing affinity purification of Rpb3-bound Pol II subcomplexes (Boulon, et al., 2010). 
Here, a Pol II subcomplex comprising subunits Rpb2/3/11/10/12 was identified, consistent with previous 
data (Kimura, et al., 1997; Cramer, et al., 2000). This subcomplex was bound by the GPN-loop GTPases 
GPN1, GPN2 and GPN3 as well as RPAP1, RPAP2 and Grinl1a (Boulon, et al., 2010) (Figure 2) that were 
known to bind Pol II (Jeronimo et al., 2004; Jeronimo, et al., 2007). Double treatment of cells with both, 
α-amanitin and leptomycin B, a specific nuclear export inhibitor of Xpo1 (also Crm1) (Fornerod et al., 
1997), led to cytoplasmic accumulation of Rpb1 (Boulon, et al., 2010). This allowed purification of an 
Rpb1/8 subcomplex and identification of associated components of the R2TP/Prefoldin-like complex. 
The yeast R2TP/Prefoldin-like complex functions as Hsp90 co-chaperone (Zhao et al., 2005) and its 
human homologous complex (Te et al., 2007; Boulon et al., 2008) contains the shared polymerase 
subunit Rpb5 (Sardiu et al., 2008). The R2TP component hSpagh (also RPAP3) binds Hsp90 and likely 
recruits it to unassembled Rpb1 to maintain free Rpb1 stability and association with other Pol II subunits 
(Boulon, et al., 2010). Hereby, the CTD heptapeptide repeat of cytoplasmic Rpb1 is mainly 
unphosphorylated. Further another component of the R2TP/Prefoldin-like complex, the yeast prefoldin 
Bud27, was implicated in biogenesis of all three RNA polymerases (Miron-Garcia et al., 2013). Bud27 
shows genetic interaction with Rpb5 and Rpb6, affects correct assembly of both subunits to Pol I, II 
and III and leads to growth defects and cytoplasmic accumulation of all three RNA polymerases upon 
deletion. Additionally, the karyopherin-like protein Rtp1 has been shown to interact with the R2TP 
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complex, Pol II subunits and nucleoporins but not with the yeast GPN1 homolog Npa3, and a function in 
assembly by binding to the N-terminal region of Rpb2 has been suggested (Gomez-Navarro et al., 2013). 
Further, deletion of Rtp1 leads to cytoplasmic accumulation of Pol II subunits but not Pol I and Pol III 
subunits. 
Taken together, in vivo assembly of Pol II requires the help of several factors but their molecular 
function is not very well understood. Lack of structural data for many biogenesis factors, especially the 
essential GPN-loop GTPases, so far prevented detailed understanding of their function in Pol II 
biogenesis. 
 
Figure 2| Model of Pol II biogenesis.  
The model combines results from yeast and human. (i) Subunits derived from protein synthesis and nucleocytoplasmic 
recycling assemble with the help of assembly factors (black) that may stabilize assembly intermediates. (ii) Formation of two 
major subassemblies comprising subunit Rpb1 and Rpb2, respectively plus additional subunits (in color if determined 
experimentally or in grey if presumed to be present) and assembly factors (black, human names). Assembly factors shown in 
grey may leave assembling Pol II. (iii) Fully assembled Pol II is bound by the nuclear import adaptor Iwr1 which recruits 
importin α/β via its NLS for nuclear import. Some assembly factors may stay bound to Pol II. (iv) Biogenesis factors are released 
and general transcription factors bind Pol II for transcription initiation. (v) Nucleocytoplasmic recycling of assembly factors in a 
Crm1/Xpo1-dependant manner. (vi) Degradation or nucleocytoplasmic recycling of subunits derived from disassembly of 
stalled Pol II. Adapted from (Wild & Cramer, 2012). 
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1.2.2. Nuclear Import 
Nuclear import of RNA polymerase II is most likely restricted to fully assembled enzymes, because 
depletion of any Pol II subunit leads to cytoplasmic accumulation of Pol II (Boulon, et al., 2010). Since 
none of the 12 Pol II subunits contain a nuclear localization sequence (NLS), additional proteins are 
required to mediate its nuclear translocation. Here, a critical role is attributed to Iwr1 which contains a 
N-terminal bipartite NLS (Czeko et al., 2011). Deletion of yeast Iwr1 or mutation of its NLS leads to 
cytoplasmic accumulation of Pol II subunits (Czeko, et al., 2011). This effect is specific for Pol II because 
Pol I and Pol III subunits are unaffected. Iwr1 functions as adaptor protein that binds Pol II and recruits 
importin-α/importin-β (Kap60/95) via its NLS. Electron microscopy revealed that Iwr1 binds Pol II 
between its two largest subunits, thus restricting Pol II import to fully assembled enzymes. Further 
nucleocytoplasmic recycling of Iwr1 is required because deletion of its nuclear export sequence (NES) 
(Peiro-Chova & Estruch, 2009) leads to Pol II import defects in yeast (Czeko, et al., 2011). This is in 
agreement with observations that treatment with leptomycin B, a specific nuclear export inhibitor of 
Xpo1 (also Crm1) (Fornerod, et al., 1997), leads to cytoplasmic accumulation of Rpb1, indicating nuclear 
trapping of the Pol II import factor (Boulon, et al., 2010). The import mechanism of Iwr1 is conserved 
between yeast and human because human Iwr1 partially rescues Pol II import defects caused by 
deletion of its yeast counterpart (Czeko, et al., 2011). However, an alternative import pathway may exist 
since Iwr1 is not essential.  
Table 3| Putative assembly and import factors of RNA polymerase II.  
Adapted from (Wild & Cramer, 2012; Forget et al., 2013; Gomez-Navarro, et al., 2013; Minaker et al., 2013; Miron-Garcia, 
et al., 2013; Guglielmi et al., 2015) 
Factor 
(human/yeast) 
Functional data 
GPN1/Npa3 Interaction with assembling Pol II and subunits Rpb1, Rpb4 and Rpb7. Depletion or mutation 
leads to cytoplasmic accumulation of Pol II subunits. Accumulates in the cytoplasm with Rpb1 
in disease characterized by protein aggregates where it shows increased expression levels. 
GPN2/YOR262W Interaction with assembling Pol II. Mutation leads to cytoplasmic accumulation of Pol II 
subunits 
GPN3/YLR243W Depletion or mutation leads to cytoplasmic accumulation of Pol II subunits 
GrinL1a/- Interaction with assembling Pol II 
RPAP1/RBA50 Interaction with assembling Pol II 
RPAP2/RTR1 Interaction with assembling Pol II and GPN1  
Hsp90/Hsp82 Interaction with assembling Pol II and Pol I. May stabilizes Rpb1 and assists in Pol II assembly. 
SLC7A6OS/Iwr1 Iwr1 binds Pol II between Rpb1 and Rpb2 and provides NLS for Pol II import in a Kap60/95-
dependant manner. Depletion leads to Pol II import defect. 
R2TP-Prefoldin complex Interaction with assembling Pol II. Depletion of the R2TP component hSpagh/RPAP3 leads to 
decreased levels of cytoplasmic Rpb1 in Pol II assembly defect conditions. Deletion of yeast 
Bud27 affects Pol I, II and III assembly, leads to growth defect and cytoplasmic accumulation 
of all polymerases 
Rtp1 Interaction with the R2TP complex and Pol II subunits. Affects Pol II nuclear import and may 
assist assembly of Rpb2/Rpb3 and its binding to Rpb1 
CCT complex Large chaperonin complex that interacts with GPN1 and Pol II subunits 
Microtubules Interference with microtubule integrity leads to cytoplasmic accumulation of Rpb1. Yeast 
Npa3 mutants are hypersensitive to microtubule depolymerization drug 
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1.2.3. Recycling and Degradation 
Disassembly and recycling or degradation of defective nuclear RNA polymerase is important to avoid 
nuclear aggregation and transcription defects. However, the underlying mechanisms are not very well 
characterized. Xpo1-dependent nucleocytoplasmic recycling of Rpb3 apparently takes place after 
disassembly of nuclear Pol II (Boulon, et al., 2010). Indications for this came from experiments were 
α-amanitin induced specific degradation of nuclear Rpb1 (Nguyen, et al., 1996) leads to cytoplasmic 
accumulation of Rpb3 (Boulon, et al., 2010).  This effect is rather caused by nucleocytoplasmic recycling 
than import defects of Rpb3 because additional treatment with the Xpo1 exportin inhibitor 
leptomycin B leads to nuclear accumulation of Rpb3 (Boulon, et al., 2010). The recycled subunit might 
then be incorporated into a new Pol II complex in the cytoplasm.  
Degradation of Pol II likely occurs individually for each subunit rather than en bloc because 
different half-lives were reported for each subunit, ranging from 22 min for Rpb1 to 87 min for Rpb9 
whereas the shared subunits Rpb6, Rpb8 and Rpb12 were described as stable in the given time course 
(Belle et al., 2006). Indeed, ubiquitination and proteasome-mediated degradation of Rpb1 from stalled 
Pol II has been reported both, in yeast and in human (Somesh et al., 2005; Daulny & Tansey, 2009). The 
responsible factors including ubiquitin-ligases were identified and their mechanisms were described in 
detail (Huibregtse et al., 1997; Beaudenon et al., 1999; Somesh, et al., 2005; Ribar et al., 2007; Somesh 
et al., 2007; Daulny et al., 2008; Harreman et al., 2009; Garrido-Godino, et al., 2013). Further 
ubiquitination and degradation of Rpb8 upon DNA damage has been reported (Wu et al., 2007). 
However, the fate of the other subunits is not known and requires further investigations.  
1.3. GPN-loop GTPases 
1.3.1. General principles and classification of GTPases 
GTPases (also called G proteins) are a large and functionally diverse family of guanosine triphosphate 
(GTP) hydrolyzing enzymes that carry out a wide variety of biological functions such as signal 
transduction, cellular transport, and macromolecular complex assembly (Wittinghofer & Vetter, 2011). 
All GTPases share a common 160-180 residue G-domain with an α,β topology that harbors five so called 
G-motifs (G1-G5) required for nucleotide binding and hydrolysis (Bourne et al., 1991; Wittinghofer & 
Vetter, 2011). Whereas G4 and G5 bind the guanine base to mediate nucleotide specificity, G1 (also 
called P-loop or Walker A motif) stabilizes the negative charge of the phosphate ions. The charge is 
further partially neutralized by an essential, octahedral coordinated Mg2+-ion. Motifs G2 and G3 (also 
called Walker B motif) are involved in nucleotide sensing, GTP hydrolysis and conformational switching 
and belong to the most flexible regions in the rather rigid G-domain, termed ‘switch 1’ and ‘switch 2’, 
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respectively. The G-domain is often extended by protein insertions and additions of sequence elements 
or whole domains to carry out specific biological functions (Wittinghofer & Vetter, 2011).  
The GTPase cycle is often highly regulated by additional factors such as guanine nucleotide 
exchange factors (GEFs), GTPase-activating proteins (GAPs) and guanine nucleotide dissociation 
inhibitors (GDIs) (Wittinghofer & Vetter, 2011). High nucleotide affinities (10 pM for Ras) and slow 
intrinsic dissociation rates (~10-4 s-1 for Ras) of most G proteins can be overcome by regulation through 
GEFs. GEFs reduce the affinity and increase dissociation of bound GDP from the cognate GTPase by 
orders of magnitude, thus facilitating GTP binding and effector protein interaction. The intrinsic GTP 
hydrolysis rate is usually very low (10-4-10-5 s-1) due to the thermodynamically unfavorable nucleophilic 
attack of the negatively charged γ-phosphate. Hereby GAPs stimulate the intrinsic hydrolysis of their 
cognate GTPase by orders of magnitude. Many GAPs protrude into the active site of the G protein and 
provide a catalytic residue and/or stabilize the intrinsic machinery. The most prominent example is the 
so called ‘arginine-finger’ which stabilizes the pentavalent transition state of the SN2 reaction by 
providing a positively charged guanidinium group to the negatively charged β- and γ-phosphates of GTP. 
For translational GTPases this function is apparently substituted by binding of a monovalent cation at an 
equivalent position (Kuhle & Ficner, 2014). Further, some GAPs use a ‘Gln/Asn thumb’ that resembles 
the catalytic Gln residue of many G proteins that is thought to stabilize and polarize the nucleophilic 
water relative to the γ-phosphate (Scheffzek et al., 1997; Vetter & Wittinghofer, 2001; Daumke et al., 
2004; Pan et al., 2006; Schuette et al., 2009). In contrast, prenylated G proteins can further be 
negatively regulated by GDIs that inhibit the cycle by binding to the prenyl groups of the cognate G 
protein to shuttle it between membrane compartments and inhibit its nucleotide dissociation 
(Wittinghofer & Vetter, 2011). GTPases activated by dimerization, so-called GADs do not rely on GEFs 
and GAPs and stimulate GTP hydrolysis by dimerization, most likely in concert with effector protein 
interaction, which in turn acts as GTPase coregulator (GCR). 
Based on a unique set of sequence and structural signatures the superclass of GTPases can be 
divided into two classes, designated as TRAFAC and SIMIBI (Leipe et al., 2002). The TRAFAC class (after 
translation factors) is characterized by a highly conserved threonine preceding strand β3 (G2 motif), has 
adjacent anti-parallel strands β3 and β4 and comprises the most prominent examples including 
translation factors, heterotrimeric G proteins and the Ras superfamily. The SIMIBI class (after signal 
recognition particle, MinD and BioD) is characterized by a highly conserved aspartate residue after 
strand β2 (G2 motif), which is adjacent and parallel to the G3 flanking β-strand and involves the signal 
recognition particle (SRP) and its receptor SR as well as the GPN-loop GTPases (also called XAB1 family) 
and many others.  
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1.3.2. Structural insights into an archaeal GPN-loop GTPase  
GPN-loop GTPases are characterized by a highly conserved motif consisting of the amino acids Gly-Pro-
Asn (single letter code: GPN) and two protein insertions (‘insertion 1’ and ‘insertion 2’) of approximately 
40 amino acids, respectively (Wittinghofer & Vetter, 2011). Insertion 1 harbors the GPN motif and is 
reminiscent to the insertion box of the SRP G domain (Freymann et al., 1997). Structural insights came 
from the archaeal GPN1 homolog Pab0955 from Pyrococcus abyssi that shares 27% sequence identity 
with its human counterpart (Gras, et al., 2007) (Figure 3). A set of crystal structures, both free and in 
complex with different nucleotides, provide mechanistic snapshots along the hydrolysis pathway. 
Pab0955 is homodimeric, independent of the bound nucleotide, both in the crystals and in solution 
(Gras et al., 2005; Gras, et al., 2007). The structures reveal that the GPN-loop of one monomer 
protrudes into the active site of the other monomer (Gras, et al., 2007). Hereby, the ‘trans’-GPN-loop 
binds the hydrolyzed orthophosphate in an anion whole formed by backbone amines and the Asn side 
chain. This neutralizes the negative charge of the phosphate ion and likely plays an essential role in 
catalysis. Further the Asn side chain may resemble the role of the catalytic Gln (G3 motif) residue of Ras, 
which is thought to stabilize the phosphate intermediate (Prive et al., 1992). Biochemical data show 
weak intrinsic GTPase activity (0.012 µM hydrolyzed GTP per min and mg protein), no ATPase activity 
and autophosphorylation of itself in the presence of GTP and Mg2+ (Gras, et al., 2007). Pull-down assays 
with cellular extracts and screening by surface plasmonic resonance identified the DNA-binding 
proteincomplexes Topoisomerase VI (subunit B) and the Replication Factor Complex RF-C (small subunit) 
as potential interaction partners. However, no large conformational changes of the different nucleotide 
states were observed and the cellular function remained largely unclear.  
Figure 3| Structure of the archaeal GPN-
loop GTPase Pab0955.  
(A) Overall structure of the Pab0955∙GDP 
dimer (pdb-code: 1YRA). Monomer’s A 
and B are shown in pink and light green, 
respectively. GDP is shown as sticks and 
G1, G2, G3, G4 and G5 are shown in 
yellow, orange, blue, green and cyan, 
respectively. The two insertions I1 and I2 
are depicted in fully and partially 
saturated colors, respectively. (B) Active 
site of the Pab0955∙PiGDP structure (pdb-
code: 1YR9). Hydrogen bonds are shown 
as dashed lines and G motifs colored as in 
(A). The GPN motif is shown in purple and 
GDP and Pi as sticks. Adapted from (Gras, 
et al., 2007) 
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1.3.3. Eukaryotic Npa3/GPN1 and its paralogs GPN2 and GPN3  
Eukaryotic cells contain three paralogs of GPN-loop GTPases. In human, these are called GPN1 (also 
RPAP4, XAB1, or MBDin), GPN2, and GPN3 (also Parcs). Archaea contain a single GPN-loop GTPase, and 
prokaryotes lack homologs. Homo- and heterodimerization of GPN1 and its paralogs were reported 
(Carre & Shiekhattar, 2011; Alonso et al., 2013; Minaker, et al., 2013; Mendez-Hernandez et al., 2014). 
Additionally to the characteristic two insertions in the G domain and the GPN motif, GPN1 and its yeast 
homolog Npa3 contain a C-terminal tail with unknown function and low conservation, which is 
truncated in its paralogs and lacking in archaea. GPN1/Npa3 contains a nuclear export sequence (NES) 
(Reyes-Pardo et al., 2012), consistent with the predominant cytoplasmic localization of Npa3 in yeast 
(Huh et al., 2003; Dez et al., 2004) and GPN1 in human cells (Nitta et al., 2000; Lembo et al., 2003; 
Forget, et al., 2010; Reyes-Pardo, et al., 2012). However, it may also play nuclear roles because Xpo1-
dependent nucleocytoplasmic shuttling of the enzyme was reported (Forget, et al., 2010; Staresincic et 
al., 2011; Reyes-Pardo, et al., 2012; Forget, et al., 2013). In the yeast Saccharomyces cerevisiae, deletion 
of Npa3 or its paralogs GPN2 (YOR262W) and GPN3 (YLR243W) is lethal (Giaever et al., 2002), indicating 
essential, non-redundant functions of these enzymes.  
GPN1 was initially identified in human cells to bind the DNA repair protein XPA (Nitta, et al., 
2000), which functions as assembly platform for the DNA repair machinery (de Laat et al., 1999) and was 
thus named ‘XPA binding protein 1’ (XAB1) (Nitta, et al., 2000). However, the suggested role of GPN1 in 
nuclear import of XPA could not be confirmed (Li et al., 2013). Further, interaction of human GPN1 with 
MBD2, a component of the large protein complex ‘Methyl-CpG-binding protein 1’ (MeCP1) was 
reported, which represses transcription of densely methylated genes and led to the name ‘MBD2-
interacting protein’ (MBDin) (Lembo, et al., 2003). Here, the interaction required both, a functional 
G-domain and the C-terminal acidic tail. A GPN1 homolog was identified in S. cerevisiae in a screen for 
ribosomal biogenesis factors and called ‘Nuclear preribosomal-associated protein 3’ (Npa3) (Dez, et al., 
2004). The corresponding homolog was also found in the yeast Schizosaccharomyces pombe (Aves et al., 
2002). GPN3 was shown to interact with the oligomerization domain of Apaf-1, which was defective to 
mediate apoptosome formation and apoptosis induction upon oncogenic stimuli when GPN3 was 
silenced (Sanchez-Olea et al., 2008). Some cancer cell lines have developed mechanisms to overcome 
GPN3-depletion defects such as cytoplasmic accumulation of Rpb1, downregulation of transcription, cell 
cycle arrest and impaired proliferation (Sanchez-Olea, et al., 2008; Calera et al., 2011). GPN-loop 
GTPases were implicated in Pol II biogenesis because interaction with Pol II subunits and assembly 
intermediates as well as Pol II biogenesis factors, such as chaperones were shown (Jeronimo, et al., 
2007; Boulon, et al., 2010; Forget, et al., 2010). Additionally global downregulation of transcription was 
observed upon silencing of yeast Npa3 and GPN3 (Jeronimo, et al., 2007). Indeed, mutation in the 
nucleotide-binding site or GPN motif in human GPN1 leads to cytoplasmic accumulation or decreased 
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nuclear levels of Rpb1 (Forget, et al., 2010; Carre & Shiekhattar, 2011). This is consistent with Pol II 
assembly and/or import defects because Pol II is assembled from its subunits in the cytoplasm (Boulon, 
et al., 2010) prior to its nuclear import (Czeko, et al., 2011). Depletion of human GPN3 (Calera, et al., 
2011) or mutation of yeast GPN2 or GPN3 (Minaker, et al., 2013) also leads to cytoplasmic accumulation 
of Rpb1, indicating a general role of all three GPN-loop GTPases in Pol II biogenesis. Depletion of the 
GPN1 homolog Npa3 from S. cerevisiae leads to cytoplasmic accumulation of Rpb1 and Rpb3 
(Staresincic, et al., 2011). Rpb1 accumulation is also observed when Npa3 is mutated in its nucleotide-
binding site or GPN motif (Forget, et al., 2010; Staresincic, et al., 2011). Association of yeast Npa3 with 
Rpb1 is regulated by GTP binding in whole-cell extracts (Staresincic, et al., 2011) and a direct interaction 
of human GPN1 and GPN3 with recombinant Pol II subunits Rpb4 and Rpb7 and the C-terminal repeat 
domain (CTD) of Rpb1 has been reported (Carre & Shiekhattar, 2011). Recent studies suggest a role in 
Pol II assembly rather than import because GPN-loop GTPases lack a nuclear localization signal (NLS), 
and mutations of GPN2 or GPN3 cannot be rescued by fusion of a NLS to Rpb3, whereas deletion of the 
import factor Iwr1 is partially rescued (Minaker, et al., 2013). Further GPN1 interacts with the CCT 
complex (Forget, et al., 2010), a chaperone complex with various functions (Leroux & Hartl, 2000) that 
interacts with Pol II subunits (Dekker et al., 2008), consistent with a role in cytoplasmic assembly. In 
patients with myofibrillar myopathies, a neuromuscular disorder characterized by protein aggregates, 
human GPN1 shows increased expression and accumulates with Rpb1 in the cytoplasm of muscle cells 
(Guglielmi, et al., 2015).  
Whether GPN-loop GTPases are involved in cytoplasmic assembly and/or nuclear import of Pol II 
is still discussed controversially. The lack of structural data for any eukaryotic GPN-loop GTPase so far 
prevented detailed molecular understanding of these essential proteins. 
1.4. Molecular chaperones 
The pioneering experiments of Anfinsen (Anfinsen, 1973) and Caspar and Klug (Caspar & Klug, 1962) 
state that all information for protein folding and correct assembly with other proteins or nucleic acids 
are stored within the primary structure of those chains. This was in contrast to findings that the mixture 
of Xenopus histones and DNA in physiological salt concentrations lead to insoluble aggregates rather 
than spontaneously assembled nucleosomes (Laskey et al., 1978). Experiments showed, that the 
addition of Xenopus egg homogenate prevents aggregation and allows nucleosome assembly. The 
responsible negatively charged factor, nucleoplasmin, was identified to bind folded histones, thus 
reducing their basic charge, preventing non-specific aggregation with negatively charged DNA and 
permitting their inherent self-assembly properties (Laskey, et al., 1978). This principle was then 
extended 1987 (Ellis, 1987) and lead to the current definition of molecular chaperones which describes 
any protein that interacts with and aids in the folding and assembly of another macromolecular 
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structure without being part of its final structure (Kim et al., 2013). The large and highly diverse group of 
molecular chaperones can be subdivided in various classes dependent on their time of action, mode of 
action or location of action.  
1.4.1. Ribosome-binding chaperones 
Emerging polypeptide chains often need to be protected from engaging unfavorable intra- and 
intermolecular interactions that may cause misfolding and aggregation (Kim, et al., 2013). This is carried 
out by ribosome-associated chaperones that usually shield exposed hydrophobic regions during 
translation. In bacteria, the trigger factor (TF) binds at the ribosomal exit tunnel (Kramer et al., 2002; 
Ferbitz et al., 2004; Merz et al., 2008), interacts with most newly synthesized cytosolic and some 
secretory proteins (Bukau et al., 2000; Oh et al., 2011; Calloni et al., 2012; Preissler & Deuerling, 2012), 
binds nascent chains after 60-100 residues (Bukau, et al., 2000; Kaiser et al., 2006; Oh, et al., 2011) and 
thereby permits prior nascent chain interaction of ribosome-binding targeting factors like the signal 
recognition particle (Eisner et al., 2003; Ullers et al., 2003) and modifying enzymes like the peptide 
deformylase (Bingel-Erlenmeyer et al., 2008). ATP-independent TF-release from the nascent chain 
allows folding or downstream transfer of the polypeptide chain to the Hsp70 chaperone DnaK that likely 
exhibits functional redundancy with TF (Bukau, et al., 2000; Genevaux et al., 2004; Calloni, et al., 2012). 
In eukaryotes, a similar role is suggested for the ribosome-associated complex (RAC) and the nascent-
chain-associated complex (NAC). RAC comprises the specialized Hsp70-like protein Ssz1 and the co-
chaperone zuotin (Hsp40) and cooperates with the ribosome-binding Hsp70 isoform Ssb in fungi to 
assist nascent chain folding (Bukau, et al., 2000; Gautschi et al., 2002; Raue et al., 2007; Peisker et al., 
2008; Koplin et al., 2010; Preissler & Deuerling, 2012). NAC interacts with the ribosome and short 
nascent chains and exhibits partially redundant function with Ssb in yeast, but its precise role in protein 
folding and quality control remains elusive (Wegrzyn et al., 2006; Koplin, et al., 2010; Pech et al., 2010; 
del Alamo et al., 2011; Preissler & Deuerling, 2012). 
1.4.2. Chaperones acting downstream of the ribosome 
A large number of molecular chaperones function downstream of the ribosome to maintain protein 
folding, proteome maintenance, macromolecular complex assembly, protein transport, degradation, 
aggregate dissociation and refolding of stress-denatured proteins (Kim, et al., 2013). In the following 
section molecular mechanisms of chaperones are explained, including GPN1- and Pol II-interacting 
members.  
Hsp70 chaperones are ATPases that interact with a myriad of nascent and newly synthesized 
polypeptides without having direct affinity for the ribosome (Calloni, et al., 2012; Niwa et al., 2012). 
Hsp70 consists of a N-terminal nucleotide binding domain (NBD) that is connected to the C-terminal 
substrate binding domain (SBD) via a conserved, flexible linker (Bukau & Horwich, 1998; Bertelsen et al., 
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2009; Mapa et al., 2010; Zuiderweg et al., 2013). ATP binding to the NBD allosterically alters the SBD 
that opens the peptide binding pocket (Zhuravleva & Gierasch, 2011; Kityk et al., 2012). In the open, 
ATP-bound state, the SBD binds extended, hydrophobic 5-7-residue long peptides, typically flanked by 
positively charged amino acids (Bukau & Horwich, 1998). The open, ATP-bound state has high on and off 
rates for the substrate peptides whereas the rates are low in the closed, ADP-bound state where the 
peptide is trapped in the pocket (Bukau & Horwich, 1998; Mayer, 2010). In turn, substrate binding 
allosterically stimulates ATP hydrolysis (Swain et al., 2007; Smock et al., 2010; Zhuravleva & Gierasch, 
2011) and stable peptide binding (Bertelsen, et al., 2009; Mapa, et al., 2010). The ATPase cycle of Hsp70 
is highly regulated by Hsp40 (J proteins) co-chaperones and nucleotide exchange factors (NEFs) (Hartl & 
Hayer-Hartl, 2009; Mayer, 2010). Besides its role in protecting nascent chains against aberrant 
interactions, the Hsp70-Hsp40 system also functions in ATP-dependent co- and posttranslational folding 
and downstream transfer of polypeptides to other chaperones like the Hsp90 and the chaperonin 
system (Kim, et al., 2013). Archaea, lacking the Hsp70 system may substitute its function with the ATP-
independent prefoldin (PFD, also known as Gim complex), a hexameric α/β complex of 14-23 kDa 
subunits that binds certain nascent chains, mediates transfer to chaperonins and assists in chaperonin 
mediated folding (Frydman, 2001; Hartl & Hayer-Hartl, 2002). 
 Chaperonins (also called Hsp60s) are large double ring complexes of 800-1000 kDa comprising 7-9 
60 kDa subunits per ring and form a central cavity where a single client protein is encapsulated for ATP-
dependent folding (Hartl, 1996; Bukau & Horwich, 1998; Hartl et al., 2011). They are structurally 
subdivided into two groups. Group I requires lid-shaped co-chaperones for client protein encapsulation. 
Group II, including the eukaryotic CCT (also TRiC) contain built-in lids (Horwich et al., 2007; Tang et al., 
2007). CCT interacts with nascent chains, assists in posttranslational folding in cooperation with Hsp70 
(Etchells et al., 2005; Cuellar et al., 2008), interacts with 5-10% of eukaryotic proteins (Yam et al., 2008), 
including GPN1 (Forget, et al., 2010) and Pol II subunits (Dekker, et al., 2008) and uses an iris-like closing 
mechanism enabling encapsulation of large multidomain proteins that don’t fit into the cavity entirely 
(Russmann et al., 2012).  
 Many eukaryotic proteins are delivered to the Hsp90 system by Hsp70 for ATP-dependent 
completion of folding and conformational regulation (McClellan et al., 2007; Zhao & Houry, 2007; 
Taipale et al., 2010). The transfer is mediated by the Hsp90 organizing protein (HOP) that bridges 
between both key chaperones (Young et al., 2001). Hsp90 is involved in many cellular process, including 
cell cycle progression, steroid and calcium signaling, protein complex assembly, immune and heat shock 
response (Young et al., 2003; McClellan, et al., 2007; Taipale, et al., 2010; Makhnevych & Houry, 2012). 
The chaperone consists of three domains, an N-terminal ATPase domain, essential for function (Young, 
et al., 2001; Pearl & Prodromou, 2006) with regulatory properties (Hainzl et al., 2009; Tsutsumi et al., 
2009), a middle domain required for substrate protein interaction and ATP hydrolysis regulation (Meyer 
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et al., 2003; Koulov et al., 2010; Retzlaff et al., 2010), and a C-terminal domain for dimerization and 
co-chaperone interaction (Young, et al., 2001; Harris et al., 2004). The structures of homodimeric Hsp90 
from different organisms has been studied extensively (Ali et al., 2006; Shiau et al., 2006; Dollins et al., 
2007) and many complex structures with various co-chaperones and inhibitors are available (Young, et 
al., 2001; Harris, et al., 2004; Roe et al., 2004; Ali, et al., 2006; Pearl & Prodromou, 2006; Vaughan et al., 
2006; Southworth & Agard, 2011). The structures together with biochemical data reveal extensive 
rearrangements (Mayer, 2010; Li et al., 2012) and high flexibility (Krukenberg et al., 2008) consistent 
with the diversity of its client proteins (Taipale, et al., 2010). The apo state adopts an open V-shaped 
conformation that closes upon binding of ATP and inactive client proteins. In the next step the 
N-terminal domains dimerize and the two subunits twist around each other to form the so-called 
molecular clamp state (Ali, et al., 2006; Southworth & Agard, 2011; Li, et al., 2012). Hydrolysis of ATP to 
ADP drives substrate activation to completion and leads to N-termini separation, release of the folded 
substrate, ADP and inorganic phosphate and the closing of the cycle by converting into the open apo 
state (Kim, et al., 2013). The reaction cycle is regulated by posttranslational modifications and various 
co-chaperones that accelerate (Aha1) or slow down (HOP, Cdc37 and p23) the cycle at different steps 
(Kim, et al., 2013). Further, stimulation of ATPase activity by client protein binding was reported 
(McLaughlin et al., 2002). Additionally to protein folding Hsp90 plays an important role in assembly of 
various macromolecular complexes, including RNA polymerase II (Makhnevych & Houry, 2012).  
1.4.3. Assembly chaperones  
Many proteins assemble to macromolecular complexes to carry out their biological function. However, 
multiprotein complex assembly not only requires universal folding chaperones and rather unspecific 
‘holdases’ like small heat shock proteins (sHsps) that shield hydrophobic regions of a wide range of 
client proteins to avoid aggregation. Specific assembly chaperones are required to orchestrate the 
assembly of individual components in a highly ordered manner (Ellis, 2013). The distinction between 
folding and assembly chaperones is not always absolute because oligomerization often involves 
conformational rearrangements. A rising number of assembly chaperones has been identified for large 
molecular machines including the nucleosome (nucleoplasmin, Asf1, CAF-1 etc.) (De Koning et al., 2007; 
Avvakumov et al., 2011), Rubisco (RbcX, Raf1) (Saschenbrecker et al., 2007; C. Liu et al., 2010; Hauser et 
al., 2015), the proteasome (PAC1/2/3, hUmp1) (Murata et al., 2009), spliceosomal snRNPs  (plCln) (Chari 
et al., 2008), ATP synthase (PAB) (Mao et al., 2015) and the ribosome (RAC, NAC, Jjj1) (Karbstein, 2010). 
Assembly chaperones hereby transiently mask surfaces that form interfaces in the 
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assembled complex thus preventing aggregation and misassembly and opening a time window for 
association with the native interaction partner (Ellis, 2013). These subunit interfaces often consist of 
hydrophobic residues and thus are especially prone for aggregation during complex assembly.  
 
1.5. Aims and scope of this study 
Biogenesis of RNA polymerase II is not very well understood and requires the help of several factors. 
Here, the essential, recently discovered GPN-loop GTPases were shown to play a critical role. However, 
no structural information for any eukaryotic GPN-loop GTPase was available and the cellular function of 
these enzymes remained largely unclear. In particular, it was not known whether GPN-loop GTPases are 
involved in assembly or nuclear import of Pol II or both and what precise function they carry out. 
Further, it was unclear whether these proteins interact with complete assembled Pol II or only with 
assembly intermediates or single subunits. Additionally, the molecular function of the GPN-loop was 
only suggested from structural studies of an archaeal GPN-loop GTPase but not confirmed biochemically 
and remained speculative in the eukaryotic system.  
To gain insights into the structure and molecular mechanisms of GPN-loop GTPases we aimed to 
solve high resolution crystal structures of the yeast GPN1 enzyme Npa3 in complex with various 
nucleotides to gain snapshots along the hydrolysis pathway. With this we intended to understand how 
Npa3 binds and hydrolyzes GTP and elucidate the molecular function of its GPN-loop to propose a 
model for enzymatic Npa3 activity. Further we aimed to confirm this model biochemically by using a 
combination of structure-guided site-directed mutagenesis and enzymatic activity assays. To unravel the 
function of Npa3 we aimed to apply biochemical approaches and characterize Pol II interaction sites 
which might hint to its role in Pol II biogenesis. 
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2. Materials and Methods  
2.1. Materials 
2.1.1. Bacterial strains 
Table 4| Escherichia Coli strains 
Strain Base strain Genotype Source 
XL1 blue K12 endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F'[ ::Tn10 
proAB+ lacIq Δ(lacZ)M15] hsdR17(rK
- mK
+) 
Stratagene 
BL21 Gold RIL DE3 B; F-; ompT; hsdS(rB- rB-); dcm+; Tetr; gal_(DE3); endA; Hte 
[argU, ileY, leuW, Camr] 
Stratagene 
Rosetta  DE3 F- ompT hsdSB(RB
- mB
-) gal dcm λ(DE3 [lacI lacUV5-T7 gene 1 
ind1 sam7 nin5]) pLysSRARE (CamR) 
Novagen 
 
2.1.2. Yeast strains 
Table 5| Saccharomyces cerevisiae strains 
Strain Genotype Source 
Npa3-C-TAP S288C; ATCC 201388: MATa his3Δ1 leu2Δ0 met15Δ0 
ura3Δ0 
Thermo Scientific Open 
Biosystems 
Pol II purification 
strain 
MATa or α; ura3-52 trp1Δ leu2Δ1 his3Δ200 pep4::HIS3 
prb1Δ1.6R can1Δ GAL rpb3::URA3-N-6xHis-RPB3 
Kashlev Lab 
 
2.1.3. Plasmids  
Table 6| Plasmids used in this study 
Vector ID Insert/Description Type Tag Primer 
B1I Sc Npa3 1-385 (fl) pOPINI N-His Npa3_Sc_pI_M1_F/Npa3_Sc_pI_N385_R 
B2I Sc Npa3 1-298 pOPINI N-His Npa3_Sc_pI_M1_F/Npa3_Sc_pI_K298_R 
B3I Sc Npa3 1-264 pOPINI N-His Npa3_Sc_pI_M1_F/Npa3_Sc_pI_K264_R 
B4I Sc Npa3 1-385∆203-
211 
pOPINI N-His Npa3_Sc_pI_M1_F/Npa3_Sc_∆203-211_R 
Npa3_Sc_∆203-211_F/Npa3_Sc_pI_N385_R 
B5I Sc Npa3 1-298∆203-
211 
pOPINI N-His Npa3_Sc_pI_M1_F/Npa3_Sc_∆203-211_R 
Npa3_Sc_∆203-211_F/Npa3_Sc_pI_K298_R 
B1E Sc Npa3 1-385 (fl) pOPINE C-His Npa3_Sc_pE_M1_F/Npa3_Sc_pE_N385_R 
B2E Sc Npa3 1-298 pOPINE C-His Npa3_Sc_pE_M1_F/Npa3_Sc_pE_K298_R 
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B3E Sc Npa3 1-264 pOPINE C-His Npa3_Sc_pE_M1_F/Npa3_Sc_pE_K264_R 
B4E Sc Npa3 1-385∆203-
211 
pOPINE C-His Npa3_Sc_pE_M1_F/Npa3_Sc_∆203-211_R 
Npa3_Sc_∆203-211_F/Npa3_Sc_pE_N385_R 
B6E Sc Npa3 1-264∆203-
211 
pOPINE C-His Npa3_Sc_pE_M1_F/Npa3_Sc_∆203-211_R 
Npa3_Sc_∆203-211_F/Npa3_Sc_pE_K264_R  
B1E_GPN-AAA Sc Npa3 1-385_GPN-
AAA 
pOPINE C-His Npa3_Sc_pE_M1_F/ Npa3_Sc_GPN-AAA_R  
Npa3_Sc_GPN-AAA_F /Npa3_Sc_pE_N385_R 
B1E_D40A Sc Npa3 1-385_D40A pOPINE C-His Npa3_Sc_pE_M1_F/Npa3_Sc_D40A_R  
Npa3_Sc_D40A_F/Npa3_Sc_pE_N385_R 
B1E_D106A Sc Npa3 1-385_D106A pOPINE C-His Npa3_Sc_pE_M1_F/Npa3_Sc_D106A_R  
Npa3_Sc_D106A_F/Npa3_Sc_pE_N385_R 
B1E_Q110L Sc Npa3 1-385_Q110L pOPINE C-His Npa3_Sc_pE_M1_F/Npa3_Sc_Q110L_R  
Npa3_Sc_Q110L_F/Npa3_Sc_pE_N385_R 
B6E_D106A Sc Npa3 1-264∆203-
211 D106A 
pOPINE C-His B6E w. Npa3_Sc_pE_M1_F/Npa3_Sc_D106A_R  
Npa3_Sc_D106A_F/ Npa3_Sc_pE_K264_R 
Npa3_265-385 Sc Npa3 265-385 pOPINE C-His Npa3_Sc_Q265_pE_F /Npa3_Sc_pE_N385_R 
B1Enotag Sc Npa3 1-385 (fl) pOPINE - Npa3_Sc_pE_M1_F/Npa3_Sc_pE_N385no-tag_R 
C1I Sp Npa3 1-367 (fl) pOPINI N-His Npa3_POM_pI_M1_F/Npa3_POM_pI_Q367_R 
C3I Sp Npa3 1-273  pOPINI N-His Npa3_POM_pI_M1_F/Npa3_POM_pI_R273_R 
C5I Sp Npa3 1-301∆208-
215 
pOPINI N-His Npa3_POM_pI_M1_F/Npa3_POM_∆208-215_R 
Npa3_POM_∆208-215_R/Npa3_POM_pI_K301_R 
C1E Sp Npa3 1-367  pOPINE C-His Npa3_POM_pE_M1_F/Npa3_POM_pE_Q367_R 
C2E Sp Npa3 1-301  pOPINE C-His Npa3_POM_pE_M1_F/Npa3_POM_pE_K301_R 
C3E Sp Npa3 1-273  pOPINE C-His Npa3_POM_pE_M1_F/Npa3_POM_pE_R273_R 
A1I Hs GPN1 1-374 (fl) pOPINI N-His GPN1_pI_M1_F/GPN1_pI_K374_R 
A2I Hs GPN1 1-304 pOPINI N-His GPN1_pI_M1_F/GPN1_pI_L304_R 
A3I Hs GPN1 1-275 pOPINI N-His GPN1_pI_M1_F/GPN1_pI_R275_R 
A5I Hs GPN1 18-304  pOPINI N-His GPN1_pI_H18_F/GPN1_pI_L304_R 
A6I Hs GPN1 18-275  pOPINI N-His GPN1_pI_H18_F/GPN1_pI_R275_R 
A1E Hs GPN1 1-374 (fl) pOPINE C-His GPN1_pE_M1_F/GPN1_pE_K374_R 
A2E Hs GPN1 1-304 pOPINE C-His GPN1_pE_M1_F/GPN1_pE_L304_R 
A3E Hs GPN1 1-275 pOPINE C-His GPN1_pE_M1_F/GPN1_pE_R275_R 
A4E Hs GPN1 18-374 pOPINE C-His GPN1_pE_H18_F/GPN1_pE_R275_R 
A5E Hs GPN1 18-304  pOPINE C-His GPN1_pE_H18_F/GPN1_pE_L304_R 
A6E Hs GPN1 18-275  pOPINE C-His GPN1_pE_H18_F/GPN1_pE_R275_R 
D1I Sc GPN3 1-272 (fl) pOPINI N-His YLR243W_pI_M1_F/ YLR243W_pI_E272_R 
D1E Sc GPN3 1-272 (fl) pOPINE C-His YLR243W_pE_M1_F/ YLR243W_pE_E272_R 
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E1I Sp GPN3 1-276 (fl) pOPINI N-His Fet5_pI_F/Fet5_pI_R 
E1E Sp GPN3 1-276 (fl) pOPINE C-His Fet5_pE_F/Fet5_pE_R 
E1A_no-tag Sp GPN3 1-276 (fl) pOPINA - Fet5_pA_noHis_F/ Fet5_pA_noHis_R 
F1A Sc GPN2 1-347 (fl) pOPINA C-His GPN2_Sc_M1_pA_F/GPN2_Sc_R347_pA_R 
F2A Sc GPN2 1-264 pOPINA C-His GPN2_Sc_M1_pA_F/GPN2Sc_G264_pA_R 
 
F3A Sc GPN2_1-243 pOPINA C-His GPN2_Sc_M1_pA_F/GPN2Sc_D243_pA_F 
 
F4A Sc GPN2 1-347∆206-
211 
pOPINA C-His GPN2_Sc_M1_pA_F/GPN2Sc∆I206-S211_pA_R 
GPN2Sc∆I206-S211_pA_F/GPN2_Sc_R347_pA_R 
 
F5A Sc GPN2 1-264∆206-
211 
pOPINA C-His GPN2_Sc_M1_pA_F/GPN2Sc∆I206-S211_pA_R 
GPN2Sc∆I206-S211_pA_F/GPN2Sc_G264_pA_R 
F6A Sc GPN2_1-243∆206-
211 
pOPINA C-His GPN2_Sc_M1_pA_F/GPN2Sc∆I206-S211_pA_R 
GPN2Sc∆I206-S211_pA_F/GPN2Sc_D243_pA_F 
His-N-Iwr1 Sc Iwr1 1-353 (fl) pET21b N-His Cloned by E. Czeko 
Iwr1-C-His Sc Iwr1 1-353 (fl) pET21b C-His Cloned by E. Czeko 
N-Cys-Iwr1_9-
223 
Sc Cys-Iwr1 9-223 pOPINB N-His- Iwr1_Sc_pB_Cys-A9_F/Iwr1_Sc_pB_D223_R (N-
term. Cys for site-directed fluorescence-labeling) 
 
 
2.1.4. Oligonucleotides 
Table 7| Oligonucleotides used for molecular cloning 
Primer name Sequence (5’ to 3’) Target 
vector 
Npa3_Sc_pI_M1_F ACCATCACAGCAGCGGCAGTCTCAGCACAATCATATG  pOPINI 
Npa3_Sc_pI_N385_R ATGGTCTAGAAAGCTTTAGTTTCTAATATACTTCGCGATATTTTC  pOPINI 
Npa3_Sc_pI_K298_R ATGGTCTAGAAAGCTTTACTTCTCGTTTAACCCTAGATCC  pOPINI 
Npa3_Sc_pI_K264_R ATGGTCTAGAAAGCTTTACTTATAGTATTGGTCGTATTCATCAAC  pOPINI 
Npa3_Sc_pE_M1_F AGGAGATATACCATGAGTCTCAGCACAATCATATG  pOPINE 
Npa3_Sc_pE_N385_R GTGATGGTGATGTTTGTTTCTAATATACTTCGCGATATTTTC  pOPINE 
Npa3_Sc_pE_K298_R GTGATGGTGATGTTTCTTCTCGTTTAACCCTAGATCC  pOPINE 
Npa3_Sc_pE_K264_R GTGATGGTGATGTTTCTTATAGTATTGGTCGTATTCATCAAC  pOPINE 
Npa3_Sc_pE_N385no-
tag_R 
GTGATGGTGATGTTTTTAGTTTCTAATATACTTCGCGATATTTTC  pOPINE 
Npa3_Sc_Q265_pE_F AGGAGATATACCATGCAAGAACGTGAAAAAGCATTG  pOPINE 
Npa3_POM_pI_M1_F ACCATCACAGCAGCGGCATGACAGATAAAGAGAAGAAGCC  pOPINI 
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Npa3_POM_pI_Q367_R 
Npa3_POM_pI_K301_R 
ATGGTCTAGAAAGCTTTATTGCTTCATACGCTCTGTAAG 
ATGGTCTAGAAAGCTTTATTTAGAAACATGCATGTCTTTC 
 pOPINI 
Npa3_POM_pI_R273_R ATGGTCTAGAAAGCTTTATCGTTCCATTTCTGGAAC  pOPINI 
Npa3_POM_pE_M1_F AGGAGATATACCATGACAGATAAAGAGAAGAAGCC  pOPINE 
Npa3_POM_pE_Q367_R GTGATGGTGATGTTTTTGCTTCATACGCTCTGTAAG  pOPINE 
Npa3_POM_pE_K301_R GTGATGGTGATGTTTTTTAGAAACATGCATGTCTTTC  pOPINE 
Npa3_POM_pE_R273_R GTGATGGTGATGTTTTCGTTCCATTTCTGGAAC  pOPINE 
GPN1_pI_M1_F ACCATCACAGCAGCGGCATGGCGGCGTCCG  pOPINI 
GPN1_pI_H18_F ACCATCACAGCAGCGGCCACCCAGTGTGTCTGTTGG  pOPINI 
GPN1_pI_K374_R ATGGTCTAGAAAGCTTTACTATTTATTGTTTCTCTTCCAGTATTGTG  pOPINI 
GPN1_pI_L304_R   ATGGTCTAGAAAGCTTTACAAGGCTACAGAACCCATATCTTTTC  pOPINI 
GPN1_pI_R275_R ATGGTCTAGAAAGCTTTAACGTTCATATTCAGGACGATACTC  pOPINI 
GPN1_pE_M1_F AGGAGATATACCATGGCGGCGTCCG  pOPINE 
GPN1_pE_H18_F AGGAGATATACCATGCACCCAGTGTGTCTGTTGG  pOPINE 
GPN1_pE_K374_R GTGATGGTGATGTTTTTTATTGTTTCTCTTCCAGTATTGTG  pOPINE 
GPN1_pE_L304_R GTGATGGTGATGTTTCAAGGCTACAGAACCCATATCTTTTC  pOPINE 
GPN1_pE_R275_R GTGATGGTGATGTTTACGTTCATATTCAGGACGATACTC  pOPINE 
GPN2_Sc_M1_pA_F AGGAGATATACCATGCCCTTCGCTCAGAT  pOPINA 
GPN2_Sc_R347_pA_R GTGGTGGTGGTGTTTCCTAACAAAATCCATTCCTTG  pOPINA 
GPN2_Sc_G264_pA_R GTGGTGGTGGTGTTTGCCGAATATGTAGCCATTTG  pOPINA 
GPN2Sc_D243_pA_R GTGGTGGTGGTGTTTATCCACGGACAAAACCTC  pOPINA 
YLR243W_pI_F ACCATCACAGCAGCGGCTCTCGCGTTGGTGTC  pOPINI 
YLR243W_pI_R ATGGTCTAGAAAGCTTTATTCTTCGACATCTATTTGGTCG  pOPINI 
YLR243W_pE_F AGGAGATATACCATGTCTCGCGTTGGTGTC  pOPINE 
YLR243W_pE_R GTGATGGTGATGTTTTTCTTCGACATCTATTTGGTCG  pOPINE 
Fet5_pI_F ACCATCACAGCAGCGGGTTAAGGTGGCAGCTTTTGTTTG  pOPINI 
Fet5_pI_R ATGGTCTAGAAAGCTTTATTCATCGTCTTCTAAATCATCTGC  pOPINI 
Fet5_pE_F AGGAGATATACCATGGTTAAGGTGGCAGCTTT  pOPINE 
Fet5_pE_R GTGATGGTGATGTTTTTCATCGTCTTCTAAATCATCTGC  pOPINE 
Fet5_pA_noHis_F AGGAGATATACCATGGTTAAGGTGGCAGCTTTTGTTTG  pOPINA 
Fet5_pA_noHis_R GTGGTGGTGGTGTTTCTATTCATCGTCTTCTAAATCATCTGC  pOPINA 
    
Mutagenic Primer 
Npa3_Sc_∆203-211_F CAAGGAAGATCAAGACGGGTACATGAGCTCATTG   independent 
Npa3_Sc_∆203-211_R CAATGAGCTCATGTACCCGTCTTGATCTTCCTTG  independent 
Npa3_Sc_GPN-AAA_F GAGAATTACCAGCTAGCTGCGGCCGGTGCCATTGTCACC  independent 
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Npa3_Sc_GPN-AAA_R GGTGACAATGGCACCGGCCGCAGCTAGCTGGTAATTCTC  independent 
Npa3_Sc_D40A_F CCATACGTAATCAATCTTGCTCCTGCAGTATTGAGAGTCC  independent 
Npa3_Sc_D40A_R GGACTCTCAATACTGCAGGAGCAAGATTGATTACGTATGG  independent 
Npa3_Sc_D106A_F CAAAACTGCATCATCGCCACTCCAGGCC   independent 
Npa3_Sc_D106A_R GGCCTGGAGTGGCGATGATGCAGTTTTG  independent 
Npa3_Sc_Q110L_F CATCGACACTCCAGGCTTAATCGAATGTTTTGTGTG  independent 
Npa3_Sc_Q110L_R CACACAAAACATTCGATTAAGCCTGGAGTGTCGAT  independent 
Npa3_POM_∆208-215_F GACTAAAGACGAAGGTGGATATATGGGTTCG  independent 
Npa3_POM_∆208-215_R CGAACCCATATATCCACCTTCGTCTTTAGTC  independent 
GPN2Sc_d_I206-
S211_pA_F 
CAGGATCTGGATTATTTGGAGCCATATAGTGTACTGGGAAAGAAATATAGC
AAG 
 independent 
GPN2Sc_d_I206-
S211_pA_R 
CTTGCTATATTTCTTTCCCAGTACACTATATGGCTCCAAATAATCCAGATCCT
G 
 
 independent 
Sequencing Primer    
T7f TAATACGACTCACTATAGGG  All pOPIN  
pET-RP CTAGTTATTGCTCAGCGG  pET28-based  
pTriExDown TCGATCTCAGTGGTATTTGTG  pTriEx-based  
 
 
2.1.5. Reagents and consumables 
Chemicals were obtained from Merck (Darmstadt, Germany), Roth (Karlsruhe, Germany) or Sigma-
Aldrich (Seelze, Germany) unless stated otherwise. Enzymes and reagents for cloning were obtained 
from Fermentas (St. Leonrot, Germany), New England Biolabs (Frankfurt am Main, Germany) and 
Clontech (St. Germain-en-Leye, France). For DNA preparation commercial kits from Qiagen (Hilden, 
Germany) were used. DNA and RNA oligonucleotides were ordered at ThermoScientific (Ulm, Germany) 
and Metabion (Planegg, Germany), respectively. Crystallization reagents and tools were ordered at 
Hampton Research (Aliso Viejo, CA, USA). GTP-derivatives were obtained from Sigma-Aldrich (Seelze, 
Germany) or Jena Bioscience (Jena, Germany). 
 
2.1.6. Media and additives 
Media were usually taken from lab stocks (Table 8). Media additives (Table 9) were sterile filtered. 
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Table 8| Media for Escherichia coli and Saccharomyces cerevisiae 
Media Application Description 
LB E. coli culture 1% (w/v) Bacto tryptone, 0.5% (w/v) yeast extract, 8.6 mM NaCl, 2.6 mM 
NaOH, plates contained 1.5% (w/v) agar 
LB X-Gal plates E. coli 
transformation  
1 % (w/v) Bacto tryptone, 0.5% (w/v) yeast extract, 8.6 mM NaCl, 2.6 mM 
NaOH, 1.5 % (w/v) agar, 0.02% (w/v) 5-Brom-4-chlor-3-indoxyl-β-D-
galactopyranosid (X-Gal)[1] [2], 1 mM IPTG[2], 0.1% (w/v) ampicillin/kanamycin[2] 
YPD Yeast culture 2% (w/v) peptone, 2% (w/) glucose, 1% (w/v) yeast extract 
YPD plates Yeast plate YPD, 2% (w/v) agar 
[1] stock solution dissolved in DMF; [2]added after autoclave 
 
 
 
Table 9| Media additives for Escherichia coli and Saccharomyces cerevisiae 
Additive Description Stock solution Applied concentration 
IPTG E. coli induction 1 M in H2O 0.5 mM 
Ampicillin Antibiotic 100 mg/ml in H2O 100 µg/ml 
Kanamycin Antibiotic 30 mg/ml in H2O 30 µg/ml  
Chloramphenicol Antibiotic 50 mg/ml in EtOH 50 µg/ml 
Tetracycline Antibiotic 12.5 mg/ml in EtOH 12.5 µg/ml 
5-bromo-4-chloro-3-
indolyl-β-D-
galactopyranoside (X-Gal) 
E. coli blue/white 
screening 
20% (w/v) in DMF 0.02  (w/v) 
 
2.1.7. Buffers and solutions 
Table 10| General buffers, dyes and solutions 
Name Description Application 
10X TAE 50 mM EDTA, pH 8.0, 2.5M Tris-acetate Agarose gels 
6X DNA loading dye Fermentas Agarose gels 
5X Phusion HF buffer Finnzymes PCR 
iQ™ SYBR® Green 
Supermix 
BioRad DNA staining 
10X buffer 0 Fermentas Restriction Digest 
10X FastDigest buffer Fermentas Restriction Digest 
20X MES buffer NuPAGE® MES SDS Running buffer, Life technologies SDS-PAGE 
20X MOPS buffer NuPAGE® MOPS SDS Running buffer, Life technologies SDS-PAGE 
5X SDS loading buffer 250 mM Tris-HCl pH 8.0, 50% (v/v) glycerol, 0.5% (w/v) 
bromophenol blue, 7.5% (w/v) SDS, 500 mM DTT 
SDS-PAGE 
Protein Ladder PageRulerTM Prestained Protein Ladder (Fermentas) SDS-PAGE 
Gel staining solution 50% (v/v) ethanol, 7% (v/v) acetic acid, 0.125% (w/v) 
Coomassie brilliant blue R-250 
Coomassie staining  
Gel staining solution Instant blue, Expedeon Coomassie staining 
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100X PI 1.42 mg leupeptin, 6.85 mg pepstatine A, 850 mg PMSF, 
1650 mg benzamidine dissolved in 50 ml ethanol 
Protease inhibitor mix 
TFB-1 30 mM KOAc, 100 mM RbCl, 10 mM CaCl2, 
50 mM MnCl2
[1], 15% [v/v] glycerol, pH 5.8 (with 0.2 M 
acetic acid) 
Chemically competent E. coli 
TFB-2 10 mM MOPS, 75 mM CaCl2, 10 mM RbCl, 15% [v/v] 
Glycerol, pH 6.5 (with KOH) 
Chemically competent E. coli 
1x Bradford dye 1:5 dilution of Bradford concentrate (BioRad) Determination of protein 
concentration 
[1] added after pH adjustment 
 
 
 
Table 11| Npa3 and GPN2 purification buffers 
Name Description 
Lysis buffer 50 mM Tris pH 7.5 (6°C), 5 mM Imidazole, 300 mM NaCl, 5 mM MgCl2, 0.2% (v/v) 
Tween-20, 2 mM DTT[1], 1X PI[1] 
Nickel wash buffer 50 mM Tris pH 7.5 (6°C), 10 mM imidazole, 300 mM NaCl, 5 mM MgCl2,  2 mM DTT
[1] 
Nickel elution buffer 50 mM Tris pH 7.5 (6°C), 200 mM imidazole, 300 mM NaCl, 5 mM MgCl2,  2 mM DTT
[1] 
Anion exchange buffer A 50 mM Tris pH 7.5 (6°C), 100 mM NaCl, 5 mM MgCl2, 2 mM DTT
[1] 
Anion exchange buffer B 50 mM Tris pH 7.5 (6°C), 1 M NaCl, 5 mM MgCl2, 2 mM DTT
[1] 
SEC buffer 100 10 mM HEPES pH 7.5 (4°C), 100 mM NaCl, 5 mM MgCl2, 10 mM DTT
[1] 
SEC buffer 200 10 mM HEPES pH 7.5 (4°C), 200 mM NaCl, 5 mM MgCl2, 10 mM DTT
[1] 
[1] added directly before usage 
 
 
 
Table 12| Iwr1 purification buffers 
Name Description 
Iwr1 Lysis buffer 20 mM Tris pH 8.0 (4°C), 150 mM NaCl, 5 mM DTT[1], 1X PI[1] 
Iwr1 Nickel wash buffer 20 mM Tris pH 8.0 (4°C), 150 mM NaCl, 10/20/30/40 mM imidazole, 5 mM DTT[1] 
Iwr1 Nickel elution buffer 20 mM Tris pH 8.0 (4°C), 150 mM NaCl, 250 mM imidazole, 5 mM DTT[1] 
Iwr1 Anion exchange buffer A 20 mM Tris pH 8.0 (4°C), 100 mM NaCl, 5 mM DTT[1] 
Iwr1 Anion exchange buffer B 20 mM Tris pH 8.0 (4°C), 1 M NaCl, 5 mM DTT[1] 
Pol II buffer 5 mM HEPES pH 7.25 (20°C), 40 mM (NH4)2SO4, 10 µM ZnCl2, 10 mM DTT
[1] 
[1] added directly before usage 
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Table 13| Pol II purification buffers 
Name Description 
3X freezing buffer 150 mM Tris pH 7.9 (4°C), 3 mM EDTA, 30 µM ZnCl2, 30 % (v/v) glycerol, 3 % (v/v) 
DMSO, 30 mM DTT[1], 3X PI[1] 
HSB150 50 mM Tris pH 7.9 (4°C), 150 mM KCl, 1 mM EDTA, 10 µM ZnCl2, 10 % (v/v) glycerol, 
10 mM DTT[1], 1X PI[1] 
HSB1000/7 50 mM Tris pH 7.9 (4°C), 1000 mM KCl, 7 mM imidazole, 1 mM EDTA, 10 µM ZnCl2, 10 
% (v/v) glycerol, 2.5 mM DTT[1], 1X PI[1] 
Ni buffer 7/50/100 20 mM Tris pH 7.9 (4°C), 150 mM KCl, 7/50/100 mM imidazole 
MonoQ 150 20 mM Tris-acetate pH 7.9 (4°C), 150 mM KOAc, 10 % (v/v) glycerol, 0.5 mM EDTA pH 
7.9, 10 µM ZnCl2, 10 mM DTT
[1] 
MonoQ 2000 20 mM Tris-acetate pH 7.9 (4°C), 2 M KOAc, 10 % (v/v) glycerol, 0.5 mM EDTA pH 7.9, 
10 µM ZnCl2, 10 mM DTT
[1] 
Pol II buffer 5 mM HEPES pH 7.25 (20°C), 40 mM (NH4)2SO4, 10 µM ZnCl2, 10 mM DTT
[1] 
[1] added directly before usage 
 
 
Table 14| Rpb4/7 purification buffers 
Name Description 
Ni buffer 0/10/20/50/200 50 mM Tris pH 7.5 (4°C), 150 mM NaCl, 0/10/20/50/200 mM imidazole, 10 mM β-
mercaptoethanol[1] 
Ni salt buffer 50 mM Tris pH 7.5 (4°C), 2 M NaCl, 10 mM β-mercaptoethanol[1] 
SourceQ 100 50 mM Tris pH 7.5 (4°C), 100 mM NaCl, 10 mM β-mercaptoethanol[1] 
SourceQ 1000 50 mM Tris pH 7.5 (4°C), 1 M NaCl, 10 mM β-mercaptoethanol[1] 
Pol II buffer 5 mM HEPES pH 7.25 (20°C), 40 mM (NH4)2SO4, 10 µM ZnCl2, 10 mM DTT
[1] 
[1] added directly before usage 
 
 
Table 15| HPLC buffers 
Name Description 
Buffer A 50 mM triethylammonium acetate 
Buffer B 90 % (v/v) acetonitrile 
 
 
Table 16| Chaperone assay buffers 
Name Description 
TE 50 mM Tris pH8.0, 2 mM EDTA 
Incubation buffer 40 mM HEPES-KOH pH7.5, 5 mM MgCl2 
 
 
Table 17| Biotinylation buffer 
Name Description 
BirA dilution buffer  5 mM HEPES-NaOH pH 7.25, 16 mM MgCl2, 10 µM ZnCl2, 10 mM DTT
[1] 
[1] added directly before usage 
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2.2. General Methods 
2.2.1. Molecular cloning and site-directed mutagenesis 
Polymerase chain reaction (PCR)     Primers for InFusion cloning (Clontech) (Berrow et al., 2007) were 
designed using a target vector specific overhang of 15-20 nucleotides, followed by around 20 
nucleotides complementary to the gene of interest. Annealing temperatures were calculated using the 
Tm calculator online tool (NEB). PCR reactions were carried out using the Phusion High Fidelity PCR 
Master Mix (NEB), 0.5 µM of each primer and variable amounts of either genomic DNA, cDNA or 
plasmid DNA. Thermocycling programs comprised 30 cycles and were adjusted to the specific needs of 
the individual reactions in terms of annealing temperature and elongation times (Biometra T3000 
Thermocycler). PCR products were separated by agarose gel electrophoresis and purified using the 
QIAquick gel extraction kit (Qiagen).   
Site-directed mutagenesis     Point mutations and deletions were introduced by overlap-extension-PCR 
(Higuchi et al., 1988). Mutagenic primers were designed with a melting temperature of approximately 
78°C, containing the desired mismatches in the middle of the primer. To increase the annealing stability 
nucleotides G or C were used at the 5’ and 3’ end of the primer if possible. Two overlapping PCR 
products were synthesized in separate reactions using one primer containing the respective overhang 
for InFusion cloning (Clontech) (Berrow, et al., 2007) and one primer containing the desired mutation, 
respectively. In a second PCR reaction 40 ng of each purified PCR product were used as template to 
amplify the gene of interest with the desired mutation. PCR reactions were carried out as descried 
above. PCR products were separated by agarose gel electrophoresis and purified using the QIAquick gel 
extraction kit (Qiagen).   
Electrophoretic separation of DNA     Electrophoretic separation of DNA was carried out in horizontal 1X 
TAE agarose gels containing 0.7 µg/ml Sybr Safe (Invitrogen) and 0.5-2% agarose, depending on the DNA 
length to be separated. Electrophoresis was carried out in PerfectBlue Gelsystem electrophoresis 
chambers (Peqlab). Samples were mixed with 6X loading dye (Fermentas) prior to loading and DNA was 
visualized and documented using a Safe Imager blue light transilluminator (Invitrogen, λ=470 nm). 
Enzymatic restriction cleavage     2 µg of the desired vector were digested per 100 µl reaction prior to 
InFusion cloning using restriction endonucleases (NEB or Fermentas) as recommended by the respective 
manufacturer. Cleaved vectors were purified using the QIAquick PCR purification kit (Qiagen). 
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Restriction- and ligation-free InFusion cloning     InFusion cloning allows restriction- and ligation-free 
cloning (Berrow, et al., 2007). For this 100 ng of the linearized vector were incubated with 3X molar 
excess of the gene of interest (amplified with the respective InFusion overhangs) and the InFusion Dry-
Down PCR cloning mixture (Clontech) as recommended by the manufacturer. Then 2.5 µl of the InFusion 
product were used for transformation of the plasmid into chemically competent E. coli XL1 blue cells as 
described in 2.2.2. 
Isolation and verification of plasmid DNA     After transformation of plasmids into E. coli cells (2.2.2.), 
single colonies were picked from selective plates and used for colony PCR. For this, colonies were 
inoculated in 30 µl H2O and mixed at RT for 10 min in a thermomixer. Then 6 µl of the mixture were 
used as template for a PCR reaction carried out as described above. Colonies resulting in positive PCR 
reactions were inoculated in 5 mL LB medium and incubated at 37°C shaking overnight. Plasmids were 
isolated using the QIAprep Spin Miniprep kit (Qiagen) as recommended by the manufacturer. DNA 
sequences were verified by sequencing (GATC).  
2.2.2. Preparation and transformation of competent E. coli cells 
Preparation of chemically competent E. coli cells     E. coli cells were grown in 5 ml LB medium 
overnight at 37°C and 140 rpm. The pre-culture was diluted 1:100 with LB medium containing 
appropriate antibiotics and cells were grown for 2-3 hours at 37°C and 140 rpm until OD600=0.25 - 0.3. 
Then, cultures were chilled on ice for 5 min and centrifuged at 4,000 x g for 5 min at 4°C. After 
resuspending in 50 ml Transformation buffer 1 (TFB-1) (Table 10) per 250 ml culture, the cells were 
again incubated on ice for 5 min followed by centrifugation at 4,000 x g and 4°C for 5 min. The 
supernatant was discarded and the pellet was gently resuspended in 5 ml Transformation buffer 2 
(TFB-2) (Table 10) per 250 ml culture. After another incubation on ice for 15 min the competent cells 
were aliquoted (50 µl), flash frozen in liquid nitrogen and stored at -80°C.  
Transformation of chemically competent E. coli cells     For transformation cells were thawed on ice and 
100 ng vector or 2.5 µl InFusion product were added and incubated on ice for 5 min. The competent 
cells were heat shocked at 42°C for 45 s and cooled on ice for 5 min. Then 450 µl LB medium was added 
and the cells were grown in a thermomixer (Qiagen) at 37°C for 1 hour at 600 rpm. Finally, cells were 
plated on LB plates supplemented with appropriate antibiotics and incubated overnight at 37°C. 
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Cotransformation of electro-competent E. coli cells     For cotransformation, electro-competent E. coli 
BL21 Gold RIL cells were thawed on ice and 100 ng of the respective vectors were added and incubated 
in a cuvette on ice for 5 min. Electroporation was carried out at 2.5 kV in a MicroPulser Electroporater 
(Biorad). Cells were then cooled on ice for 5 min and grown in 300 µl LB medium at 37°C for 1 hour at 
600 rpm in a thermomixer (Qiagen). Finally, cells were plated on selective plates and incubated 
overnight at 37°C. 
2.2.3. Recombinant protein expression in E. coli 
Expression and purification screening    New constructs of the proteins of interest were screened on 
ideal expression temperature, cell density and IPTG concentration for induction as well as protein 
solubility and affinity-tag accessibility prior to large-scale purification. For this, E. coli precultures were 
grown in 1 ml LB medium supplemented with appropriate antibiotics at 37°C shaking overnight. Main 
cultures were inoculated 1:100 in 5 ml LB medium supplemented with appropriate antibiotics and 
grown to varying OD600 values at 37°C shaking. Induction was induced with varying amounts of IPTG and 
protein expression was carried out at different temperatures at 160 rpm overnight. Cells were 
harvested by centrifugation at 4,000 x g for 10 min and the pellets were frozen at -20°C. Then, cells 
were resuspended in 1 ml of the respective lysis buffer and lysed by sonication. Cell debris and insoluble 
proteins were removed by centrifugation at 15,000 rpm and 4°C for 15 min in a microcentrifuge. The 
supernatant was incubated for 25 min at 8°C with 10 µl Magnetic Ni-NTA agarose beads (Life 
Technologies) pre-equilibrated with the respective wash buffer. The sample was washed four times with 
500 µl of the respective wash buffer before protein elution was carried out with 50 µl of the respective 
elution buffer. Samples were taken from every step for SDS-PAGE analysis as described in 2.2.4. 
Protein expression in E. coli     For recombinant protein expression from a single vector chemically 
competent E. coli Rosetta (DE3) cells were used whereas coexpression from two different plasmids was 
carried out in electro-competent E. coli Codon-Plus (DE3) RIL cells. For this, the plasmids encoding the 
proteins of interest were transformed as described in 2.2.2. Precultures were grown in 20 ml LB medium 
supplemented with appropriate antibiotics at 37°C shaking overnight. Main cultures were inoculated 
1:100 in LB medium supplemented with appropriate antibiotics and grown at 37°C and 160 rpm till 
OD600=0.6-0.8. Expression was induced by addition of varying amounts of IPTG and carried out at 
18-20°C and 160 rpm overnight. Cells were harvested by centrifugation at 5,000 rpm for 10 min and 
pellets were stored at -20°C. 
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2.2.4. Protein analysis 
Determination of protein concentration     Total protein concentrations were usually determined by 
measuring the absorption at 280 nm using a ND-1000 (NanoDrop) spectrometer. Molar absorption 
coefficients of individual proteins were calculated using the ProtParam software (Gasteiger E, 2005). If 
the protein didn’t contain UV absorbing residues or the sample was contaminated with large amounts 
of non-protein molecules absorbing at 280 nm, such as nucleic acids and detergents, protein 
concentrations were determined by Bradford assay (Bradford, 1976).  For this, the dye reagent (BioRad) 
was used as recommended by the manufacturer and samples were measured at 595 nm. Reference 
curves were generated for every new batch of the dye reagent using bovine serum albumin (Fraction V, 
Roth). 
SDS-Polyacrylamide gel electrophoresis     Electrophoretic separation of proteins was carried out using 
NuPAGE Novex 4-12% Bis-Tris Mini gels (Invitrogen) as recommended by the manufacturer. Vertical 
electrophoresis was carried out in X-Cell Sure Lock tanks (Invitrogen) using either NuPAGE MES or 
NuPAGE MOPS SDS running buffer (Table 10), dependent on the size of proteins to be separated. 
Samples were mixed with 5X SDS loading buffer (Table 10) prior to loading. Gels were stained with 
either Coomassie staining solution or InstantBlue (Expedeon) followed by destaining with H2O.  
TCA precipitation     If protein concentrations were too low to be visible on an SDS gel, TCA precipitation 
was carried out before. For this, the sample was mixed with an equal volume of 20% (v/v) 
trichloroacetic acid and incubated on ice for 10 min. Then the sample was centrifuged at 15,000 rpm 
and 4°C for 10 min and the pellet was washed with 1 ml ice-cold acetone. The sample was centrifuged 
again at 15,000 rpm and 4°C for 10 min, the supernatant was discarded and the pellet was boiled at 
95°C until completely dry. Then, the sample was resuspended in 1X SDS loading buffer (Table 10) for 
SDS-PAGE analysis. If the sample turned yellow, 5 µl Tris pH 8 were added to neutralize the acid. 
Limited proteolysis     Limited proteolysis time courses were performed to identify stable and compactly 
folded protein regions. 50 µg/ml of the protein of interest were digested with either 1 µg/ml trypsin, 
1 µg/ml chymotrypsin, 0.2 µg/ml subtilisin A or 0.1 µg/ml proteinase K at 37°C. Samples were taken at 0, 
1, 2, 4, 8, 15 and 60 min, respectively and the reaction was immediately stopped by the addition of 2X 
SDS loading dye (Table 10) followed by subsequent boiling at 95°C for 10 min. The degraded protein 
bands were separated by SDS-PAGE, excised and analyzed by mass spectrometry. 
Mass spectrometry     Unknown protein bands were identified by peptide mass fingerprinting by the 
Zentrallabor für Proteinanalytik (ZfP), Adolf-Butenandt-Institut, Munich using LC-MS/MS followed by a 
database search to identify the corresponding proteins. 
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2.2.5. Crystallization screening 
Pre-Crystallization Test     The Pre-Crystallization Test (Hampton Research) was used to determine 
appropriate protein concentrations prior to crystallization screening. The assay was performed as 
recommended by the manufacturer. 
Initial crystallization screening     Initial screening was performed at the Crystallization Facility of the 
Max-Planck-Institute of Biochemistry, Martinsried. Using various commercially available as well as in-
house produced screens, sitting drop 96 well plates were set up at either 20°C or 4°C with a drop size 
ranging from 100 nl to 500 nl. Protein to reservoir ratios were adjusted to the specific needs and ranged 
between 1:1 and 3:1. Initial crystals were refined by varying pH values, concentrations of components 
and precipitants, temperature and drop-size either by self-designed user sitting-drop screens at the MPI 
or in-house using 24-well sitting drop plates or 15 well hanging-drop plates (Qiagen). 
2.2.6. Bioinformatic tools 
Protein and gene sequences were retrieved from NCBI or Saccharomyces cerevisiae genome databases 
(SGD). Sequence data was visualized and processed using ApE (Davis & Hammarlund, 2006) and 
Chromas (Technelysium). Multiple sequence alignments were generated using ClustalW2 or 
ClustalOmega (Larkin et al., 2007; Goujon et al., 2010; Sievers et al., 2011; McWilliam et al., 2013) and 
displayed using ESPript (Gouet et al., 1999) or Jalview (Waterhouse et al., 2009). Protein secondary 
structures were predicted by HHpred (Soding et al., 2005) and psipred (Jones, 1999). 
2.3. Expression and purification of specific proteins and protein 
complexes 
2.3.1. Npa3 and variants 
Full-length Npa3 from Saccharomyces cerevisiae was amplified from genomic DNA and subcloned into 
the pOPINI vector (provided by OPPF-UK) containing an N-terminal hexahistidine tag as described in 
2.2.1. Truncated variants of Npa3 were amplified from full-length Npa3 plasmid DNA and either cloned 
into pOPINI vector containing an N-terminal hexahistidine tag or pOPINE vector (provided by OPPF-UK) 
containing a C -terminal hexahistidine tag. Deletions or/and mutations were introduced by overlap 
extension PCR as described in 2.2.1. All variants of Npa3 were transformed and expressed in E. coli 
Rosetta (DE3) (Novagen) as described in 2.2.2. and 2.2.3., respectively. Expression was induced with 
0.5 mM IPTG for 20 h at 20°C. Cells were lysed by sonication in lysis buffer (Table 11). After 
centrifugation at 24,000 x g for 30 min, the cleared lysate was loaded onto a 2 ml Ni-NTA column 
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(Qiagen), pre-equilibrated with nickel wash buffer (Table 11). The column was washed with 10 CV nickel 
wash buffer before elution of the bound protein with 3 CV nickel elution buffer (Table 11). The 
conductivity of the eluate was adjusted to match that of the anion exchange buffer A (Table 11) and 
applied to a MonoQ 10/100 GL column (Amersham) equilibrated with anion exchange buffer A. The 
protein was eluted with a linear gradient over 15 CV from 100 mM to 1 M NaCl in anion exchange 
buffer B (Table 11). Fractions containing Npa3 were pooled and the sample was concentrated for a final 
size exclusion step. Size exclusion chromatography was carried out using either a HiPrep Sephacryl S-300 
HR column (GE Healthcare) or a HiLoad 16/600 Superdex 200 pg column (GE Healthcare) pre-
equilibrated in SEC buffer 100 (Table 11) for all variants except Npa3(1-264∆203-211) were this step was 
performed in SEC buffer 200 (Table 11). Fractions containing Npa3 were pooled and full-length Npa3 
was concentrated to 2-100 mg/ml, flash frozen in liquid nitrogen and stored as 5-20 µl aliquots at -80°C. 
Npa3(1-264∆203-211) was concentrated to 3.7 mg/ml and used for crystallization without freezing.  
2.3.2. Npa3-GPN2 complexes 
Npa3 variants were cloned into pOPINE vector (provided by OPPF-UK) and a stop codon was introduced 
at the 3’ end of the gene to avoid expression of the plasmid encoded C-terminal hexahistidine tag. GPN2 
variants were cloned into pOPINB vector (provided by OPPF-UK) with an N-terminal hexahistidine tag 
and both vectors were cotransformed into E. coli BL21 (DE3) RIL (Stratagene) cells by electroporation as 
described in 2.2.2. Protein expression was carried out as described (2.2.3) using 0.5 mM IPTG for 
induction. Purification was performed as described for full-length Npa3 (2.3.1). 
2.3.3. Iwr1 
Full-length Iwr1, cloned into a pET21b vector with an N-terminal hexahistidine tag was transformed into 
E. coli Rosetta (DE3) (Novagen) cells as described (2.2.2). Protein expression was induced with 0.5 mM 
IPTG for 20 h at 18°C as described (2.2.3). Cells were lysed by sonication in Iwr1 Nickel Lysis buffer 
(Table 12). After centrifugation at 24,000 x g for 30 min, the cleared lysate was loaded onto a 2 ml 
Ni-NTA column (Qiagen) equilibrated with Iwr1 Nickel Lysis buffer. The column was washed four times 
with 10 CV Iwr1 Nickel wash buffer sequentially containing 10, 20, 30 and 40 mM imidazole (Table 12), 
respectively and eluted with 3 CV Iwr1 Nickel elution buffer (Table 12). The eluate was applied to a 
MonoQ 10/100 GL column (Amersham) equilibrated with Iwr1 anion exchange buffer A (Table 12) and 
eluted over a linear gradient of 15 CV from 100 mM NaCl to 1 M NaCl in Iwr1 anion exchange buffer B 
(Table 12). After concentration with a partial buffer exchange using three volumes Pol II buffer (Table 
12), the sample was applied to a Superdex 75 10/300 or Superose 12 10/300 size exclusion column (GE 
Healthcare) equilibrated with Pol II buffer. Fractions containing Iwr1 were pooled and concentrated to 
2-4 mg/ml, flash frozen in liquid nitrogen and stored as 20 µl aliquots at -80°C. 
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2.3.4. Endogenous RNA polymerase II from S. cerevisiae 
Yeast cell lysis     Fermented yeast cell pellets of the Pol II purification strain (Table 5) were provided by 
Stefan Benkert and pellets were thawed in a water bath at a maximum of 30°C. 1 ml 100X PI (Table 10) 
was added to the cell suspension and cells lysis was carried out using beat beaters (Hamilton Beach). For 
this, 200 ml of the cell mixture were added to a metal chamber together with 200 ml of glass beads 
(0.5 mm diameter, BioSpec Products). Air bubbles were removed by stirring gently with a glass rod. The 
chamber was completely filled up with HSB150 (Table 13) before assembly with the impeller. Lysis was 
carried out for 80 min at 4°C with cycles of 30 s on and 90 s off. To avoid warming of the cell mixture the 
lysis chamber was covered with a salt-ice mixture. The lysate was then separated from the beads by 
filtering through a mesh funnel and washed with HSB150. Finally, the lysate was centrifuged twice for 
30 min at 13,690 x g at 4°C. 
Protein purification     The cleared lysate was subjected to ultracentrifugation for 90 min at 76,220 x g 
and 4°C. The aqueous phase was collected and protein precipitation was carried out with 50% (w/v) 
(NH4)2SO4 stirring overnight at 4°C. The solution was then centrifuged twice for 45 min at 34,200 x g and 
4°C and the precipitate was dissolved in 140 ml HSB150 per 100 g pellet by stirring for 1 to 2 h at 4°C. 
The conductivity was adjusted to that of HSB1000/7 (Table 13). The sample was then applied to pre-
equilibrated Ni-NTA resin (Qiagen) and washed with 5 CV HSB1000/7 and 3 CV Ni buffer 7 (Table 13) 
before elution of bound protein with 3 CV Ni buffer 50 and 3 CV Ni buffer 100 (Table 13). Elution 
fractions were pooled and conductivity was adjusted to that of MonoQ150 buffer (Table 13). The 
sample was loaded on a MonoQ 10/100 GL column (GE Healthcare) pre-equilibrated with MonoQ150 
and eluted with a linear gradient over 12 CV to 75% buffer MonoQ2000 (Table 13). Fractions containing 
Pol II were pooled and diluted with 3 volumes Pol II buffer (Table 13) before concentration to around 
1 ml. Then 4-fold molar excess of recombinant Rpb4/7 (for purification protocol see 2.3.5.) were added 
and incubated on ice for 45 min. Finally, the complete assembled Pol II complex was applied to a 
Superose 6 10/300 column (GE Healthcare) equilibrated with Pol II buffer and fractions containing Pol II 
were concentrated to 3-3.8 mg/ml, flash frozen in liquid nitrogen and stored in 20 µl aliquots at -80°C. 
2.3.5.  Rpb4/7 
Protein expression was performed as described in 2.2.3 and expression was induced with 0.5 mM IPTG 
for 16 hours at 20°C. Cells were lysed by sonication in Ni buffer 0 (Table 14) containing 1X PI (Table 10). 
After centrifugation at 16,000 x g for 20 min, the cleared lysate was applied to a pre-equilibrated 
(Ni buffer 0) Ni-NTA agarose column (Qiagen) (Table 14). The column was washed with 5 CV Ni buffer 0, 
3 CV Ni salt buffer, 3 CV Ni buffer 10 and 3 CV Ni buffer 20 (Table 14). Protein was eluted with 3 CV Ni 
buffer 50 followed by 6 CV Ni buffer 200. Fractions containing Rpb4/7 were pooled and applied to a 
Source15Q 16/10 column (GE Healthcare) pre-equilibrated with SourceQ 100 buffer (Table 14). The 
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column was washed with 10 CV SourceQ 100 buffer and the protein was eluted with a linear gradient 
over 10 CV to 1 M NaCl in SourceQ 1000 buffer (Table 14). Finally, fractions containing Rpb4/7 were 
pooled and a size exclusion step was performed using a HiLoad 26/60 Superdex75 pg column 
(GE Healthcare), pre-equilibrated in Pol II buffer (Table 14). Protein was concentrated to 6 mg/ml and 
40 µl aliquots were flash frozen in liquid nitrogen and stored at -80°C. 
2.4. Crystallization 
2.4.1. Crystallization of Npa3∆C∆Loop∙GMPPCP 
Npa3∆C∆Loop (comprising residues 1-264∆203-211) was freshly purified as described in 2.3.1 and 
nucleotide exchange was carried by incubation with 10 mM GMPPCP at 8°C overnight. Crystals were 
grown in a 1.5 ml Eppendorf tube in SEC buffer 200 (Table 11) for 1-3 days at 8°C. Crystals were fished 
directly from the Eppendorf tube and transferred to a spot plate containing 100 µl mother solution. 
Cryo protection was carried out at 8°C as described in 2.4.4. 
2.4.2. Crystallization of Npa3∆C∆Loop∙GDP∙AlFx 
A fresh 50 mM AlFx stock solution was prepared by mixing equal volumes of 1 M NaF and 100 mM AlCl3 
(both dissolved in SEC buffer 200 (Table 11)) followed by an incubation for 30 min at RT. Then, 5 mM 
GDP and 10 mM AlFx were incubated with freshly purified Npa3∆C∆Loop (comprising residues 
1-264∆203-211) overnight at 8°C. Crystals were grown for 1-3 days by hanging drop vapor diffusion at 
8°C with SEC buffer 200 supplemented with 10 mM AlFx as reservoir solution. Cryo protection procedure 
was carried out at 8°C as described in 2.4.4. 
2.4.3. Crystallization of Npa3∆C∆Loop∙GDP 
Npa3∆C∆Loop (comprising residues 1-264∆203-211) was freshly purified as described in 2.3.1 and the 
sample was incubated with 10 mM GDP at 8°C overnight. Crystals were grown for 6-15 days by sitting 
drop vapor diffusion at 20°C with 9 mM HEPES pH 7.0, 45 mM NaCl, 5 mM MgCl2 and 5% (v/v) Jeffamine 
M-600 as reservoir solution. Cryo protection was carried out at 20°C as described in 2.4.4. 
2.4.4. Cryo-protection and freezing 
Crystals were transferred to a spot plate containing 100 µl mother solution. Cryo-protection was carried 
out by step-wise transferring to mother solution containing 35% (v/v) glycerol (steps comprised 
incubation with 20, 40, 60, 80 and 100% of the cryo solution, respectively). Crystals were incubated for 
30 min between every cryo-step before harvesting and flash-cooling in liquid nitrogen.  
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2.5. Data collection and X-ray structure determination 
2.5.1. Data collection 
Diffraction data of crystals Npa3∆C∆Loop∙GDP∙AlFx were collected at beamline X06DA of the Swiss Light 
Source (Villigen, Switzerland) at 100 K and 1.0001 Å, respectively (Table 18). Diffraction data of crystals 
Npa3∆C∆Loop∙GMPPCP and Npa3∆C∆Loop∙GDP were collected at beamline MX1 at EMBL/DESY 
(Hamburg, Germany) at 100 K and 0.99988 Å, respectively (Table 18). 
2.5.2. Experimental phasing  
A single anomalous diffraction experiment from intrinsic sulphur atoms (S-SAD) was performed on the 
same Npa3∆C∆Loop∙GDP∙AlFx crystal as in 2.5.1 at beamline X06DA of the Swiss Light Source in Villigen, 
Switzerland. Diffraction data were collected at 100 K and a wavelength of 2.066 Å at three different χ 
angles (0°, 10° and 20°) as described recently (Weinert et al., 2015) (Table 18). For each dataset 7,200 
images were collected with an increment of 0.1°. Raw data were processed with XDS and the three 
datasets were merged using XSCALE (Kabsch, 2010b; 2010a). The programs SHELXC/D/E of the SHELX 
suite (Sheldrick, 2008) were used for detection of the sulphur atoms and for SAD phasing. 
2.5.3. Molecular Replacement 
The Npa3∆C∆Loop∙GDP structure was solved by molecular replacement using PHASER (McCoy et al., 
2005) with the Npa3∆C∆Loop∙GDP∙AlFx core structure as search model. The number of molecules per 
asymmetric unit were estimated using the program matthews from the CCP4 suite (Collaborative 
Computational Project, 1994). 
2.5.4. Model building and refinement 
The Npa3∆C∆Loop∙GMPPCP structure could be refined using the Npa3∆C∆Loop∙GDP∙AlFx structure with 
phenix.refine (Afonine et al., 2005), because the crystals had the same space group and almost identical 
unit cell parameters.  
Atomic models of all structures were iteratively built with COOT (Emsley & Cowtan, 2004) and 
refined with phenix.refine. Figures were prepared with PyMOL (deLano Scientific). 
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2.6. Functional characterization of Npa3 
2.6.1. Analysis of GTPase activity 
GTPase activity was measured in 96-well plates using the Malachite Green Phosphate Assay Kit 
(BioAssay Systems) as recommended by the manufacturer. 0.15 µM of Npa3 variants were incubated 
with 100 µM GTP (Fermentas) at 37°C and 600 rpm in SEC buffer 200 (Table 11) in a thermomixer. 
Orthophosphate concentrations from at least three independent experiments were determined at 
various time points by measuring the absorption at 620 nm at four different positions within each well 
using an Infinite M1000 plate reader (Tecan) and the values were averaged. Control experiments were 
performed to determine orthophosphate contaminations in the individual solutions and data was 
corrected for this value. 
GTPase activity in the presence of partially unfolded citrate synthase (CS) was measured at 43°C 
in SEC buffer 100 (Table 11) with the pH value adjusted to 7.5 at 43°C. 
2.6.2. Isolation of bound nucleotides 
GTPase-bound nucleotides were isolated either to check nucleotide loading after purification or to 
monitor nucleotide exchange over time after in vitro incubation with varying amounts of GTP-
derivatives.  
For this 125 µM of the purified GTPase were used and, for the latter one, incubated with excess 
of the desired nucleotide in vitro for different time periods at 4°C. Here, unbound nucleotides were 
removed by loading the sample onto a Mini Bio-Spin Chromatography column (BioRad), pre-equilibrated 
with the respective protein buffer, and elution was carried out by centrifugation for 4 min at 1,000 x g in 
a microcentrifuge. Afterwards, the bound nucleotide was released from the protein by denaturation at 
95°C for 5 min. Denatured protein was removed by centrifugation at 15,000 rpm for 10 min and the 
supernatant containing the released nucleotide was used for HPLC analysis (2.6.3). 
2.6.3. High performance liquid chromatography (HPLC) 
Identification and quantification of nucleotides was performed by HPLC. Here, a 50 µl sample containing 
125 µM nucleotide was loaded on a C18 reversed phase column (25 cm x 4.6 mm, 5 µm particle size, 
Sigma-Aldrich) pre-equilibrated in buffer A (Table 15). Elution was carried out at 1 ml/min for 55 min 
before very strongly bound components were eluted with buffer B (Table 15). Retention times for 
nucleotide standards were determined experimentally using 250 µM GTP, GMPPCP, GMPPNP, GDP or 
GMP, respectively. Nucleotides were detected by measuring the absorption at 260 nm. Comparative 
quantification of eluted samples was carried out by peak integral calculation and comparison with 
known standards.  
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2.6.4. Chaperone assay 
Thermal aggregation of citrate synthase (CS), a general chaperone substrate protein, was essentially 
carried out  as described (Buchner et al., 1998) with modifications. An ammonium sulfate solution of CS 
from porcine heart (Sigma) was dialyzed against TE buffer (Table 16) overnight at 4°C. CS was 
concentrated to 17 mg/ml and aliquots were flash frozen in liquid nitrogen. For each experiment an 
aliquot of CS was supplemented with TE buffer to yield a concentration of 30 µM. Possible precipitates 
were removed by centrifugation at 14,000 rpm for 30 min at 4°C and protein concentrations were 
measured again prior to experimental procedure.  
Varying amounts of Npa3 were added to a quartz cuvette containing either 800 µl preheated 
(43°) incubation buffer (Table 16) in the absence of nucleotides or 800 µl pre-heated (43°C) 
SEC buffer  100 (Table 11) (pH 7.5 at 43°C) and 1 mM GMPPCP, GTP or GDP, respectively. The cuvette 
was transferred to a thermostated Fluoromax 3 fluorometer (HORIBA Scientific) and light scattering was 
measured at 360 nm and 43°C to check whether Npa3 aggregates under the assay conditions. If a stable 
baseline was observed, CS (monomer) was added to reach a final concentration of 0.15 µM and CS 
aggregation was measured every 0.2 s for 50 min by light scattering at 360 nm. Data was normalized on 
the baseline and measurement of at least three independent experiments were averaged.  
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2.7. Interaction studies  
2.7.1. In vitro Biotin-Pulldown 
Biotinylation of RNA polymerase II     RNA polymerase II containing a biotin acceptor peptide at the 
N-terminus of Rpb3 was purified as described (2.3.4). Enzymatic biotinylation was carried out in vitro in 
200 µl reactions containing 270 µg of Pol II, 15 µg BirA (thankfully provided by Dr. Laurent Larivière), 
2 mM ATP pH7 and 100 µM biotin supplemented with BirA dilution buffer (Table 17). The mixture was 
incubated for 2.5 h in a thermomixer at 20°C and 600 rpm before buffer exchange to SEC buffer 100 
(Table 11) was carried out using Micro Bio-Spin™ Chromatography columns (BioRad) as recommended by 
the manufacturer. Aliquots of biotinylated Pol II were prepared, flash frozen in liquid nitrogen and 
stored at -80°C. 
Pull-Down of RNA polymerase II associated proteins    3-5 µg of biotinylated Pol II were incubated with 
5-15 times molar excess of the purified putative binding protein at 8°C and 600 rpm overnight (and 
1 mM of the respective nucleotide if required). The mixture was then incubated with 20 µl of pre-
equilibrated magnetic streptavidin beads (Invitrogen) in a thermomixer at 22°C and 750 rpm for 30 min 
and unbound proteins were removed by washing three times with SEC buffer 100 (Table 11) containing 
0.05 % (v/v) NP-40. The supernatant was removed and elution was carried out by adding 15 µl of 1x SDS 
buffer (Table 10) followed by incubation at 95°C for 2 min. The elution fraction was analyzed by SDS-
PAGE as described (2.2.4). 
2.7.2. Native gel electrophoresis 
3 µg of RNA polymerase II were incubated with 3-10 times molar excess of the purified putative binding 
proteins at 8°C overnight. Native gel electrophoresis was carried out at 100 V using the NativePAGE™ 
Novex® Bis-Tris Gel System (Life Technologies) as recommended by the manufacturer. Gels were stained 
using Instant blue (Expedeon). 
2.7.3. Analytical size exclusion chromatography 
Purified, putatively interacting proteins were incubated in 200 µl reactions in the respective protein 
buffers at 20°C for 30 min or at 8°C overnight. The sample was then loaded on a Superose 6 or 
Superose 12 column (GE Healthcare) depending on the size of the proteins. Protein fractions were TCA 
precipitated (2.2.4) if necessary and analyzed by SDS-PAGE as described (2.2.4). 
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2.7.4. Coexpression and His-Affinity purification 
Interactions between various constructs of the GPN-loop GTPases as well as the Pol II nuclear import 
factor Iwr1 were analyzed by coexpression followed by His-tag affinity purification. Therefore electro-
competent BL21 Gold (RIL) cells were cotransformed (2.2.2) with only one of the proteins containing a 
hexahistidine-tag. Protein expression was performed as described (2.2.3) and the cleared cell lysate was 
incubated at 8°C for 25 min with 10 µl magnetic Ni-NTA beads (Life Technologies) equilibrated with Lysis 
buffer (Table 11). The beads were then washed four times with 500 µl Nickel wash buffer (Table 11) 
before elution was performed by incubation with 50 µl Nickel elution buffer (Table 11) for 3 min on ice. 
Samples were then analyzed by SDS-PAGE (2.2.4). 
2.7.5. Tandem affinity purification  
TAP-tagged yeast strains were obtained from Thermo Scientific Open Biosystems (Table 5). Tandem 
affinity purifications (TAP) from 2l yeast cultures were done as described (Puig et al., 2001) by Anja 
Kieser from the Sträßer Lab. 
2.7.6. Immobilized peptide microarrays  
An array of 1,139 15meric peptides covering the complete sequence of RNA polymerase II with an 
overlap of 11 amino acids were synthesized and triplicates were N-terminally immobilized on a glass 
surface via a Ttds-linker by JPT Peptide Technologies, Berlin, Germany. Purified N-terminal hexahistidine 
tagged wild-type Npa3 was pre-incubated with either 10 mM GMPPCP or 10 mM GDP overnight at 4°C 
in SEC buffer 100 (Table 11). Incubation with 10 mM GTP was started 5 min prior to experimental 
procedure. Microarray incubations and data analysis was carried out by JPT Peptide Technologies. 
Microarrays were blocked with blocking buffer (Pierce International, Superblock TBST20) for 60 min, 
washed with TBS containing 0.1% Tween20 (TBS-T) and incubated with 1 mg/ml of the respective Npa3 
sample for 60 min at 4°C. After an additional TBS-T washing step 0.4 μg/ml Penta His antibody Alexa 647 
(Qiagen) were incubated for 45 min followed by washing with 3 mM SSC buffer (JPT Peptide 
Technologies, Berlin, Germany). The microarrays were dried and fluorescence signal was analyzed using 
a Genepix Scanner 4200AL (Molecular Devices) and GenePix spot-recognition software by JPT Peptide 
Technologies. In case of false positive binding, neighboring overlapping peptides containing partially the 
same sequence were also not taken into consideration. 
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3. Results and Discussion 
3.1. Structure and function of Npa3-nucleotide complexes 
3.1.1. Npa3 domain organization and crystallization 
Npa3 contains 385 amino acid residues and consists of a central GTPase core (residues 1-41, 83-184, and 
225-263), two protein insertions (‘insertion 1’ and ‘insertion 2’ containing residues 42-82 and 185-224, 
respectively), and a C-terminal tail (residues 264-385) (Figure 4A). The GTPase core harbors the motifs 
G1-G5 that are required for GTP binding and hydrolysis (Bourne, et al., 1991). The C-terminal tail is 
poorly conserved among eukaryotes and is absent in archaea. Because efforts to crystallize full-length 
Npa3 failed, we removed the C-terminal tail and part of a loop (residues 203-211 in insertion 2) that is 
predicted to be disordered and absent in most eukaryotic homologs (variant Νpa3ΔCΔLoop, comprising 
residues 1-202 and 212-264). We co-crystallized Νpa3ΔCΔLoop (Figure 4) with the non-hydrolyzable GTP 
analog GMPPCP, but also with GDP, and with GDP and AlFx (‘GDP∙AlFx’), which mimics the pentavalent 
transition state (Wittinghofer, 1997). 
 
 
 
Figure 4| Npa3 domain organization, purification and crystallization.  
(A) Schematic representation of Npa3 from the yeast Saccharomyces cerevisiae. NES: Nuclear export sequence. The color-
code is used throughout the figures. (B) Purification of Npa3∆C∆Loop. The chromatogram of the final gel filtration step 
(HiPrep Sephacryl S300) and the corresponding SDS gel of the peak fraction is shown. (C) Crystals of Npa3 in complex with 
various nucleotides. 
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Figure 5| X-ray diffraction and structure solution. 
(A) Diffraction image of Npa3∆C∆Loop∙GDP∙AlFx in the S-SAD (left panel) and native diffraction experiment (right 
panel). (B) Structure solution of Npa3∆C∆Loop∙GDP∙AlFx using SHELX revealed a clear solution (CCall=50.72, CCweak=28.5, 
left panel). The occupancy of 17 sulfur sites is shown in the middle panel (red areas, with occupancies below 30% were 
discarded as noise or bound solvent molecules). The anomalous signal vs resolution is shown in the right panel and 
data >2.7 Å (d’’/sig > 1.2) were used for further processing. (C) Initial density of the S-SAD experiments shows clearly 
defined densities for side-chains. Shown is a representative portion of the initial density before refinement with the 
high-resolution native-data set. (D) Diffraction images of GMPPCP- (left panel) and GDP- bound (right panel) crystals. 
3.1.2. Structure determination of Npa3 complexes 
The structure with GDP∙AlFx was solved using single anomalous diffraction from intrinsic sulfur atoms 
(Figure 5) and a protein model was built and refined to a free R-factor of 23.9% at 1.85 Å resolution 
(Table 18). The model was used to solve the structures containing GMPPCP, or GDP, which were refined 
to free R-factors of 22.7% and 27.6% at 2.2 Å and 2.3 Å resolution, respectively (Table 18). The electron 
density of the GDP∙AlFx complex was not clearly interpretable in the active site region, where it showed 
a mixture of different nucleotide configurations. Thus this structure was discarded, although the protein 
model was excellent. The structures containing GMPPCP or GDP showed very well defined densities for 
bound nucleotides, represented defined enzyme states, showed great stereochemistry, and were used 
for further analysis. The structures are relevant for all eukaryotic orthologs because Npa3 is highly 
conserved, with 50% of the residues in the crystallized variant being identical between S. cerevisiae and 
human enzymes (Figure 6A and C). The structures revealed a closed GDP-bound and open GMPPCP-
bound state (Figure 6B) that are described in the following sections (3.1.3 and 3.1.4). 
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Figure 6| Crystal structures of Npa3 in GDP- (closed) and GMPPCP-bound (open) forms. 
(A) Amino acid sequence alignment of Npa3 from S. cerevisiae (S.c.), with eukaryotic homologs from S. pombe (S.p.),  
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Table 18| X-ray diffraction data collection and refinement statistics 
 Native S-SAD 
 GDPa GMPPCPa GDP-AlFx
b GDP-AlFx
b, c  
Data collection     
Space group C2221 P41212 P41212 P41212 
Cell dimensions   
a, b, c (Å) 
 
108.0, 119.2, 
347.5 
 
116.2, 116.2, 56.8 
 
116.2, 116.2, 55.9 
 
116.2, 116.2, 55.9 
Wavelength (Å) 0.99988 0.99888 1.0001 2.066 
Resolution (Å) 50-2.3 (2.36-2.3)d 50-2.2 (2.26-2.20)d 80-1.85 (1.90-1.85)d 50-2.15 (2.21-2.15)c 
Rsym (%) 5.7 (126.9) 4.5 (155) 3.8 (145.6) 5.2 (89.8) 
I/σI 20.16 (1.88) 28.50 (1.94) 38.32 (2.16) 66.37 (2.00) 
Completeness (%) 99.7 (99.8) 99.5 (98.0) 100 (100) 98.2 (79.9) 
Redundancy 7.15 (6.91) 14.11 (13.12) 14.39 (14.42) 63.07 (7.31) 
CC (1/2)
e (%) 100 (69.0) 100 (83.2) 100 (72.0) 100 (62.3) 
Refinement     
Resolution (Å) 45.3-2.3 36.8-2.2 46.2-1.85  
No. reflections 99,343 20,172 33,217  
Rwork/ Rfree (%) 23.8/27.6 21.4/22.7 20.1/23.9  
No. atoms     
   Protein 12065 1998 2036  
   Nucleotide  168 32 28  
   AlFx - - 4  
   Mg2+ 6 1 1  
   Lauric acid - 14 14  
   Glycerol 24 12 12  
   Water 121 5 108  
B-factorsf (Å2)     
   Protein 83.5 121.2 59.4  
   Nucleotide  69.6 123.6 57.6  
   AlFx - - 107.1  
   Mg2+ 64.2 166.6 104.7  
   Lauric acid - 108.0 49.7  
   Glycerol 107.7 145.2 63.8  
   Water 60.1 110.7 53.5  
R.m.s deviations     
    Bond lengths (Å)  0.011 0.007 0.008  
    Bond angles (°) 1.29 1.15 1.18  
aDiffraction data were collected at beamline MX1 at EMBL/DESY, Hamburg, Germany and processed with XDS (Kabsch, 2010b).  
bDiffraction data were collected at beamline X06DA, Swiss Light Source, Switzerland and processed with XDS (Kabsch, 2010b).  
cData are merged form three data sets, measured at different χ angles (0°, 10°, 20°) from a single crystal.  
dNumbers in parenthesis refer to the highest resolution shell.  
eCC1/2 = percentage of correlation between intensities from random half-datasets (Karplus & Diederichs, 2012).  
fThe average over all copies in the asymmetric unit is given. 
GPN1 from H. sapiens (H.s.) and the archaeal homolog Pab0955 from P. abyssi (P.a.). Secondary structure elements are 
indicated above the sequence (cylinders: α-helices; arrows: β-strands). Amino acid numbering above the sequence 
corresponds to Npa3 from S.c. Invariant residues are in green and conserved residues in yellow. Motifs G1-G5 and 
insertions 1 and 2 are marked with bars, residues of the hydrophobic pocket with black squares, residues involved in 
nucleotide-binding with asterisks, and residues involved in magnesium binding with pink spheres. (B) Ribbon 
representation of the closed (GDP-bound, left) and open (GMPPCP-bound, right) conformation. The G motifs and insertion 
regions are colored according to (A). A fatty acid bound to the hydrophobic pocket that is opened in the Npa3∙GMPPCP 
structure is shown as slate blue sticks. Missing residues are indicated with dashed lines. (C) Surface conservation of Npa3 in 
the closed, GDP-bound (left panels) and open, GMPPCP-bound (right panels) state. Invariant residues are shown in green, 
conserved residues in yellow, variable residues in grey. 
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3.1.3. Npa3∙GDP structure shows eukaryote-specific features 
The Npa3 core consists of a central, six-stranded parallel β-sheet surrounded by helices (Figure 6B and 
Figure 7). The two insertion regions extend the Npa3 core, resulting in an overall L-like shape of the 
enzyme. The asymmetric unit of the Npa3∙GDP crystals contains six enzymes that differ only slightly in 
regions forming crystal contacts. The Npa3∙GDP structure resembles the homologous archaeal structure 
Pab0955∙MgGDP (Gras, et al., 2007) (PDB-code 1YRB), but also reveals major differences in insertions 1 
and 2 (Figure 7) and in regions connecting the core to insertion 2. A single residue links strand β7 in the 
core to the C-terminal end of helix α10, which is bent by ~50° (Figure 7A and B). In the archaeal 
structure, strand β7 is shorter and the linker region to α10 comprises five residues, allowing for a 
straight conformation of the helix. Whereas helices α9 and α10 in Npa3∙GDP lie side by side, they are 
tilted in the archaeal structure (Figure 7A and C). Helix α3 in insertion 1 of Npa3∙GDP is apparently  
 
 
 
 
Figure 7| Superposition of Npa3∙GDP (blue) and the archaeal GPN-loop GTPase Pab0955∙GDP (green) reveals 
eukaryote-specific structural features.  
(A) Superposition of overall structures from Npa3∙GDP and Pab0955∙GDP (pdb code: 1YRB,(Gras et al., 2007)) shown as 
front view (left) and side view (right). Significant differences between the two structures are indicated with black 
arrows and the insertion regions are shown with dashed lines. Boxes highlight areas shown in B-D. (B) The linker 
between strand β7 and helix α10 is shorter in Npa3 leading to a strong bending of helix α10. (C) Helix α9 of Npa3 is 
rotated, leading to significant differences of insertion 2 compared to the archaeal GPN-loop GTPase. (D) Helix α3 of 
insertion 1 is rotated and the GPN-loop is shifted. 
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rotated by 37° towards the core, and helix α4 and the GPN-loop are shifted by ~3 Å towards the G3 
motif (Figure 7A and D).  
Taken together, the core of the eukaryotic enzyme generally resembles its archaeal counterpart, 
whereas the two insertions differ significantly. 
3.1.4. Npa3∙GMPPCP structure reveals novel open conformation 
Our Npa3∙GMPPCP structure reveals a novel open conformation that differs significantly from the 
Npa3∙GDP structure (Figure 6B and Figure 8). Both insertions are rearranged and the position of helix α7 
is changed, opening an extended hydrophobic pocket. Insertion 2 adopts a different fold, and remotely 
resembles the helical bundle of the N domain of the prokaryotic GTPase Ffh from T. aquaticus (pdb-
code 1LS1) (Ramirez et al., 2002). In the GMPPCP-bound state, residues D189 of insertion 2 and C179 
show peptide flips (Figure 8B and E) that enable a straight conformation of helices α8 and α9 and the 
formation of a single helix. Helix α10, which is bent in the Npa3∙GDP structure, adopts a straight 
conformation, and helix α7 is rotated by ~15° (Figure 8A-C and F). This disrupts a methionine-rich 
hydrophobic core formed between helices α7, α8, and α9 that kept the pocket closed in the Npa3∙GDP 
structure (Figure 8C). Rotation of helix α7 enables it to hydrogen bond to residue E112, which no longer 
interacts with Q110 in motif G3 and N72 in the GPN-loop, as observed in the closed Npa3∙GDP structure 
(Figure 8F). Mutation of any one of these residues (E112, Q110, N72) is lethal in yeast (Forget, et al., 
2010; Staresincic, et al., 2011; Alonso, et al., 2013). In addition, insertion 1 is changed in the 
Npa3∙GMPPCP structure, including motif G3, which binds the GPN-loop (Figure 8D). Insertion 1 is more 
flexible than in the GDP-bound structure. Its hydrogen bonds with Y48 to D106 (G3) and with Y60 to the 
carbonyl of P71 (GPN-loop) are lost, helix α3 is unfolded, and residues 64-69 are mobile. Positioning of 
insertion 1 apparently involves a novel “DIRD” motif that comprises the invariant residues D53, I54, R55, 
and D56 (Figure 8D). The DIRD motif is, along with the GPN motif, the most highly conserved region 
within the sequence of the yeast Npa3 paralogs GPN2 and GPN3 (Figure 9). Residue N38 in motif G2 
bridges between D106 in motif G3 and D53 in the DIRD motif to keep helix α2 and thus insertion 1 in 
close proximity to the core (Figure 8D). The side chain of D56 in the DIRD motif is flipped in the 
Npa3∙GMPPCP structure and hydrogen bonds to D53, possibly stabilizing the changed position of 
insertion 1. Taken together, Npa3 can adopt two very different conformations, a closed conformation 
observed with bound GDP, and a novel open conformation observed when the GTP analog GMPPCP is 
bound. 
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Figure 8| Superposition of closed Npa3∙GDP (blue) and open Npa3∙GMPPCP (grey) structures. 
Magnesium ions are shown as blue (Npa3∙GDP) or grey (Npa3∙GMPPCP) spheres, water molecules as small red spheres and 
hydrogen bonds as dashed lines. (A) Superposition of overall structures from Npa3∙GDP and Npa3∙GMPPCP shown as front 
view (left) and side view (right). Significant differences between the two structures are indicated with black arrows and 
boxes highlight areas shown in B-F (B) Peptide flip of D189 enables pocket opening and the formation of a single helix from 
helices α8 and α9. (C) Conformational changes in insertion 2 and helix α7 facilitate the opening of an extended, 
hydrophobic pocket. (D) A set of residues in insertion 1 rearranges, including the GPN-loop and a DIRD-motif leading to 
increased flexibility of this region in the GMPPCP-bound state. (E) Pocket opening allosterically alters the active site via the 
G4 motif. (F) Conformational changes in helix α7 are linked to the G3 motif and the GPN-loop. 
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Figure 9| Amino acid sequence alignment of GPN-loop GTPases Npa3 from S. cerevisiae, and its paralogs GPN2 and GPN3. 
Secondary structure elements are indicated above the sequence (cylinders: α-helices; arrows: β-strands; dashed line: no 
structural data available). Numbering above the sequence corresponds to Npa3. Invariant residues are in green whereas 
conserved residues are in yellow. The G-domains G1-G5 and insertion regions are marked with bars, residues of the 
hydrophobic pocket with black squares, residues involved in nucleotide binding with asterisks and residues involved in 
magnesium binding are marked with pink spheres. 
 
 
3.1.5. Nucleotide binding and conformational states 
The two structures reveal atomic details of how Npa3 binds GMPPCP or GDP using its motifs G1-G5 
(Figure 10). In the Npa3∙GMPPCP structure, strong electron density corresponding to the γ-phosphate of 
the nucleotide is observed (Figure 10A). The octahedral coordination of the magnesium ion by oxygen 
atoms of the β- and γ-phosphate of GMPPCP and Thr17 of the G1 motif (P-loop, 10-GMAGSGKT-17) is 
completed by three water molecules, hydrogen bonded by D40 in the G2 motif (36-VINLD-40) and D106 
and T107 in the G3 motif (106-DTPGQ-110) (Figure 10B). After GTP hydrolysis an additional water 
molecule apparently replaces the coordination sphere previously occupied by the γ-phosphate oxygen 
of GMPPCP (Figure 10C). Residues in the G1 motif stabilize the negative charge of the phosphate ions. 
Guanine specificity is conferred by hydrogen bonds of the Watson-Crick edge of GMPPCP to motifs G4 
(173-NKTD-176) and G5 (238-SSF-240). F240 in motif G5 stacks against the guanine base. Thus our 
structures explain how Npa3 specifically binds GDP and the GTP analog. 
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3.1.6. Catalytic mechanism of Npa3 
The catalytic mechanism for hydrolysis of GTP to GDP and inorganic phosphate by GPN-loop GTPases 
was suggested for the archaeal enzyme (Gras, et al., 2007). To probe the catalytic mechanism in the 
eukaryotic system we prepared Npa3 variants with point mutations and tested their ability to hydrolyze 
GTP (Figure 11A). Whereas residue D106 in motif G3 stabilizes the Mg2+ ion, residue D40 in motif G2 
positions the nucleophilic water molecule (N) (Figure 11B), as observed for the bacterial GTPase FtsY 
(Voigts-Hoffmann et al., 2013). Consistent with this, the D106A and D40A variants of Npa3 were both 
inactive (Figure 11A). 
Figure 10| Nucleotide-binding pocket and active site. 
(A) Initial unbiased Fo-Fc difference electron density of GMPPCP and the magnesium ion, including coordinated water 
molecules contoured at 3σ (green mesh). The final Npa3∙GMPPCP model is superimposed. Motifs G1-G5 are color-
coded as in Fig. 4A. Water molecules are shown as small red spheres, magnesium ions as pink spheres and hydrogen 
bonds as dashed lines. (B-C) Nucleotide interaction network of Npa3 with GMPPCP (B) and GDP (C). Metal-ion-ligand 
interactions are shown as solid black lines. 
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Figure 11| Catalytic mechanism of Npa3.  
(A) GTPase activity of Npa3 mutants. Bars represent free orthophosphate concentrations after 40 min at 37°C. Kinetics are 
shown for wild-type Npa3 (grey) and the crystallized variant Npa3ΔCΔLoop (blue). (B) Schematic mechanism of GTP 
hydrolysis. The active site of Npa3∙GMPPCP is shown. The GPN-loop of monomer B is modeled by superpositioning of two 
Npa3∙GMPPCP enzymes on the archaeal Pab0955 dimer (PDB-code: 1YRB) (Gras, et al., 2007). The nucleophilic water (N) 
that attacks the γ-phosphate and the buttressing water (B) are superimposed from the Npa3∙GDP structure. Hydrogen 
bonds are shown as dashed black lines, potential hydrogen bonds derived from dimer modeling as dashed grey lines, water 
molecules as small red spheres, the magnesium ion as pink sphere and metal ion-ligand interactions as solid black lines. 
The catalytic mechanism was suggested to also involve the GPN-loop. In the archaeal enzyme 
dimer, the GPN-loop of one monomer protrudes into the active site of the other monomer, where it 
binds the hydrolyzed GTP γ-phosphate (Gras, et al., 2007) (Figure 3). Indeed, Npa3 variants with a 
mutation of the GPN-loop (70GPN72 changed to 70AAA72) lacked GTPase activity, supporting the 
suggested mechanism (Figure 11). In addition, a single Q110L mutation, predicted to disrupt buttressing 
of the GPN-loop by residue Q110 in motif G3, was also inactive. All mutated residues shown here to be 
involved in catalysis in vitro are essential in vivo (Forget, et al., 2010; Staresincic, et al., 2011). Further, 
purified Npa3 formed a dimer, and in the Npa3∙GDP crystals, two symmetry-related complexes formed a 
dimer that contained the GPN-loop of one monomer in the active site of the other monomer, as 
observed in the archaeal structure. 
From these results emerges the catalytic mechanism of GPN-loop GTPases. The nucleophilic 
water molecule (N) is positioned in-line of the scissile phosphodiester bond at the γ-phosphate of GTP 
by residue D40 and a buttressing water molecule bound to the backbone of residue G109 of motif G3, 
which stabilizes the GPN-loop via residue Q110 and positions it in the active site of monomer B. The 
negative charge in the transition state of the SN2 reaction is partially neutralized by a magnesium ion 
that is positioned also by D106 in motif G3. Modeling of the Npa3 dimer, based on the archaeal dimer 
structure, shows that the GPN-loop of one monomer protrudes into the active site of the other 
monomer even in the open enzyme conformation, and could bind the hydrolyzed orthophosphate. 
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Figure 12| A highly conserved, putative peptide-binding pocket is exposed upon transition from the closed to the 
open state.  
(A) Initial unbiased Fo-Fc difference electron density for lauric acid (slate blue sticks) bound to the putative peptide-
binding pocket of Npa3, contoured at 2σ (green mesh). (B) Highly conserved surface of the putative peptide-binding 
pocket. Invariant residues are in green, conserved residues in yellow, and variable residues in grey. Insertion regions and 
G motifs are depicted. Lauric acid is shown as slate blue spheres. 
3.1.7. A putative peptide binding pocket 
In the Npa3∙GMPPCP structure we observed a strong, extended electron density in the hydrophobic 
pocket that is created upon the transition from the closed to the open state of the enzyme (Figure 12A). 
This density could be explained by a molecule of lauric acid, a C12 fatty acid that may have been derived 
from hydrolysis of Tween20, a lauric acid ester that was present in the lysis buffer. The fatty acid 
carboxyl group binds residues N144 and W186, whereas the acid tail is close (within 5 Å) to the 
hydrophobic residues Y137, V139, F150, M154, A157, C158, L161, M168, V170, F172, W186, F190, L225, 
F228, Y229 and L232. The surface of the pocket is highly conserved between species (Figure 12B). 
In the cellular context, it is likely that the newly observed hydrophobic pocket of Npa3 binds 
hydrophobic peptides. GPN1 is known to interact with assembling Pol II subunits (Boulon, et al., 2010; 
Forget, et al., 2010), which expose hydrophobic peptide regions, because large hydrophobic subunit 
interfaces are present in the functional Pol II assembly (Armache, et al., 2005). We therefore considered 
that the hydrophobic pocket naturally binds to hydrophobic protein regions as described for molecular 
chaperones that prevent misassembly and aggregation of multisubunit complexes (Ellis, 2013; Kim, et 
al., 2013). Indeed, modeling showed that hydrophobic peptides may be accommodated in the pocket in 
an extended conformation. 
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3.1.8. Npa3 has GTPase stimulating chaperone activity 
The existence of a putative hydrophobic peptide-binding pocket prompted us to ask whether Npa3 has 
chaperone activity. We tested for chaperone-like activity of Npa3 in vitro with a standard assay that 
uses citrate synthase (CS) as a general chaperone substrate protein, whose temperature-induced 
aggregation is suppressed when a chaperone is added (Buchner, et al., 1998). Indeed, Npa3 was able to 
suppress temperature-induced aggregation of CS (Figure 13A). We next investigated whether this effect 
was nucleotide-dependent. Because no GTPase activity was observed in the standard chaperone assay 
buffer (not shown), we changed to SEC buffer 100 (Table 11) and adjusted the pH value to 7.5 at 43°C. 
This buffer supported GTP hydrolysis, albeit at about 5-fold reduced levels, apparently due to the 
increased temperature of 43°C (compare wild-type Npa3 in Figure 11A and Figure 13C). Chaperone-like 
activity was readily observed in the presence of nucleotides, but no significant differences occurred 
after the addition of GMPPCP, GTP, or GDP (Figure 13B).  
These data indicated that the open Npa3 conformation is not induced by GTP binding but rather 
by binding of hydrophobic unfolded protein peptide regions. Pocket opening in Npa3 goes along with a 
conformational change in motifs G3 (Figure 8C and F) and G4 (Figure 8B and E) that widens the 
nucleotide-binding pocket. Indeed, a similar conformational change in Ffh from T. aquaticus, one of the 
closest folding homologs of Npa3, was proposed to allosterically alter the active site via the G4 motif 
(Freymann, et al., 1997). Thus we speculated that peptide binding would allosterically widen the active 
center, may promote GDP displacement, and facilitate GTP binding and thus may lead to an increased 
GTP turnover rate.  
To investigate this, we analyzed the GTPase activity of Npa3 both in the presence and in the 
absence of partially unfolded CS at 43°C. Indeed, the presence of CS stimulated GTPase activity more 
than four-fold, providing a link between chaperone and GTPase functions (Figure 13C).  
Taken together, our results show that Npa3 exhibits chaperone-like activity and indicate that it 
can bind unfolded protein peptide regions without GTP addition. They also suggested that peptide 
binding triggers opening of the pocket, promotes GDP displacement and thus facilitates GTP rebinding, 
whereas peptide release is regulated by GTP hydrolysis. 
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3.2. Analysis of Npa3 interactions with RNA polymerase II 
 
3.2.1. Npa3 does not interact with complete assembled Pol II complexes 
It is not clear whether Npa3 functions in assembly or nuclear import of Pol II (Wild & Cramer, 2012). 
Binding of Npa3/GPN1 to Pol II subunits and subassemblies has been shown (Jeronimo, et al., 2007; 
Boulon, et al., 2010; Forget, et al., 2010; Carre & Shiekhattar, 2011; Staresincic, et al., 2011) but it’s 
unknown whether it also binds the mature, complete assembled polymerase. Because only complete 
assembled Pol II is imported into the nucleus (Boulon, et al., 2010; Czeko, et al., 2011), a nuclear import 
factor likely interacts with the assembled Pol II complex. To investigate this, we tested for Npa3 binding 
to complete assembled, purified, endogenous Pol II from S. cerevisiae with both analytical gel filtration 
and pull-down experiments (Figure 14). Npa3 did neither interact with assembled, mature Pol II (Figure 
14A and B), nor with a Pol II complex bound to the nuclear import factor Iwr1 (Figure 14B).  
Figure 13| Npa3 has chaperone-like activity that stimulates GTPase activity. 
(A) Npa3 has chaperone-like activity in vitro. Npa3 suppresses thermally induced (43°C) aggregation of the general non-
native chaperone-substrate protein citrate synthase (CS). Different amounts of wild-type Npa3 were added as indicated on 
the right. (B) Chaperone-like activity of Npa3 is independent of added nucleotides under limiting conditions. 1 mM of 
GMPPCP, GTP, or GDP, were added and relative CS aggregation in the presence of 0.5 x molar amounts of Npa3 was 
determined after 30 min. (C) GTPase activity of Npa3 is stimulated > 4-fold in the presence of the non-native chaperone-
substrate protein citrate synthase. Free orthophosphate concentrations were determined after 40 min at 43°C (compare 
Methods). 
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Figure 14| Npa3 does neither interact with assembled Pol II nor with a Pol II-Iwr1 complex. 
(A) Analytical gel filtration (Superose 6 10/300, GE healthcare) of Pol II and Npa3-nucleotide complexes. Purified  Pol II 
(12 µg), 5x molar excess of purified Npa3 and 1 mM GMPPNP (upper panel) or 1 mM GDP (lower panel) were incubated 
overnight at 4°C for nucleotide exchange and potential complex assembly. After gel filtration the fractions were TCA 
precipitated and analyzed by SDS-PAGE. Marker: (top to bottom: 170, 130, 100, 70, 55, 40, 35, 25, 15, 10 kDa) (B) 
Streptavidin pull-down of biotinylated Pol II and associated factors. Purified Pol II was biotinylated at Rpb3 and 4.2 µg Pol II 
were incubated with 15x molar excess of Npa3 and 1 mM GMPPCP or GDP overnight at 8°C or with 1 mM GTP for 30 min at 
RT and 600 rpm. Pol II-Iwr1 complexes were preformed by incubation with 5x molar excess of Iwr1 over Pol II at RT for 45 
min before Npa3 was added. 
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3.2.2. Npa3 binds peptides derived from hydrophobic Pol II subunit interfaces 
Because Npa3 was implicated in biogenesis of Pol II, we investigated whether Npa3 may act as an 
assembly chaperone for Pol II. Unfortunately, this could not be tested directly, because Pol II is not 
available in recombinant form and endogenous Pol II is not amenable to chaperone assays. We could 
however ask whether Npa3 would be able to bind peptides derived from Pol II subunits that may be 
exposed during Pol II assembly. To address this in an unbiased fashion, we used peptide arrays to screen 
a total of 1,139 Pol II-derived 15 residue long peptides (overlap of 11 residues, respectively; Table 20) 
covering all regions of all 12 Pol II subunits, for binding Npa3 in the presence of GMPPCP, GTP, or GDP. 
In this assay 55 peptides bound Npa3 significantly (signal intensity >3.5) (Table 19). The binding 
efficiency generally did not depend on nucleotides (Figure 16-Figure 20 and Figure 25), consistent with 
the model that opening of the hydrophobic pocket is triggered by peptide binding. The 55 Npa3-binding 
peptides stemmed from all Pol II subunits except Rpb3, Rpb6, and Rpb12. When we mapped the 
Npa3-binding peptides onto the Pol II structure (Figure 15), we found that 42 of the 55 peptides were at 
least partially located in interfaces between Pol II subunits and were enriched in hydrophobic residues 
(Table 19, Figure 16-Figure 20).  
 
 
 
 
Figure 15| Location of Npa3-binding peptides in the assembled Pol II complex. 
Npa3 binding to Pol II peptides is depicted in yellow (signal intensity 3.5-3.75), orange (3.75-4) and red (>4) whereas 
unbound regions are in grey (<3.5). Zinc atoms are shown as cyan spheres and the magnesium ion as pink sphere. A 
schematic representation of the 12 Pol II subunits Rpb1-Rpb12 in the folded Pol II complex is shown on the right. (pdb-code 
1WCM) (Armache et al., 2005). 
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Table 19| Npa3-binding Pol II-derived peptides 
Pol II subunit Peptide No Start a.a. End a.a. Sequence Interface 
Rpb1 3 9 23 APLRTVKEVQFGLFS Yes 
  20 77 91 CPGHFGHIDLAKPVF Yes 
  21 81 95 FGHIDLAKPVFHVGF Yes 
  24 93 107 VGFIAKIKKVCECVC Yes 
  26 101 115 KVCECVCMHCGKLLL No 
  32 125 139 ALAIKDSKKRFAAIW No 
  57 225 239 NEVFSRPEWMILTCL Yes 
  85 337 351 RGNLMGKRVDFSART Yes 
  105 417 431 YSKRAGDIQLQYGWK Yes 
  106 421 435 AGDIQLQYGWKVERH Yes 
  115 457 471 AHRVKVIPYSTFRLN Yes 
  193 769 783 SVEGKRIAFGFVDRT Yes 
  194 773 787 KRIAFGFVDRTLPHF Yes 
  201 801 815 ENSYLRGLTPQEFFF Yes 
  234 933 947 YKQLVKDRKFLREVF Yes 
  261 1041 1055 AFDWVLSNIEAQFLR Yes 
  275 1097 1111 GVPRLKEILNVAKNM No 
  305 1217 1231 KQTFKNDLFVIWSED No 
  375 1497 1511 DSGSNDAMAGGFTAY Lacking in 1WCM 
Rpb2 463 116 130 EARLRNLTYSSGLFV Yes 
  464 120 134 RNLTYSSGLFVDVKK No 
  465 124 138 YSSGLFVDVKKRTYE No 
  481 188 202 DLYKLKECPFDMGGY Yes 
  482 192 206 LKECPFDMGGYFIIN Yes 
  525 364 378 ITQLEGFESRKAFFL No 
  527 372 386 SRKAFFLGYMINRLL No 
  539 420 434 LFKKLTKDIFRYMQR No 
  547 452 466 TITSGLKYALATGNW  No 
  630 784 798 NYNVRMDTMANILYY  Yes 
  645 844 858 SSIDRGLFRSLFFRS Yes 
  646 848 862 RGLFRSLFFRSYMDQ  Yes 
  647 852 866 RSLFFRSYMDQEKKY Yes 
  730 1184 1198 GCDNKIDIYQIHIPY Yes 
Rpb4 833 54 68 EARLVIKEALVERRR  Yes 
  834 58 72 VIKEALVERRRAFKR  Yes 
  837 70 84 FKRSQKKHKKKHLKH  Yes 
  855 142 156 KNTMQYLTNFSRFRD  Yes 
Rpb5 892 69 83 ISKFPDMGSLWVEFC  No 
  921 185 199 ALYLGLKRGEVVKII No 
Rpb7 970 11 25 ITLHPSFFGPRMKQY Yes 
  971 15 29 PSFFGPRMKQYLKTK Yes 
  975 31 45 LEEVEGSCTGKFGYI Yes 
  976 35 49 EGSCTGKFGYILCVL Yes 
  977 39 53 TGKFGYILCVLDYDN Yes 
  984 67 81 SAEFNVKYRAVVFKP Yes 
Rpb8 1036 104 118 FEEVSKDLIAVYYSF Yes 
  1037 108 122 SKDLIAVYYSFGGLL Yes 
  1038 112 126 IAVYYSFGGLLMRLE  Yes 
  1039 116 130 YSFGGLLMRLEGNYR  Yes 
  1043 132 146 LNNLKQENAYLLIRR  Yes 
Rpb9 1047 2 16 TTFRFCRDCNNMLYP  Yes 
Rpb11 1106 46 60 IRAELLNDRKVLFAA  Yes 
  1108 54 68 RKVLFAAYKVEHPFF  Yes 
  1109 58 72 FAAYKVEHPFFARFK Yes 
  1110 62 76 KVEHPFFARFKLRIQ Yes 
 
    RESULTS AND DISCUSSION 
55 
 
 
We therefore mapped residues in subunit interfaces in the mature Pol II complex using CoCoMaps 
(https://www.molnac.unisa.it/BioTools/cocomaps), and compared them with peptides that are bound 
by Npa3. In the following sections a detailed analysis of Npa3 binding peptides derived from Rpb1, 
Rpb8, Rpb11, Rpb4 and Rpb7 is provided. 
3.2.3. Npa3 binds peptides derived from Rpb1 interfaces 
We identified numerous Npa3-binding peptides within the interface between the two largest Pol II 
subunits, Rpb1 and Rpb2 (Figure 16). In particular, many peptides mapped to the extended Rpb1-Rpb2 
interface within the clamp domain of Pol II (Rpb1 peptides 3, 20, 21, 24, 57, 85, and Rpb2 peptide 730). 
We also detected three Npa3-binding peptides (193, 194, 201) in the funnel domain of Rpb1. 
Npa3 interacted also with peptides from subunits Rpb8, Rpb9 and Rpb11 that are located in 
critical interfaces with Rpb1.  
 
 
 
 
 
 
 
 
 
 
 
    RESULTS AND DISCUSSION 
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    RESULTS AND DISCUSSION 
57 
 
 
Figure 16| Npa3 binds peptides derived from Rpb1 interfaces. 
(A) Boxplot representation of the heatmap describing the Npa3 peptide-binding landscape of Rpb1-derived peptides in the 
presence of GTP, GDP and GMPPCP, respectively. Control experiments were performed without Npa3 and nucleotides to test 
cross-reactivity of the anti-His antibody. Intensity distribution is shown in logarithmic scale. Peptides with signal intensity <3.5 
were defined as unbound (grey area). Red boxes indicate false-positive binding of the antibody to the peptides, either directly or 
in overlapping regions. These peptides were not used for further analysis. The sample intensity distribution corresponds to all 
Rpb1-derived peptides. Peptide numbers are shown for Npa3-binding peptides above the boxplots. Box labeled with 9x shows a 
representative portion of nine identical regions of CTD peptides (B) Surface representations of Rpb1 show that Npa3 interacts 
with hydrophobic peptides located at Rpb1 interfaces. Numbers correspond to the peptide numbers from the array (see Table 19 
for Npa3-binding peptides and Table 20 for all tested peptides). Left panel: Npa3 binding to Rpb1-peptides is depicted in yellow 
(signal intensity 3.5-3.75), orange (3.75-4) and red (>4) whereas unbound regions are in grey (<3.5). Npa3 binding peptides 
derived from other Pol II subunits that form interfaces with Rpb1 are shown as sticks and colored according to their signal 
intensity as described (compare Figure 17, Figure 18 and Figure 25 for analysis of these subunits). Middle panel: Rpb1 interfaces 
are shown in black. Dashed lines indicate positions of interacting subunits in the assembled Pol II complex. Right panel: Surface 
charge of Rpb1. White solid lines highlight hydrophobic interface regions. (C) Rpb1-Rpb2 interfaces bound by Npa3 in the peptide 
array.  Left panel: Interface between Rpb1 (grey) and Rpb2 (brown). The extended clamp interface is highlighted. The clamp and 
funnel domain is shown in the middle and right panel, respectively. Residues involved in the interface are shown as sticks and 
Npa3-binding interface residues are labeled. The corresponding peptide numbers are shown at the sides. All structural figures 
were made using the Pol II structure pdb-code:1WCM (Armache, et al., 2005). 
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3.2.4. Npa3 binds Rpb8-derived peptides at the interface to Rpb1 
Three overlapping Npa3-binding peptides (peptides 1,037; 1,038; 1,039) contained a hydrophobic region 
in Rpb8 (117-SFGGLLMR-124) that forms an interface with Rpb1.  
Figure 17| Npa3 binds Rpb8-derived peptides located at the subunit interface to Rpb1. 
(A) Position of Rpb8 (green) and its interacting subunit Rpb1 (dark grey) in the assembled Pol II complex. (B) Boxplot representation 
of the heatmap describing Npa3 peptide-binding landscape of Rpb8-derived peptides in the presence of GTP, GDP and GMPPCP, 
respectively. Control experiments were performed without Npa3 and nucleotides to test cross-reactivity of the anti-His antibody. 
Intensity distribution is shown in logarithmic scale. Peptides with signal intensity <3.5 were defined as unbound (grey area). (C) 
Surface representations of Rpb8 show that Npa3 interacts with hydrophobic Rpb8-derived peptides located at the subunit interface 
to Rpb1. Left panel: Npa3 binding to Rpb8 peptides is depicted in yellow (signal intensity 3.5-3.75), orange (3.75-4) and red (>4) 
whereas unbound regions are in green (<3.5). Middle panel: Subunit interfaces are shown in black. Dashed lines indicate Rpb1 
position in the assembled Pol II complex. Right panel: Surface charge of Rpb8. White solid lines highlight hydrophobic interface 
regions. Numbers correspond to the peptide numbers from the array (see Table 19 for Npa3-binding peptides and Table 20 for all 
tested peptides) (D) Putative Npa3 binding region of Rpb8. Residues involved in the interface are shown as sticks and Npa3 binding 
interface residues are labeled. All structural figures were made using the Pol II structure pdb-code:1WCM (Armache, et al., 2005) 
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3.2.5. Npa3 binds Rpb11-derived peptides at the interface to Rpb1 
In Rpb11, 18 of a total of 25 residues that form the interface with Rpb1 were found in overlapping Npa3-
binding peptides (peptides 1,106;1,108-1,110). Peptide 1,109 covers most interface residues and shows 
the strongest Npa3 binding among Rpb11-derived peptides.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18| Npa3 binds Rpb11-derived peptides located at the subunit interface to Rpb1 but not to Rpb3. 
(A) Position of Rpb11 (green) and its interacting subunits Rpb1 (dark grey) and Rpb3 (red) in the assembled Pol II. The Rpb1 and Rpb3 
interface of Rpb11 is shown in the middle and right panel, respectively and Rpb11 interface residues are highlighted as dark green 
sticks. (B) Boxplot representation of the heatmap describing Npa3 peptide-binding landscape of Rpb11-derived peptides in the 
presence of GTP, GDP and GMPPCP, respectively. Control experiments were performed without Npa3 and nucleotides to test cross-
reactivity of the anti-His antibody. Intensity distribution is shown in logarithmic scale. Peptides with signal intensity <3.5 were defined 
as unbound (grey area). (C) Surface representations of Rpb11 show that Npa3 interacts with hydrophobic Rpb11-derived peptides 
located at the subunit interface to Rpb1. Left panel: Npa3 binding to Rpb11 peptides is depicted in yellow (signal intensity 3.5-3.75), 
orange (3.75-4) and red (>4) whereas unbound regions are in green (<3.5). Middle panel: Subunit interfaces are shown in black. 
Dashed lines indicate subunit positions in the assembled Pol II complex. Right panel: Surface charge of Rpb11. White solid lines 
highlight hydrophobic interface regions. Numbers correspond to the peptide numbers from the array (Table 19 and Table 20) (D) 
Putative Npa3 binding region of Rpb11. Residues involved in the subunit interface are shown as sticks and Npa3 binding interface 
residues are labeled. All structural figures were made using the Pol II structure pdb-code:1WCM (Armache, et al., 2005). 
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3.2.6. Npa3 binds Rpb4- and Rpb7-derived peptides at their subunit interface 
We also identified interactions of Npa3 with ten peptides in the Rpb4-Rpb7 interface (Rpb4 peptides 
833, 834, 837, 855; Rpb7 peptides 970, 971, 975, 976, 977, 984) (Figure 19 and Figure 20), consistent 
with a reported interaction of human GPN1 with Rpb4 and Rpb7 (Carre & Shiekhattar, 2011). Npa3 did 
not interact with a purified yeast Rpb4-Rpb7 complex (not shown), supporting the model that Npa3 
binds peptide regions located at the subunit interface that are only accessible during subcomplex 
assembly.  
Figure 19| Npa3 binds Rpb4-derived peptides located at the subunit interface to Rpb7. 
(A) Position of Rpb4 (dark red) and its interacting subunit Rpb7 (blue) in the assembled Pol II complex. The Rpb4/7 subcomplex 
is shown in the middle and right panel and Rpb4 interface residues are highlighted as dark red sticks. (B) Boxplot 
representation of the heatmap describing Npa3 peptide-binding landscape of Rpb4-derived peptides in the presence of GTP, 
GDP and GMPPCP, respectively. Control experiments were performed without Npa3 and nucleotides to test cross-reactivity  
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of the anti-His antibody. Intensity distribution is shown in logarithmic scale. Peptides with signal intensity <3.5 were defined 
as unbound (grey area). (C) Surface representations of Rpb4 show that Npa3 interacts with hydrophobic Rpb4 peptides 
located at the subunit interface to Rpb7. Left panel: Npa3 binding to Rpb4 peptides is depicted in yellow (signal intensity 3.5-
3.75), orange (3.75-4) and red (>4) whereas unbound regions are in dark red (<3.5). Middle panel: Subunit interfaces of Rpb4 
are shown in black. Npa3-binding Rpb7 peptides at the same interface are shown. Dashed lines indicate subunit positions in 
the assembled Pol II complex. Right panel: Surface charge of Rpb4. White solid lines highlight hydrophobic interface regions. 
Numbers correspond to the peptide numbers from the array (Table 19, Table 20). (D) Putative Npa3 binding region of Rpb4. 
Residues involved in the interface are shown as sticks and Npa3 binding interface residues are labeled. All structural figures 
were made using the Pol II structure pdb-code:1WCM (Armache, et al., 2005). 
Figure 20| Npa3 binds Rpb7-derived peptides located at the subunit interface to Rpb4. 
(A) Position of Rpb7 (blue) and its interacting subunits in the assembled Pol II complex. The Rpb4/7 subcomplex is shown in 
the middle and right panel and Rpb7 interface residues are highlighted as sticks. (B) Boxplot representation of the heatmap 
describing Npa3 peptide-binding landscape of Rpb7-derived peptides in the presence of GTP, GDP and GMPPCP, respectively. 
Control experiments were performed without Npa3 and nucleotides to test cross-reactivity of the anti-His antibody. Intensity  
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Taken together, these data show that Npa3 binds numerous Pol II-derived hydrophobic peptides that 
are located at subunit interfaces, consistent with a function of Npa3 as an assembly chaperone for Pol II 
complex formation. 
 
3.2.7. Discussion and model for RNA polymerase II biogenesis 
Many macromolecular complexes were shown to require assembly chaperones for their biogenesis 
(Ellis, 2013), including the nucleosome (De Koning, et al., 2007; Avvakumov, et al., 2011), Rubisco (Liu, et 
al., 2010), the proteasome (Murata, et al., 2009), spliceosomal snRNPs (Chari, et al., 2008), and the 
ribosome (Karbstein, 2010). In contrast, biogenesis of the 12-subunit Pol II complex remains poorly 
understood. It was shown that Pol II biogenesis requires the R2TP/Prefoldin-like complex and the 
ATPase Hsp90 (Boulon, et al., 2010), a chaperone that is involved in the assembly of several protein 
complexes (Makhnevych & Houry, 2012), but additional assembly chaperones are likely required to 
enable correct Pol II assembly. 
Here we provide evidence that the new family of GPN-loop GTPases are Pol II assembly 
chaperones. We present the first structure of a eukaryotic GPN-loop GTPase, the GPN1 homolog Npa3 
from yeast. We show that Npa3 can adopt an open state with a hydrophobic pocket, that it can bind 
peptides derived from Pol II subunit interfaces, that it has chaperone activity, and that a chaperone 
substrate protein can stimulate its GTPase activity, which apparently triggers closing of the pocket. The 
latter observation is reminiscent to the reported stimulation of ATPase activity of chaperones Hsp70 
(Swain, et al., 2007; Smock, et al., 2010; Zhuravleva & Gierasch, 2011) and Hsp90 (McLaughlin, et al., 
2002) by substrate binding. GTPases were also shown to play a key role during ribosome assembly in 
bacteria (Britton, 2009) and in eukaryotes (Kressler et al., 2010). 
In the light of published data, our results close a gap in understanding Pol II biogenesis. In our 
model, GPN-loop GTPases first enable correct Pol II assembly in the cytoplasm (Figure 21). Assembled 
Pol II would then be recognized by Iwr1 and imported into the nucleus (Czeko, et al., 2011). Several lines 
of evidence argue for a role of GPN-loop GTPases in Pol II assembly rather than nuclear import of Pol II. 
First, GPN1, GPN2 and GPN3 interact with Pol II assembly intermediates (Boulon, et al., 2010). Second, 
GPN1 interacts with the CCT complex (Forget, et al., 2010), a chaperone complex with various functions 
distribution is shown in logarithmic scale. Peptides with signal intensity <3.5 were defined as unbound (grey area). (C) 
Surface representations of Rpb7 show that Npa3 interacts with hydrophobic Rpb7 peptides located at the subunit 
interface to Rpb4. Left panel: Npa3 binding to Rpb4 peptides is depicted in yellow (signal intensity 3.5-3.75), orange (3.75-
4) and red (>4) whereas unbound regions are in blue (<3.5). Middle panel: Subunit interfaces of Rpb7 are shown in black. 
Npa3 binding Rpb4 peptides at the same interface are shown. Dashed lines indicate subunit positions in the assembled Pol 
II complex. Right panel: Surface charge of Rpb7. White solid lines highlight hydrophobic interface regions. Numbers 
correspond to the peptide numbers from the array (Table 19, Table 20). (D) Putative Npa3 binding region of Rpb7. 
Residues involved in the interface are shown as sticks and Npa3 binding interface residues are labeled. All structural 
figures were made using the Pol II structure pdb-code: 1WCM (Armache, et al., 2005). 
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(Leroux & Hartl, 2000) that interacts with Pol II subunits (Dekker, et al., 2008). Third, GPN-loop GTPases 
lack a nuclear localization signal (NLS), and mutations of GPN2 or GPN3 cannot be rescued by fusion of a 
NLS to Rpb3, whereas deletion of Iwr1 is partially rescued (Minaker, et al., 2013). Forth, in patients with 
myofibrillar myopathies, a neuromuscular disorder characterized by protein aggregates, human GPN1 
shows increased expression and accumulates with Rpb1 in the cytoplasm of muscle cells (Guglielmi, et 
al., 2015), consistent with a Pol II-specific chaperone function of GPN1. However, Npa3 may additionally 
play nuclear roles, because nucleocytoplasmic shuttling of GPN1/Npa3 has been reported (Forget, et al., 
2010; Staresincic, et al., 2011; Reyes-Pardo, et al., 2012; Forget, et al., 2013). 
From these results emerges the molecular basis of GPN-loop GTPase function. In our model 
(Figure 21), an exposed hydrophobic peptide region in a newly synthesized Pol II subunit triggers the 
opening of the Npa3 pocket in its GDP-bound state. Npa3 then traps exposed hydrophobic regions of 
Pol II subunits, preventing their misassembly and opening a time window for association with the 
cognate Pol II subunit. Peptide binding allosterically alters the active site, decreasing its affinity for GDP, 
to provoke GDP displacement, and increasing its affinity for GTP, to facilitate GTP rebinding. Subsequent 
GTP hydrolysis would lead to release of the bound Pol II subunit, to enable association with cognate 
subunits and Pol II assembly. Assembled Pol II is then recognized by Iwr1, which binds between the two 
largest polymerase subunits (Czeko, et al., 2011), and serves as an adaptor for import of Pol II into the 
nucleus. 
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Figure 21| Model for RNA polymerase II biogenesis. 
Whereas the ‘Npa3 cycle’ drives cytoplasmic assembly of Pol II, the ‘Iwr1 cycle’ drives Pol II nuclear import. In the Npa3 
cycle, pocket opening of Npa3∙GDP is induced by binding of hydrophobic regions of Pol II subunits that form interfaces in 
the assembled Pol II complex, thereby preventing misassembly (step 1). Pocket opening allosterically communicates with 
the active site, stimulates GDP displacement, and thereby facilitates GTP rebinding (step 2). GTP hydrolysis leads to release 
of Pol II peptides, facilitating formation of Pol II subunit interfaces and assembly of Pol II in the cytoplasm. In the Iwr1 cycle, 
assembled Pol II is recognized by Iwr1, which provides an import adaptor for nuclear import via its nuclear localization 
sequence (NLS). Iwr1 is recycled with the use of its nuclear export signal (NES).  
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Figure 22| Additional Npa3∆C∆Loop crystallization conditions. 
Npa3∆C∆Loop was purified as described for wild-type Npa3 (2.3.1) (lower salt concentration than in ‘standard’ protocol 
for this construct). This prevents crystallization in the ‘standard’ condition and crystal shape but allows only low protein 
concentrations (< 1mg/ml) due to stability problems. Npa3∆C∆Loop was concentrated to 0.4 mg/ml and crystal were 
obtained by sitting drop vapor diffusion in 200 nl drops at 20°C in the indicated conditions. 
3.3. Further analysis of Npa3 and Npa3/GPN2 complexes 
Data presented in this chapter have been obtained during this thesis, but are not part of a publication. 
3.3.1. Additional Npa3∆C∆Loop crystallization conditions 
In addition to the crystallization conditions that led to the described structures (3.1), other conditions 
were identified to promote crystal growth of Npa3∆C∆Loop in complex with GDP or GMPPCP, 
respectively (Figure 22). Even though the crystals were very small and did not diffract synchrotron 
radiation, optimization of the conditions could may lead to bigger, diffracting crystals. The crystals 
showed different macroscopic shapes than the ones described and may serve as a starting point if a 
different crystal packing is desired. This could for instance be potentially interesting to analyze 
homodimeric Npa3 assemblies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2. Npa3 preferentially heterodimerizes with GPN2 and is required for its 
stable expression 
Attempts to recombinantly express various GPN2 constructs from S. cerevisiae in E. coli did hardly yield 
any protein neither in the soluble nor in the insoluble fraction (not shown) indicating that GPN2 is 
degraded within the cells. Recent studies reported that GPN2 is not able to homodimerize but 
heterodimerizes with Npa3 (Minaker, et al., 2013). We therefore co-transformed E. coli cells with 
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plasmids encoding both Npa3 without a tag and GPN2 with an N-terminal hexahistidine tag, 
respectively. Expression and subsequent Ni2+-affinity purification isolated stoichiometric Npa3/GPN2 
complexes that could be purified to homogeneity (Figure 23) with yields, equivalent to those of Npa3 
alone (approx. 100 mg per 4 liter E. coli culture). Notably, co-expression of N-terminal hexahistidine 
tagged Npa3 with untagged GPN2 also led to almost stoichiometric Npa3/GPN2 complexes (not shown), 
indicating that Npa3 has higher affinities for hetero- than for homodimerization. This is consistent with 
observations for GPN1 and GPN3 in mammalian cells (Mendez-Hernandez, et al., 2014). 
3.3.3. The Npa3/GPN2 complex does not interact with assembled Pol II 
Interaction of GPN2 with Pol II subunits has been reported (Boulon, et al., 2010; Forget, et al., 2010). We 
thus investigated whether the Npa3/GPN2 complex interacts with mature, complete assembled, 
purified Pol II using both analytical gel filtration and pull-down experiments with biotinylated Pol II. As 
observed for Npa3 alone (Figure 14) the Npa3/GPN2 complex did not interact with assembled Pol II 
(Figure 23) indicating that GPN2 interaction is restricted to the assembling polymerase. 
 
 
 
Figure 23| The Npa3/GPN2 complex does not interact with 
assembled, mature Pol II. 
(A) SDS-Page analysis of Pol II- and higher molecular weight 
fractions after analytical gel filtration (Superose 6 10/300, GE 
healthcare) upon incubation of Pol II with Npa3/GPN2-
nucleotide complexes. Purified  Pol II (12 µg), 5x molar excess of 
the purified Npa3/GPN2 complex and 1 mM GDP (left panel), 1 
mM GTP (middle panel) or 1 mM GMPPCP (right panel) were 
incubated over night at 4°C for nucleotide exchange and 
potential complex assembly. After gel filtration the fractions 
were TCA precipitated and analyzed by SDS-PAGE. Rpb3 bands 
were further analyzed by mass spectrometry because GPN2 
runs at a similar position on the gel (B) Streptavidin pull-down 
of biotinylated Pol II and associated factors. Purified Pol II was 
biotinylated at Rpb3 and 4.2 µg Pol II were incubated with 15x 
molar excess of the Npa3/GPN2 complex and 1 mM of the 
respective nucleotide over night at 8°C and 600 rpm. Marker: 
(top to bottom: 170, 130, 100, 70, 55, 40, 35, 25, 15, 10 kDa). 
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Figure 24| The C-terminal tail of both, Npa3 and GPN2 is not required for heterodimerization of the GPN-loop GTPases. 
SDS-PAGE analysis of Ni2+ affinity pull-downs after co-expression experiments using hexahistidine-tagged GPN2 variants 
and untagged Npa3 variants as described in the text. (A) Ni2+-affinity pull-down of hexahistidine-tagged GPN2∆C∆Loop 
(lacking the C-terminal tail and part of an internal loop) and full-length Npa3. (B) Ni2+-affinity pull-down of hexahistidine-
tagged full length GPN2 and Npa3∆C∆Loop (lacking the C-terminal tail and part of an internal loop). (B) Ni2+-affinity pull-
down of hexahistidine-tagged GPN2∆C∆Loop and untagged Npa3∆C∆Loop (both lacking the equivalent parts of the C-
terminal tail and an internal loop). 
3.3.4. The C-terminal tail is not required for Npa3/GPN2 complex formation 
In order to investigate the function of the C-terminal tail in Npa3/GPN2 complex formation we 
performed co-expression experiments using both, full-length and C-terminal deletion variants of 
hexahistidine-tagged GPN2 and untagged Npa3. Therefore we prepared a GPN2 variant lacking both the 
C-terminal tail (residues 265-347) and part of an internal loop (residues 206-211), (GPN2∆C∆Loop 
comprising residues 1-205 and 212-264), equivalent to the crystallized Npa3∆C∆Loop construct. Here, 
co-expression of untagged, full-length Npa3 with tagged GPN2∆C∆Loop and subsequent Ni2+-affinity 
purification isolated stoichiometric heterodimers, indicating that the C-terminal tail of GPN2 is not 
required for complex formation (Figure 24A). Vice versa, co-expression of tagged, full-length GPN2 with 
untagged Npa3∆C∆Loop also led to heterodimerization (Figure 24B). We then co-expressed both 
deletion variants, tagged GPN2∆C∆Loop and untagged Npa3∆C∆Loop (Figure 24C). Here, a single band 
was identified on the SDS gel due to the similar molecular weight of both constructs and analysis by 
mass-spectrometry revealed that both proteins co-eluted from the affinity column, indicating that none 
of the proteins requires the C-terminal tail for heterodimerization. 
 
 
 
 
 
 
 
 
 
3.3.5. Crystallization trials of Npa3/GPN2 complexes 
Because intense attempts to crystalize a full-length Npa3/GPN2 complex did not reveal crystals we 
tested various truncated constructs and combinations, including an Npa3∆C∆Loop/GPN2∆C∆Loop 
heterodimer (3.3.4). This complex represents the equivalent heterodimer to the crystallized Npa3 
variant. However, crystallization was hampered also in conditions were Npa3∆C∆Loop alone crystallized.
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4. Conclusion and outlook 
In this thesis a combination of X-ray crystallography, site-directed mutagenesis, enzymatic activity 
assays, chaperone assays, protein-protein interaction techniques and a systemic Pol II peptide 
interaction screen were used to investigate the structure and function of the GPN-loop GTPase Npa3. In 
previous studies, functional characterization of Npa3 or its human homolog GPN1 mainly focused on 
cellular localization of Pol II subunits (Wild & Cramer, 2012), but biochemical and structural data were 
lacking and the question whether Npa3 functions in assembly or nuclear import of Pol II remained 
unanswered. In this thesis we report the first structure of a eukaryotic GPN-loop GTPase, show that it 
can adopt a closed GDP-bound state that reveals eukaryote-specific features, and a novel open GTP-
analog-bound state that exposes a conserved hydrophobic pocket. We further show that Npa3 has 
chaperone activity and that a chaperone substrate protein can stimulate its GTPase activity, which 
apparently triggers closing of the pocket. Using a systemic Pol II peptide interaction screen covering all 
regions of all 12 Pol II subunits we describe for the first time putative, particular interaction sites of a 
GPN-loop GTPase with Pol II subunits. We show that these regions are located at Pol II subunit 
interfaces and enriched in hydrophobic residues, consistent with a function of Npa3 as assembly 
chaperone. Such peptide arrays were successfully used in the past to characterize assembly chaperone 
interactions sites (Saschenbrecker, et al., 2007). The 15-residue long peptides can form small secondary 
structures, mimic partially folded Pol II subunit regions, and allow accessibility to Pol II subunit 
interfaces that are hard to grasp with conventional methods and bound by assembly chaperones.  
Our studies provide a framework for future validation and characterization of these interactions. 
Attempts to co-crystallize Npa3 with Rpb1- or Rpb11-derived peptides identified in our screen failed 
because they are hydrophobic and aggregated in the crystallization condition (not shown). 
Crystallographic studies of a fusion protein consisting of the crystallized Npa3 variant and a C-terminally 
fused Pol II peptide, separated by a short, flexible linker could solve the solubility problem and should 
allow peptide-binding to the nearby hydrophobic pocket. However, screening for new crystallization 
conditions may be required because crystal contacts separate the pocket from the C-terminus in the 
current crystal packing. Here, other crystallization conditions identified in this thesis to promote Npa3 
crystals growth (3.3.1) could provide a promising starting point for the identification of a different 
crystal packing. Further, here identified Npa3 interactions with Pol II subunits could for instance be 
verified with yeast two-hybrid assays as done for other assembly chaperones (Mao, et al., 2015) or 
recombinant co-expression experiments to additionally enable complex analysis. Structure-guided site-
directed mutagenesis of the hydrophobic Npa3 pocket could be used and impaired subunit interactions, 
Pol II assembly defects and growth defects could be analyzed.  
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In addition, structural characterization of Npa3 in complex with Pol II subunits or subassemblies 
should be of major interest for future Pol II biogenesis research. Our model (Figure 21) shows that Pol II 
subunit release from Npa3 is regulated by GTP hydrolysis and our high resolution crystal structures in 
combination with site-directed mutagenesis provide atomic details of how to abolish both processes 
and trap the complexes. For this, yeast cells expressing both, a functional Npa3 variant for cell viability 
and a tagged GTP hydrolysis-deficient mutant variant should allow purification of Npa3-bound Pol II 
subcomplexes. Further urea- (Kimura, et al., 1997) or α-amanitin (Boulon, et al., 2010) treatment of 
Pol II may be considered for subcomplex production. Chemical crosslinking and mass-spectrometry in 
combination with our Npa3 and the Pol II (Cramer, et al., 2000; Armache, et al., 2005) crystals structures 
could now be used to determine the complex architecture.  
Notably, no structure of any assembly factor in complex with Pol II subassemblies is available so 
far. Here, cryo-electron microscopy could be increasingly important in the future because recent 
advances in imaging hardware and processing software (Kuhlbrandt, 2014) may allow high resolution 
cryo-EM structures of Npa3-bound Pol II subassemblies and may also shed light into the structure and 
function of the C-terminal tail of Npa3 which is lacking in the crystal structure. 
In this study we showed that Npa3 is a Pol II assembly chaperone but the structure and function 
of its paralogs GPN2 and GPN3 is still unknown. However, they likely have similar, non-redundant 
functions and thus Npa3 may represents the founding member of a new family of assembly chaperones. 
Heterodimerization of Npa3/GPN1 with both paralogs was reported (Minaker, et al., 2013; Mendez-
Hernandez, et al., 2014) and likely needs to be considered to completely understand the function of 
Npa3. Interestingly, Npa3/GPN1 seems to preferentially heterodimerize with its paralogs because 
coexpression of human GPN1 and GPN3 (Mendez-Hernandez, et al., 2014) and recombinant co-
expression of yeast Npa3 and GPN2 (3.3.2) mainly leads to heterodimers. This, together with the 
proposed enzymatic mechanism that likely requires the ‘trans’-GPN-loop of a GPN-loop GTPase dimer 
for GTP hydrolysis (3.1.6; (Gras, et al., 2007)) and Pol II subunit release, may indicate an intriguing 
mechanism for Pol II assembly: Given that the other GPN-loop GTPases also function as assembly 
chaperones, they may bind Pol II regions at the opposite site of the interface than Npa3. In this case, 
GPN-loop GTPases could bring interacting subunits together by heterodimerization, orchestrate their 
assembly in a highly regulated manner and get released by GTP hydrolysis upon dimer formation to 
facilitate subunit association. To initially test this hypothesis, the Npa3/GPN2 complex could be used in 
our Pol II peptide array to analyze whether the presence of GPN2 leads to additional interactions on Pol 
II subunit regions that form interfaces with the ones identified for Npa3 binding. Further, this 
Npa3/GPN2 complex should be tested for chaperone activity, GPN2 hydrolysis-deficient mutants could 
be used for in vivo subunit pull-downs and the complex structures of GPN-loop GTPase heterodimers 
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should be investigated. Here, homology modeling of GPN2 and GPN3 with our Npa3 structure and 
analysis of their putative substrate binding pocket may give first insights into substrate specificities. 
Over the last decades, all efforts to recombinantly express and in-vitro assemble Pol II failed 
making analysis of its assembly steps including associated factors potentially challenging. Here, the 
addition of GPN-loop GTPases could be a prerequisite for subunit stability and interface formation and a 
step towards in vitro assembly. This would in fact allow many new possibilities to identify and analyze 
assembly intermediates, characterize assembly factor functions, and determine the chronological order 
of subunit assembly and chaperone action. For instance, it remains elusive whether Npa3 already 
interacts with nascent chains or at a later state of Pol II subunit maturation.  
  Further, regulation of Pol II biogenesis should be investigated in more detail because Npa3 is 
phosphorylated by Pcl1-PHO85, a cyclin-CDK complex involved in cell cycle progression (Keniry et al., 
2004; Albuquerque et al., 2008; Holt et al., 2009), indicating that Pol II biogenesis is linked to the cell 
cycle. This may regulate transcription by controlling the amount of assembled, functional Pol II, 
dependent on the specific needs of the cell. Additionally Pol I and Pol III biogenesis may need to be 
considered since they share subunits with Pol II (Vannini & Cramer, 2012) and biogenesis of all three 
polymerases is may mutually dependent.  
In this thesis we propose the cytoplasmic function of Npa3 but nucleocytoplasmic shuttling was 
reported (Forget, et al., 2010; Staresincic, et al., 2011; Forget, et al., 2013) indicating additional nuclear 
functions. One option would be that Npa3 not only assists cytoplasmic Pol II assembly but also nuclear 
disassembly of defective Pol II. Further, nucleocytoplasmic recycling of Pol II subunits may couple 
disassembly and assembly as observed for Rpb3 (Boulon, et al., 2010) and may be considered for Npa3 
function. To investigate disassembly, degradation and recycling of Pol II subunits, α-amanitin, a 
transcription inhibitor that specifically leads to degradation of nuclear Rpb1 has been shown to be an 
effective tool (Nguyen, et al., 1996; Jung & Lippard, 2006; Boulon, et al., 2010) and could be used to 
analyze Npa3 function in this processes. 
Taken together, the structural and functional data presented in this thesis provide novel insights 
into the role of GPN-loop GTPases in Pol II biogenesis and provide a framework for future analysis 
towards the understanding of this fundamental process. 
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5. Supplementary Information 
Table 20| Pol II-derived peptides tested for Npa3 binding. 
Pol II 
subunit 
Peptide 
No. 
Start 
a.a. 
End 
a.a. 
Sequence  Pol II 
subunit 
Peptide 
No. 
Start 
a.a. 
End 
a.a. 
Sequence 
Rpb1 1 1 15 MVGQQYSSAPLRTVK  Rpb1 42 165 179 GGCGNTQPTIRKDGL 
 2 5 19 QYSSAPLRTVKEVQF   43 169 183 NTQPTIRKDGLKLVG 
 3 9 23 APLRTVKEVQFGLFS   44 173 187 TIRKDGLKLVGSWKK 
 4 13 27 TVKEVQFGLFSPEEV   45 177 191 DGLKLVGSWKKDRAT 
 5 17 31 VQFGLFSPEEVRAIS   46 181 195 LVGSWKKDRATGDAD 
 6 21 35 LFSPEEVRAISVAKI   47 185 199 WKKDRATGDADEPEL 
 7 25 39 EEVRAISVAKIRFPE   48 189 203 RATGDADEPELRVLS 
 8 29 43 AISVAKIRFPETMDE   49 193 207 DADEPELRVLSTEEI 
 9 33 47 AKIRFPETMDETQTR   50 197 211 PELRVLSTEEILNIF 
 10 37 51 FPETMDETQTRAKIG   51 201 215 VLSTEEILNIFKHIS 
 11 41 55 MDETQTRAKIGGLND   52 205 219 EEILNIFKHISVKDF 
 12 45 59 QTRAKIGGLNDPRLG   53 209 223 NIFKHISVKDFTSLG 
 13 49 63 KIGGLNDPRLGSIDR   54 213 227 HISVKDFTSLGFNEV 
 14 53 67 LNDPRLGSIDRNLKC   55 217 231 KDFTSLGFNEVFSRP 
 15 57 71 RLGSIDRNLKCQTCQ   56 221 235 SLGFNEVFSRPEWMI 
 16 61 75 IDRNLKCQTCQEGMN   57 225 239 NEVFSRPEWMILTCL 
 17 65 79 LKCQTCQEGMNECPG   58 229 243 SRPEWMILTCLPVPP 
 18 69 83 TCQEGMNECPGHFGH   59 233 247 WMILTCLPVPPPPVR 
 19 73 87 GMNECPGHFGHIDLA   60 237 251 TCLPVPPPPVRPSIS 
 20 77 91 CPGHFGHIDLAKPVF   61 241 255 VPPPPVRPSISFNES 
 21 81 95 FGHIDLAKPVFHVGF   62 245 259 PVRPSISFNESQRGE 
 22 85 99 DLAKPVFHVGFIAKI   63 249 263 SISFNESQRGEDDLT 
 23 89 103 PVFHVGFIAKIKKVC   64 253 267 NESQRGEDDLTFKLA 
 24 93 107 VGFIAKIKKVCECVC   65 257 271 RGEDDLTFKLADILK 
 25 97 111 AKIKKVCECVCMHCG   66 261 275 DLTFKLADILKANIS 
 26 101 115 KVCECVCMHCGKLLL   67 265 279 KLADILKANISLETL 
 27 105 119 CVCMHCGKLLLDEHN   68 269 283 ILKANISLETLEHNG 
 28 109 123 HCGKLLLDEHNELMR   69 273 287 NISLETLEHNGAPHH 
 29 113 127 LLLDEHNELMRQALA   70 277 291 ETLEHNGAPHHAIEE 
 30 117 131 EHNELMRQALAIKDS   71 281 295 HNGAPHHAIEEAESL 
 31 121 135 LMRQALAIKDSKKRF   72 285 299 PHHAIEEAESLLQFH 
 32 125 139 ALAIKDSKKRFAAIW   73 289 303 IEEAESLLQFHVATY 
 33 129 143 KDSKKRFAAIWTLCK   74 293 307 ESLLQFHVATYMDND 
 34 133 147 KRFAAIWTLCKTKMV   75 297 311 QFHVATYMDNDIAGQ 
 35 137 151 AIWTLCKTKMVCETD   76 301 315 ATYMDNDIAGQPQAL 
 36 141 155 LCKTKMVCETDVPSE   77 305 319 DNDIAGQPQALQKSG 
 37 145 159 KMVCETDVPSEDDPT   78 309 323 AGQPQALQKSGRPVK 
 38 149 163 ETDVPSEDDPTQLVS   79 313 327 QALQKSGRPVKSIRA 
 39 153 167 PSEDDPTQLVSRGGC   80 317 331 KSGRPVKSIRARLKG 
 40 157 171 DPTQLVSRGGCGNTQ   81 321 335 PVKSIRARLKGKEGR 
 41 161 175 LVSRGGCGNTQPTIR   82 325 339 IRARLKGKEGRIRGN 
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Pol II 
subunit 
Peptide 
No. 
Start 
a.a. 
End 
a.a. 
Sequence  Pol II 
subunit 
Peptide 
No. 
Start 
a.a. 
End 
a.a. 
Sequence 
Rpb1 83 329 343 LKGKEGRIRGNLMGK  Rpb1 129 513 527 SPQSNKPCMGIVQDT 
 84 333 347 EGRIRGNLMGKRVDF   130 517 531 NKPCMGIVQDTLCGI 
 85 337 351 RGNLMGKRVDFSART   131 521 535 MGIVQDTLCGIRKLT 
 86 341 355 MGKRVDFSARTVISG   132 525 539 QDTLCGIRKLTLRDT 
 87 345 359 VDFSARTVISGDPNL   133 529 543 CGIRKLTLRDTFIEL 
 88 349 363 ARTVISGDPNLELDQ   134 533 547 KLTLRDTFIELDQVL 
 89 353 367 ISGDPNLELDQVGVP   135 537 551 RDTFIELDQVLNMLY 
 90 357 371 PNLELDQVGVPKSIA   136 541 555 IELDQVLNMLYWVPD 
 91 361 375 LDQVGVPKSIAKTLT   137 545 559 QVLNMLYWVPDWDGV 
 92 365 379 GVPKSIAKTLTYPEV   138 549 563 MLYWVPDWDGVIPTP 
 93 369 383 SIAKTLTYPEVVTPY   139 553 567 VPDWDGVIPTPAIIK 
 94 373 387 TLTYPEVVTPYNIDR   140 557 571 DGVIPTPAIIKPKPL 
 95 377 391 PEVVTPYNIDRLTQL   141 561 575 PTPAIIKPKPLWSGK 
 96 381 395 TPYNIDRLTQLVRNG   142 565 579 IIKPKPLWSGKQILS 
 97 385 399 IDRLTQLVRNGPNEH   143 569 583 KPLWSGKQILSVAIP 
 98 389 403 TQLVRNGPNEHPGAK   144 573 587 SGKQILSVAIPNGIH 
 99 393 407 RNGPNEHPGAKYVIR   145 577 591 ILSVAIPNGIHLQRF 
 100 397 411 NEHPGAKYVIRDSGD   146 581 595 AIPNGIHLQRFDEGT 
 101 401 415 GAKYVIRDSGDRIDL   147 585 599 GIHLQRFDEGTTLLS 
 102 405 419 VIRDSGDRIDLRYSK   148 589 603 QRFDEGTTLLSPKDN 
 103 409 423 SGDRIDLRYSKRAGD   149 593 607 EGTTLLSPKDNGMLI 
 104 413 427 IDLRYSKRAGDIQLQ   150 597 611 LLSPKDNGMLIIDGQ 
 105 417 431 YSKRAGDIQLQYGWK   151 601 615 KDNGMLIIDGQIIFG 
 106 421 435 AGDIQLQYGWKVERH   152 605 619 MLIIDGQIIFGVVEK 
 107 425 439 QLQYGWKVERHIMDN   153 609 623 DGQIIFGVVEKKTVG 
 108 429 443 GWKVERHIMDNDPVL   154 613 627 IFGVVEKKTVGSSNG 
 109 433 447 ERHIMDNDPVLFNRQ   155 617 631 VEKKTVGSSNGGLIH 
 110 437 451 MDNDPVLFNRQPSLH   156 621 635 TVGSSNGGLIHVVTR 
 111 441 455 PVLFNRQPSLHKMSM   157 625 639 SNGGLIHVVTREKGP 
 112 445 459 NRQPSLHKMSMMAHR   158 629 643 LIHVVTREKGPQVCA 
 113 449 463 SLHKMSMMAHRVKVI   159 633 647 VTREKGPQVCAKLFG 
 114 453 467 MSMMAHRVKVIPYST   160 637 651 KGPQVCAKLFGNIQK 
 115 457 471 AHRVKVIPYSTFRLN   161 641 655 VCAKLFGNIQKVVNF 
 116 461 475 KVIPYSTFRLNLSVT   162 645 659 LFGNIQKVVNFWLLH 
 117 465 479 YSTFRLNLSVTSPYN   163 649 663 IQKVVNFWLLHNGFS 
 118 469 483 RLNLSVTSPYNADFD   164 653 667 VNFWLLHNGFSTGIG 
 119 473 487 SVTSPYNADFDGDEM   165 657 671 LLHNGFSTGIGDTIA 
 120 477 491 PYNADFDGDEMNLHV   166 661 675 GFSTGIGDTIADGPT 
 121 481 495 DFDGDEMNLHVPQSE   167 665 679 GIGDTIADGPTMREI 
 122 485 499 DEMNLHVPQSEETRA   168 669 683 TIADGPTMREITETI 
 123 489 503 LHVPQSEETRAELSQ   169 673 687 GPTMREITETIAEAK 
 124 493 507 QSEETRAELSQLCAV   170 677 691 REITETIAEAKKKVL 
 125 497 511 TRAELSQLCAVPLQI   171 681 695 ETIAEAKKKVLDVTK 
 126 501 515 LSQLCAVPLQIVSPQ   172 685 699 EAKKKVLDVTKEAQA 
 127 505 519 CAVPLQIVSPQSNKP   173 689 703 KVLDVTKEAQANLLT 
 128 509 523 LQIVSPQSNKPCMGI   174 693 707 VTKEAQANLLTAKHG 
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Pol II 
subunit 
Peptide 
No. 
Start 
a.a. 
End 
a.a. 
Sequence  Pol II 
subunit 
Peptide 
No. 
Start 
a.a. 
End 
a.a. 
Sequence 
Rpb1 175 697 711 AQANLLTAKHGMTLR  Rpb1 221 881 895 QSLDTIGGSDAAFEK 
 176 701 715 LLTAKHGMTLRESFE   222 885 899 TIGGSDAAFEKRYRV 
 177 705 719 KHGMTLRESFEDNVV   223 889 903 SDAAFEKRYRVDLLN 
 178 709 723 TLRESFEDNVVRFLN   224 893 907 FEKRYRVDLLNTDHT 
 179 713 727 SFEDNVVRFLNEARD   225 897 911 YRVDLLNTDHTLDPS 
 180 717 731 NVVRFLNEARDKAGR   226 901 915 LLNTDHTLDPSLLES 
 181 721 735 FLNEARDKAGRLAEV   227 905 919 DHTLDPSLLESGSEI 
 182 725 739 ARDKAGRLAEVNLKD   228 909 923 DPSLLESGSEILGDL 
 183 729 743 AGRLAEVNLKDLNNV   229 913 927 LESGSEILGDLKLQV 
 184 733 747 AEVNLKDLNNVKQMV   230 917 931 SEILGDLKLQVLLDE 
 185 737 751 LKDLNNVKQMVMAGS   231 921 935 GDLKLQVLLDEEYKQ 
 186 741 755 NNVKQMVMAGSKGSF   232 925 939 LQVLLDEEYKQLVKD 
 187 745 759 QMVMAGSKGSFINIA   233 929 943 LDEEYKQLVKDRKFL 
 188 749 763 AGSKGSFINIAQMSA   234 933 947 YKQLVKDRKFLREVF 
 189 753 767 GSFINIAQMSACVGQ   235 937 951 VKDRKFLREVFVDGE 
 190 757 771 NIAQMSACVGQQSVE   236 941 955 KFLREVFVDGEANWP 
 191 761 775 MSACVGQQSVEGKRI   237 945 959 EVFVDGEANWPLPVN 
 192 765 779 VGQQSVEGKRIAFGF   238 949 963 DGEANWPLPVNIRRI 
 193 769 783 SVEGKRIAFGFVDRT   239 953 967 NWPLPVNIRRIIQNA 
 194 773 787 KRIAFGFVDRTLPHF   240 957 971 PVNIRRIIQNAQQTF 
 195 777 791 FGFVDRTLPHFSKDD   241 961 975 RRIIQNAQQTFHIDH 
 196 781 795 DRTLPHFSKDDYSPE   242 965 979 QNAQQTFHIDHTKPS 
 197 785 799 PHFSKDDYSPESKGF   243 969 983 QTFHIDHTKPSDLTI 
 198 789 803 KDDYSPESKGFVENS   244 973 987 IDHTKPSDLTIKDIV 
 199 793 807 SPESKGFVENSYLRG   245 977 991 KPSDLTIKDIVLGVK 
 200 797 811 KGFVENSYLRGLTPQ   246 981 995 LTIKDIVLGVKDLQE 
 201 801 815 ENSYLRGLTPQEFFF   247 985 999 DIVLGVKDLQENLLV 
 202 805 819 LRGLTPQEFFFHAMG   248 989 1003 GVKDLQENLLVLRGK 
 203 809 823 TPQEFFFHAMGGREG   249 993 1007 LQENLLVLRGKNEII 
 204 813 827 FFFHAMGGREGLIDT   250 997 1011 LLVLRGKNEIIQNAQ 
 205 817 831 AMGGREGLIDTAVKT   251 1001 1015 RGKNEIIQNAQRDAV 
 206 821 835 REGLIDTAVKTAETG   252 1005 1019 EIIQNAQRDAVTLFC 
 207 825 839 IDTAVKTAETGYIQR   253 1009 1023 NAQRDAVTLFCCLLR 
 208 829 843 VKTAETGYIQRRLVK   254 1013 1027 DAVTLFCCLLRSRLA 
 209 833 847 ETGYIQRRLVKALED   255 1017 1031 LFCCLLRSRLATRRV 
 210 837 851 IQRRLVKALEDIMVH   256 1021 1035 LLRSRLATRRVLQEY 
 211 841 855 LVKALEDIMVHYDNT   257 1025 1039 RLATRRVLQEYRLTK 
 212 845 859 LEDIMVHYDNTTRNS   258 1029 1043 RRVLQEYRLTKQAFD 
 213 849 863 MVHYDNTTRNSLGNV   259 1033 1047 QEYRLTKQAFDWVLS 
 214 853 867 DNTTRNSLGNVIQFI   260 1037 1051 LTKQAFDWVLSNIEA 
 215 857 871 RNSLGNVIQFIYGED   261 1041 1055 AFDWVLSNIEAQFLR 
 216 861 875 GNVIQFIYGEDGMDA   262 1045 1059 VLSNIEAQFLRSVVH 
 217 865 879 QFIYGEDGMDAAHIE   263 1049 1063 IEAQFLRSVVHPGEM 
 218 869 883 GEDGMDAAHIEKQSL   264 1053 1067 FLRSVVHPGEMVGVL 
 219 873 887 MDAAHIEKQSLDTIG   265 1057 1071 VVHPGEMVGVLAAQS 
 220 877 891 HIEKQSLDTIGGSDA   266 1061 1075 GEMVGVLAAQSIGEP 
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Rpb1 267 1065 1079 GVLAAQSIGEPATQM  Rpb1 313 1249 1263 DAETEAEEDHMLKKI 
 268 1069 1083 AQSIGEPATQMTLNT   314 1253 1267 EAEEDHMLKKIENTM 
 269 1073 1087 GEPATQMTLNTFHFA   315 1257 1271 DHMLKKIENTMLENI 
 270 1077 1091 TQMTLNTFHFAGVAS   316 1261 1275 KKIENTMLENITLRG 
 271 1081 1095 LNTFHFAGVASKKVT   317 1265 1279 NTMLENITLRGVENI 
 272 1085 1099 HFAGVASKKVTSGVP   318 1269 1283 ENITLRGVENIERVV 
 273 1089 1103 VASKKVTSGVPRLKE   319 1273 1287 LRGVENIERVVMMKY 
 274 1093 1107 KVTSGVPRLKEILNV   320 1277 1291 ENIERVVMMKYDRKV 
 275 1097 1111 GVPRLKEILNVAKNM   321 1281 1295 RVVMMKYDRKVPSPT 
 276 1101 1115 LKEILNVAKNMKTPS   322 1285 1299 MKYDRKVPSPTGEYV 
 277 1105 1119 LNVAKNMKTPSLTVY   323 1289 1303 RKVPSPTGEYVKEPE 
 278 1109 1123 KNMKTPSLTVYLEPG   324 1293 1307 SPTGEYVKEPEWVLE 
 279 1113 1127 TPSLTVYLEPGHAAD   325 1297 1311 EYVKEPEWVLETDGV 
 280 1117 1131 TVYLEPGHAADQEQA   326 1301 1315 EPEWVLETDGVNLSE 
 281 1121 1135 EPGHAADQEQAKLIR   327 1305 1319 VLETDGVNLSEVMTV 
 282 1125 1139 AADQEQAKLIRSAIE   328 1309 1323 DGVNLSEVMTVPGID 
 283 1129 1143 EQAKLIRSAIEHTTL   329 1313 1327 LSEVMTVPGIDPTRI 
 284 1133 1147 LIRSAIEHTTLKSVT   330 1317 1331 MTVPGIDPTRIYTNS 
 285 1137 1151 AIEHTTLKSVTIASE   331 1321 1335 GIDPTRIYTNSFIDI 
 286 1141 1155 TTLKSVTIASEIYYD   332 1325 1339 TRIYTNSFIDIMEVL 
 287 1145 1159 SVTIASEIYYDPDPR   333 1329 1343 TNSFIDIMEVLGIEA 
 288 1149 1163 ASEIYYDPDPRSTVI   334 1333 1347 IDIMEVLGIEAGRAA 
 289 1153 1167 YYDPDPRSTVIPEDE   335 1337 1351 EVLGIEAGRAALYKE 
 290 1157 1171 DPRSTVIPEDEEIIQ   336 1341 1355 IEAGRAALYKEVYNV 
 291 1161 1175 TVIPEDEEIIQLHFS   337 1345 1359 RAALYKEVYNVIASD 
 292 1165 1179 EDEEIIQLHFSLLDE   338 1349 1363 YKEVYNVIASDGSYV 
 293 1169 1183 IIQLHFSLLDEEAEQ   339 1353 1367 YNVIASDGSYVNYRH 
 294 1173 1187 HFSLLDEEAEQSFDQ   340 1357 1371 ASDGSYVNYRHMALL 
 295 1177 1191 LDEEAEQSFDQQSPW   341 1361 1375 SYVNYRHMALLVDVM 
 296 1181 1195 AEQSFDQQSPWLLRL   342 1365 1379 YRHMALLVDVMTTQG 
 297 1185 1199 FDQQSPWLLRLELDR   343 1369 1383 ALLVDVMTTQGGLTS 
 298 1189 1203 SPWLLRLELDRAAMN   344 1373 1387 DVMTTQGGLTSVTRH 
 299 1193 1207 LRLELDRAAMNDKDL   345 1377 1391 TQGGLTSVTRHGFNR 
 300 1197 1211 LDRAAMNDKDLTMGQ   346 1381 1395 LTSVTRHGFNRSNTG 
 301 1201 1215 AMNDKDLTMGQVGER   347 1385 1399 TRHGFNRSNTGALMR 
 302 1205 1219 KDLTMGQVGERIKQT   348 1389 1403 FNRSNTGALMRCSFE 
 303 1209 1223 MGQVGERIKQTFKND   349 1393 1407 NTGALMRCSFEETVE 
 304 1213 1227 GERIKQTFKNDLFVI   350 1397 1411 LMRCSFEETVEILFE 
 305 1217 1231 KQTFKNDLFVIWSED   351 1401 1415 SFEETVEILFEAGAS 
 306 1221 1235 KNDLFVIWSEDNDEK   352 1405 1419 TVEILFEAGASAELD 
 307 1225 1239 FVIWSEDNDEKLIIR   353 1409 1423 LFEAGASAELDDCRG 
 308 1229 1243 SEDNDEKLIIRCRVV   354 1413 1427 GASAELDDCRGVSEN 
 309 1233 1247 DEKLIIRCRVVRPKS   355 1417 1431 ELDDCRGVSENVILG 
 310 1237 1251 IIRCRVVRPKSLDAE   356 1421 1435 CRGVSENVILGQMAP 
 311 1241 1255 RVVRPKSLDAETEAE   357 1425 1439 SENVILGQMAPIGTG 
 312 1245 1259 PKSLDAETEAEEDHM   358 1429 1443 ILGQMAPIGTGAFDV 
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Rpb1 359 1433 1447 MAPIGTGAFDVMIDE  Rpb1 405 1617 1631 PSYSPTSPSYSPTSP 
 360 1437 1451 GTGAFDVMIDEESLV   406 1621 1635 PTSPSYSPTSPSYSP 
 361 1441 1455 FDVMIDEESLVKYMP   407 1625 1639 SYSPTSPSYSPTSPS 
 362 1445 1459 IDEESLVKYMPEQKI   408 1629 1643 TSPSYSPTSPSYSPT 
 363 1449 1463 SLVKYMPEQKITEIE   409 1633 1647 YSPTSPSYSPTSPSY 
 364 1453 1467 YMPEQKITEIEDGQD   410 1637 1651 SPSYSPTSPSYSPTS 
 365 1457 1471 QKITEIEDGQDGGVT   411 1641 1655 SPTSPSYSPTSPSYS 
 366 1461 1475 EIEDGQDGGVTPYSN   412 1645 1659 PSYSPTSPSYSPTSP 
 367 1465 1479 GQDGGVTPYSNESGL   413 1649 1663 PTSPSYSPTSPAYSP 
 368 1469 1483 GVTPYSNESGLVNAD   414 1653 1667 SYSPTSPAYSPTSPS 
 369 1473 1487 YSNESGLVNADLDVK   415 1657 1671 TSPAYSPTSPSYSPT 
 370 1477 1491 SGLVNADLDVKDELM   416 1661 1675 YSPTSPSYSPTSPSY 
 371 1481 1495 NADLDVKDELMFSPL   417 1665 1679 SPSYSPTSPSYSPTS 
 372 1485 1499 DVKDELMFSPLVDSG   418 1669 1683 SPTSPSYSPTSPSYS 
 373 1489 1503 ELMFSPLVDSGSNDA   419 1673 1687 PSYSPTSPSYSPTSP 
 374 1493 1507 SPLVDSGSNDAMAGG   420 1677 1691 PTSPSYSPTSPSYSP 
 375 1497 1511 DSGSNDAMAGGFTAY   421 1681 1695 SYSPTSPSYSPTSPN 
 376 1501 1515 NDAMAGGFTAYGGAD   422 1685 1699 TSPSYSPTSPNYSPT 
 377 1505 1519 AGGFTAYGGADYGEA   423 1689 1703 YSPTSPNYSPTSPSY 
 378 1509 1523 TAYGGADYGEATSPF   424 1693 1707 SPNYSPTSPSYSPTS 
 379 1513 1527 GADYGEATSPFGAYG   425 1697 1711 SPTSPSYSPTSPGYS 
 380 1517 1531 GEATSPFGAYGEAPT   426 1701 1715 PSYSPTSPGYSPGSP 
 381 1521 1535 SPFGAYGEAPTSPGF   427 1705 1719 PTSPGYSPGSPAYSP 
 382 1525 1539 AYGEAPTSPGFGVSS   428 1709 1723 GYSPGSPAYSPKQDE 
 383 1529 1543 APTSPGFGVSSPGFS   429 1713 1727 GSPAYSPKQDEQKHN 
 384 1533 1547 PGFGVSSPGFSPTSP   430 1717 1731 YSPKQDEQKHNENEN 
 385 1537 1551 VSSPGFSPTSPTYSP  Rpb1/2 431   QDEQKHNENENSRMS 
 386 1541 1555 GFSPTSPTYSPTSPA   432   KHNENENSRMSDLAN 
 387 1545 1559 TSPTYSPTSPAYSPT   433   NENSRMSDLANSEKY 
 388 1549 1563 YSPTSPAYSPTSPSY   434   RMSDLANSEKYYDED 
 389 1553 1567 SPAYSPTSPSYSPTS  Rpb2 435 4 18 LANSEKYYDEDPYGF 
 390 1557 1571 SPTSPSYSPTSPSYS   436 8 22 EKYYDEDPYGFEDES 
 391 1561 1575 PSYSPTSPSYSPTSP   437 12 26 DEDPYGFEDESAPIT 
 392 1565 1579 PTSPSYSPTSPSYSP   438 16 30 YGFEDESAPITAEDS 
 393 1569 1583 SYSPTSPSYSPTSPS   439 20 34 DESAPITAEDSWAVI 
 394 1573 1587 TSPSYSPTSPSYSPT   440 24 38 PITAEDSWAVISAFF 
 395 1577 1591 YSPTSPSYSPTSPSY   441 28 42 EDSWAVISAFFREKG 
 396 1581 1595 SPSYSPTSPSYSPTS   442 32 46 AVISAFFREKGLVSQ 
 397 1585 1599 SPTSPSYSPTSPSYS   443 36 50 AFFREKGLVSQQLDS 
 398 1589 1603 PSYSPTSPSYSPTSP   444 40 54 EKGLVSQQLDSFNQF 
 399 1593 1607 PTSPSYSPTSPSYSP   445 44 58 VSQQLDSFNQFVDYT 
 400 1597 1611 SYSPTSPSYSPTSPS   446 48 62 LDSFNQFVDYTLQDI 
 401 1601 1615 TSPSYSPTSPSYSPT   447 52 66 NQFVDYTLQDIICED 
 402 1605 1619 YSPTSPSYSPTSPSY   448 56 70 DYTLQDIICEDSTLI 
 403 1609 1623 SPSYSPTSPSYSPTS   449 60 74 QDIICEDSTLILEQL 
 404 1613 1627 SPTSPSYSPTSPSYS   450 64 78 CEDSTLILEQLAQHT 
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Rpb2 451 68 82 TLILEQLAQHTTESD  Rpb2 497 252 266 STLQVKLYGREGSSA 
 452 72 86 EQLAQHTTESDNISR   498 256 270 VKLYGREGSSARTIK 
 453 76 90 QHTTESDNISRKYEI   499 260 274 GREGSSARTIKATLP 
 454 80 94 ESDNISRKYEISFGK   500 264 278 SSARTIKATLPYIKQ 
 455 84 98 ISRKYEISFGKIYVT   501 268 282 TIKATLPYIKQDIPI 
 456 88 102 YEISFGKIYVTKPMV   502 272 286 TLPYIKQDIPIVIIF 
 457 92 106 FGKIYVTKPMVNESD   503 276 290 IKQDIPIVIIFRALG 
 458 96 110 YVTKPMVNESDGVTH   504 280 294 IPIVIIFRALGIIPD 
 459 100 114 PMVNESDGVTHALYP   505 284 298 IIFRALGIIPDGEIL 
 460 104 118 ESDGVTHALYPQEAR   506 288 302 ALGIIPDGEILEHIC 
 461 108 122 VTHALYPQEARLRNL   507 292 306 IPDGEILEHICYDVN 
 462 112 126 LYPQEARLRNLTYSS   508 296 310 EILEHICYDVNDWQM 
 463 116 130 EARLRNLTYSSGLFV   509 300 314 HICYDVNDWQMLEML 
 464 120 134 RNLTYSSGLFVDVKK   510 304 318 DVNDWQMLEMLKPCV 
 465 124 138 YSSGLFVDVKKRTYE   511 308 322 WQMLEMLKPCVEDGF 
 466 128 142 LFVDVKKRTYEAIDV   512 312 326 EMLKPCVEDGFVIQD 
 467 132 146 VKKRTYEAIDVPGRE   513 316 330 PCVEDGFVIQDRETA 
 468 136 150 TYEAIDVPGRELKYE   514 320 334 DGFVIQDRETALDFI 
 469 140 154 IDVPGRELKYELIAE   515 324 338 IQDRETALDFIGRRG 
 470 144 158 GRELKYELIAEESED   516 328 342 ETALDFIGRRGTALG 
 471 148 162 KYELIAEESEDDSES   517 332 346 DFIGRRGTALGIKKE 
 472 152 166 IAEESEDDSESGKVF   518 336 350 RRGTALGIKKEKRIQ 
 473 156 170 SEDDSESGKVFIGRL   519 340 354 ALGIKKEKRIQYAKD 
 474 160 174 SESGKVFIGRLPIML   520 344 358 KKEKRIQYAKDILQK 
 475 164 178 KVFIGRLPIMLRSKN   521 348 362 RIQYAKDILQKEFLP 
 476 168 182 GRLPIMLRSKNCYLS   522 352 366 AKDILQKEFLPHITQ 
 477 172 186 IMLRSKNCYLSEATE   523 356 370 LQKEFLPHITQLEGF 
 478 176 190 SKNCYLSEATESDLY   524 360 374 FLPHITQLEGFESRK 
 479 180 194 YLSEATESDLYKLKE   525 364 378 ITQLEGFESRKAFFL 
 480 184 198 ATESDLYKLKECPFD   526 368 382 EGFESRKAFFLGYMI 
 481 188 202 DLYKLKECPFDMGGY   527 372 386 SRKAFFLGYMINRLL 
 482 192 206 LKECPFDMGGYFIIN   528 376 390 FFLGYMINRLLLCAL 
 483 196 210 PFDMGGYFIINGSEK   529 380 394 YMINRLLLCALDRKD 
 484 200 214 GGYFIINGSEKVLIA   530 384 398 RLLLCALDRKDQDDR 
 485 204 218 IINGSEKVLIAQERS   531 388 402 CALDRKDQDDRDHFG 
 486 208 222 SEKVLIAQERSAGNI   532 392 406 RKDQDDRDHFGKKRL 
 487 212 226 LIAQERSAGNIVQVF   533 396 410 DDRDHFGKKRLDLAG 
 488 216 230 ERSAGNIVQVFKKAA   534 400 414 HFGKKRLDLAGPLLA 
 489 220 234 GNIVQVFKKAAPSPI   535 404 418 KRLDLAGPLLAQLFK 
 490 224 238 QVFKKAAPSPISHVA   536 408 422 LAGPLLAQLFKTLFK 
 491 228 242 KAAPSPISHVAEIRS   537 412 426 LLAQLFKTLFKKLTK 
 492 232 246 SPISHVAEIRSALEK   538 416 430 LFKTLFKKLTKDIFR 
 493 236 250 HVAEIRSALEKGSRF   539 420 434 LFKKLTKDIFRYMQR 
 494 240 254 IRSALEKGSRFISTL   540 424 438 LTKDIFRYMQRTVEE 
 495 244 258 LEKGSRFISTLQVKL   541 428 442 IFRYMQRTVEEAHDF 
 496 248 262 SRFISTLQVKLYGRE   542 432 446 MQRTVEEAHDFNMKL 
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Rpb2 543 436 450 VEEAHDFNMKLAINA  Rpb2 589 620 634 REKELKIFTDAGRVY 
 544 440 454 HDFNMKLAINAKTIT   590 624 638 LKIFTDAGRVYRPLF 
 545 444 458 MKLAINAKTITSGLK   591 628 642 TDAGRVYRPLFIVED 
 546 448 462 INAKTITSGLKYALA   592 632 646 RVYRPLFIVEDDESL 
 547 452 466 TITSGLKYALATGNW   593 636 650 PLFIVEDDESLGHKE 
 548 456 470 GLKYALATGNWGEQK   594 640 654 VEDDESLGHKELKVR 
 549 460 474 ALATGNWGEQKKAMS   595 644 658 ESLGHKELKVRKGHI 
 550 464 478 GNWGEQKKAMSSRAG   596 648 662 HKELKVRKGHIAKLM 
 551 468 482 EQKKAMSSRAGVSQV   597 652 666 KVRKGHIAKLMATEY 
 552 472 486 AMSSRAGVSQVLNRY   598 656 670 GHIAKLMATEYQDIE 
 553 476 490 RAGVSQVLNRYTYSS   599 660 674 KLMATEYQDIEGGFE 
 554 480 494 SQVLNRYTYSSTLSH   600 664 678 TEYQDIEGGFEDVEE 
 555 484 498 NRYTYSSTLSHLRRT   601 668 682 DIEGGFEDVEEYTWS 
 556 488 502 YSSTLSHLRRTNTPI   602 672 686 GFEDVEEYTWSSLLN 
 557 492 506 LSHLRRTNTPIGRDG   603 676 690 VEEYTWSSLLNEGLV 
 558 496 510 RRTNTPIGRDGKLAK   604 680 694 TWSSLLNEGLVEYID 
 559 500 514 TPIGRDGKLAKPRQL   605 684 698 LLNEGLVEYIDAEEE 
 560 504 518 RDGKLAKPRQLHNTH   606 688 702 GLVEYIDAEEEESIL 
 561 508 522 LAKPRQLHNTHWGLV   607 692 706 YIDAEEEESILIAMQ 
 562 512 526 RQLHNTHWGLVCPAE   608 696 710 EEEESILIAMQPEDL 
 563 516 530 NTHWGLVCPAETPEG   609 700 714 SILIAMQPEDLEPAE 
 564 520 534 GLVCPAETPEGQACG   610 704 718 AMQPEDLEPAEANEE 
 565 524 538 PAETPEGQACGLVKN   611 708 722 EDLEPAEANEENDLD 
 566 528 542 PEGQACGLVKNLSLM   612 712 726 PAEANEENDLDVDPA 
 567 532 546 ACGLVKNLSLMSCIS   613 716 730 NEENDLDVDPAKRIR 
 568 536 550 VKNLSLMSCISVGTD   614 720 734 DLDVDPAKRIRVSHH 
 569 540 554 SLMSCISVGTDPMPI   615 724 738 DPAKRIRVSHHATTF 
 570 544 558 CISVGTDPMPIITFL   616 728 742 RIRVSHHATTFTHCE 
 571 548 562 GTDPMPIITFLSEWG   617 732 746 SHHATTFTHCEIHPS 
 572 552 566 MPIITFLSEWGMEPL   618 736 750 TTFTHCEIHPSMILG 
 573 556 570 TFLSEWGMEPLEDYV   619 740 754 HCEIHPSMILGVAAS 
 574 560 574 EWGMEPLEDYVPHQS   620 744 758 HPSMILGVAASIIPF 
 575 564 578 EPLEDYVPHQSPDAT   621 748 762 ILGVAASIIPFPDHN 
 576 568 582 DYVPHQSPDATRVFV   622 752 766 AASIIPFPDHNQSPR 
 577 572 586 HQSPDATRVFVNGVW   623 756 770 IPFPDHNQSPRNTYQ 
 578 576 590 DATRVFVNGVWHGVH   624 760 774 DHNQSPRNTYQSAMG 
 579 580 594 VFVNGVWHGVHRNPA   625 764 778 SPRNTYQSAMGKQAM 
 580 584 598 GVWHGVHRNPARLME   626 768 782 TYQSAMGKQAMGVFL 
 581 588 602 GVHRNPARLMETLRT   627 772 786 AMGKQAMGVFLTNYN 
 582 592 606 NPARLMETLRTLRRK   628 776 790 QAMGVFLTNYNVRMD 
 583 596 610 LMETLRTLRRKGDIN   629 780 794 VFLTNYNVRMDTMAN 
 584 600 614 LRTLRRKGDINPEVS   630 784 798 NYNVRMDTMANILYY 
 585 604 618 RRKGDINPEVSMIRD   631 788 802 RMDTMANILYYPQKP 
 586 608 622 DINPEVSMIRDIREK   632 792 806 MANILYYPQKPLGTT 
 587 612 626 EVSMIRDIREKELKI   633 796 810 LYYPQKPLGTTRAME 
 588 616 630 IRDIREKELKIFTDA   634 800 814 QKPLGTTRAMEYLKF 
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Rpb2 635 804 818 GTTRAMEYLKFRELP  Rpb2 681 988 1002 GTIGITYRREDMPFT 
 636 808 822 AMEYLKFRELPAGQN   682 992 1006 ITYRREDMPFTAEGI 
 637 812 826 LKFRELPAGQNAIVA   683 996 1010 REDMPFTAEGIVPDL 
 638 816 830 ELPAGQNAIVAIACY   684 1000 1014 PFTAEGIVPDLIINP 
 639 820 834 GQNAIVAIACYSGYN   685 1004 1018 EGIVPDLIINPHAIP 
 640 824 838 IVAIACYSGYNQEDS   686 1008 1022 PDLIINPHAIPSRMT 
 641 828 842 ACYSGYNQEDSMIMN   687 1012 1026 INPHAIPSRMTVAHL 
 642 832 846 GYNQEDSMIMNQSSI   688 1016 1030 AIPSRMTVAHLIECL 
 643 836 850 EDSMIMNQSSIDRGL   689 1020 1034 RMTVAHLIECLLSKV 
 644 840 854 IMNQSSIDRGLFRSL   690 1024 1038 AHLIECLLSKVAALS 
 645 844 858 SSIDRGLFRSLFFRS   691 1028 1042 ECLLSKVAALSGNEG 
 646 848 862 RGLFRSLFFRSYMDQ   692 1032 1046 SKVAALSGNEGDASP 
 647 852 866 RSLFFRSYMDQEKKY   693 1036 1050 ALSGNEGDASPFTDI 
 648 856 870 FRSYMDQEKKYGMSI   694 1040 1054 NEGDASPFTDITVEG 
 649 860 874 MDQEKKYGMSITETF   695 1044 1058 ASPFTDITVEGISKL 
 650 864 878 KKYGMSITETFEKPQ   696 1048 1062 TDITVEGISKLLREH 
 651 868 882 MSITETFEKPQRTNT   697 1052 1066 VEGISKLLREHGYQS 
 652 872 886 ETFEKPQRTNTLRMK   698 1056 1070 SKLLREHGYQSRGFE 
 653 876 890 KPQRTNTLRMKHGTY   699 1060 1074 REHGYQSRGFEVMYN 
 654 880 894 TNTLRMKHGTYDKLD   700 1064 1078 YQSRGFEVMYNGHTG 
 655 884 898 RMKHGTYDKLDDDGL   701 1068 1082 GFEVMYNGHTGKKLM 
 656 888 902 GTYDKLDDDGLIAPG   702 1072 1086 MYNGHTGKKLMAQIF 
 657 892 906 KLDDDGLIAPGVRVS   703 1076 1090 HTGKKLMAQIFFGPT 
 658 896 910 DGLIAPGVRVSGEDV   704 1080 1094 KLMAQIFFGPTYYQR 
 659 900 914 APGVRVSGEDVIIGK   705 1084 1098 QIFFGPTYYQRLRHM 
 660 904 918 RVSGEDVIIGKTTPI   706 1088 1102 GPTYYQRLRHMVDDK 
 661 908 922 EDVIIGKTTPISPDE   707 1092 1106 YQRLRHMVDDKIHAR 
 662 912 926 IGKTTPISPDEEELG   708 1096 1110 RHMVDDKIHARARGP 
 663 916 930 TPISPDEEELGQRTA   709 1100 1114 DDKIHARARGPMQVL 
 664 920 934 PDEEELGQRTAYHSK   710 1104 1118 HARARGPMQVLTRQP 
 665 924 938 ELGQRTAYHSKRDAS   711 1108 1122 RGPMQVLTRQPVEGR 
 666 928 942 RTAYHSKRDASTPLR   712 1112 1126 QVLTRQPVEGRSRDG 
 667 932 946 HSKRDASTPLRSTEN   713 1116 1130 RQPVEGRSRDGGLRF 
 668 936 950 DASTPLRSTENGIVD   714 1120 1134 EGRSRDGGLRFGEME 
 669 940 954 PLRSTENGIVDQVLV   715 1124 1138 RDGGLRFGEMERDCM 
 670 944 958 TENGIVDQVLVTTNQ   716 1128 1142 LRFGEMERDCMIAHG 
 671 948 962 IVDQVLVTTNQDGLK   717 1132 1146 EMERDCMIAHGAASF 
 672 952 966 VLVTTNQDGLKFVKV   718 1136 1150 DCMIAHGAASFLKER 
 673 956 970 TNQDGLKFVKVRVRT   719 1140 1154 AHGAASFLKERLMEA 
 674 960 974 GLKFVKVRVRTTKIP   720 1144 1158 ASFLKERLMEASDAF 
 675 964 978 VKVRVRTTKIPQIGD   721 1148 1162 KERLMEASDAFRVHI 
 676 968 982 VRTTKIPQIGDKFAS   722 1152 1166 MEASDAFRVHICGIC 
 677 972 986 KIPQIGDKFASRHGQ   723 1156 1170 DAFRVHICGICGLMT 
 678 976 990 IGDKFASRHGQKGTI   724 1160 1174 VHICGICGLMTVIAK 
 679 980 994 FASRHGQKGTIGITY   725 1164 1178 GICGLMTVIAKLNHN 
 680 984 998 HGQKGTIGITYRRED   726 1168 1182 LMTVIAKLNHNQFEC 
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Rpb2 727 1172 1186 IAKLNHNQFECKGCD  Rpb3 773 132 146 PIIQDKEGNGVLICK 
 728 1176 1190 NHNQFECKGCDNKID   774 136 150 DKEGNGVLICKLRKG 
 729 1180 1194 FECKGCDNKIDIYQI   775 140 154 NGVLICKLRKGQELK 
 730 1184 1198 GCDNKIDIYQIHIPY   776 144 158 ICKLRKGQELKLTCV 
 731 1188 1202 KIDIYQIHIPYAAKL   777 148 162 RKGQELKLTCVAKKG 
 732 1192 1206 YQIHIPYAAKLLFQE   778 152 166 ELKLTCVAKKGIAKE 
 733 1196 1210 IPYAAKLLFQELMAM   779 156 170 TCVAKKGIAKEHAKW 
 734 1200 1214 AKLLFQELMAMNITP   780 160 174 KKGIAKEHAKWGPAA 
 735 1204 1218 FQELMAMNITPRLYT   781 164 178 AKEHAKWGPAAAIEF 
 736 1208 1222 MAMNITPRLYTDRSR   782 168 182 AKWGPAAAIEFEYDP 
Rpb2/3 737   ITPRLYTDRSRDFMS   783 172 186 PAAAIEFEYDPWNKL 
 738   LYTDRSRDFMSEEGP   784 176 190 IEFEYDPWNKLKHTD 
 739   RSRDFMSEEGPQVKI   785 180 194 YDPWNKLKHTDYWYE 
 740   FMSEEGPQVKIREAS   786 184 198 NKLKHTDYWYEQDSA 
Rpb3 741 4 18 EGPQVKIREASKDNV   787 188 202 HTDYWYEQDSAKEWP 
 742 8 22 VKIREASKDNVDFIL   788 192 206 WYEQDSAKEWPQSKN 
 743 12 26 EASKDNVDFILSNVD   789 196 210 DSAKEWPQSKNCEYE 
 744 16 30 DNVDFILSNVDLAMA   790 200 214 EWPQSKNCEYEDPPN 
 745 20 34 FILSNVDLAMANSLR   791 204 218 SKNCEYEDPPNEGDP 
 746 24 38 NVDLAMANSLRRVMI   792 208 222 EYEDPPNEGDPFDYK 
 747 28 42 AMANSLRRVMIAEIP   793 212 226 PPNEGDPFDYKAQAD 
 748 32 46 SLRRVMIAEIPTLAI   794 216 230 GDPFDYKAQADTFYM 
 749 36 50 VMIAEIPTLAIDSVE   795 220 234 DYKAQADTFYMNVES 
 750 40 54 EIPTLAIDSVEVETN   796 224 238 QADTFYMNVESVGSI 
 751 44 58 LAIDSVEVETNTTVL   797 228 242 FYMNVESVGSIPVDQ 
 752 48 62 SVEVETNTTVLADEF   798 232 246 VESVGSIPVDQVVVR 
 753 52 66 ETNTTVLADEFIAHR   799 236 250 GSIPVDQVVVRGIDT 
 754 56 70 TVLADEFIAHRLGLI   800 240 254 VDQVVVRGIDTLQKK 
 755 60 74 DEFIAHRLGLIPLQS   801 244 258 VVRGIDTLQKKVASI 
 756 64 78 AHRLGLIPLQSMDIE   802 248 262 IDTLQKKVASILLAL 
 757 68 82 GLIPLQSMDIEQLEY   803 252 266 QKKVASILLALTQMD 
 758 72 86 LQSMDIEQLEYSRDC   804 256 270 ASILLALTQMDQDKV 
 759 76 90 DIEQLEYSRDCFCED   805 260 274 LALTQMDQDKVNFAS 
 760 80 94 LEYSRDCFCEDHCDK   806 264 278 QMDQDKVNFASGDNN 
 761 84 98 RDCFCEDHCDKCSVV   807 268 282 DKVNFASGDNNTASN 
 762 88 102 CEDHCDKCSVVLTLQ   808 272 286 FASGDNNTASNMLGS 
 763 92 106 CDKCSVVLTLQAFGE   809 276 290 DNNTASNMLGSNEDV 
 764 96 110 SVVLTLQAFGESEST   810 280 294 ASNMLGSNEDVMMTG 
 765 100 114 TLQAFGESESTTNVY   811 284 298 LGSNEDVMMTGAEQD 
 766 104 118 FGESESTTNVYSKDL   812 288 302 EDVMMTGAEQDPYSN 
 767 108 122 ESTTNVYSKDLVIVS   813 292 306 MTGAEQDPYSNASQM 
 768 112 126 NVYSKDLVIVSNLMG   814 296 310 EQDPYSNASQMGNTG 
 769 116 130 KDLVIVSNLMGRNIG   815 300 314 YSNASQMGNTGSGGY 
 770 120 134 IVSNLMGRNIGHPII   816 304 318 SQMGNTGSGGYDNAW 
 771 124 138 LMGRNIGHPIIQDKE  Rpb3/4 817   NTGSGGYDNAWMNVS 
 772 128 142 NIGHPIIQDKEGNGV   818   GGYDNAWMNVSTSTF 
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 819   NAWMNVSTSTFQTRR   865 182 196 SLACDTADEAKTLIP 
Rpb4 820 2 16 NVSTSTFQTRRRRLK   866 186 200 DTADEAKTLIPSLNN 
 821 6 20 STFQTRRRRLKKVEE   867 190 204 EAKTLIPSLNNKISD 
 822 10 24 TRRRRLKKVEEEENA   868 194 208 LIPSLNNKISDDELE 
 823 14 28 RLKKVEEEENAATLQ   869 198 212 LNNKISDDELERILK 
 824 18 32 VEEEENAATLQLGQE   870 202 216 ISDDELERILKELSN 
 825 22 36 ENAATLQLGQEFQLK   871 206 220 ELERILKELSNLETL 
 826 26 40 TLQLGQEFQLKQINH  Rpb4/5 872   ILKELSNLETLYMDQ 
 827 30 44 GQEFQLKQINHQGEE   873   LSNLETLYMDQENER 
 828 34 48 QLKQINHQGEEEELI   874   ETLYMDQENERNISR 
 829 38 52 INHQGEEEELIALNL  Rpb5 875 1 15 MDQENERNISRLWRA 
 830 42 56 GEEEELIALNLSEAR   876 5 19 NERNISRLWRAFRTV 
 831 46 60 ELIALNLSEARLVIK   877 9 23 ISRLWRAFRTVKEMV 
 832 50 64 LNLSEARLVIKEALV   878 13 27 WRAFRTVKEMVKDRG 
 833 54 68 EARLVIKEALVERRR   879 17 31 RTVKEMVKDRGYFIT 
 834 58 72 VIKEALVERRRAFKR   880 21 35 EMVKDRGYFITQEEV 
 835 62 76 ALVERRRAFKRSQKK   881 25 39 DRGYFITQEEVELPL 
 836 66 80 RRRAFKRSQKKHKKK   882 29 43 FITQEEVELPLEDFK 
 837 70 84 FKRSQKKHKKKHLKH   883 33 47 EEVELPLEDFKAKYC 
 838 74 88 QKKHKKKHLKHENAN   884 37 51 LPLEDFKAKYCDSMG 
 839 78 92 KKKHLKHENANDETT   885 41 55 DFKAKYCDSMGRPQR 
 840 82 96 LKHENANDETTAVED   886 45 59 KYCDSMGRPQRKMMS 
 841 86 100 NANDETTAVEDEDDD   887 49 63 SMGRPQRKMMSFQAN 
 842 90 104 ETTAVEDEDDDLDED   888 53 67 PQRKMMSFQANPTEE 
 843 94 108 VEDEDDDLDEDDVNA   889 57 71 MMSFQANPTEESISK 
 844 98 112 DDDLDEDDVNADDDD   890 61 75 QANPTEESISKFPDM 
 845 102 116 DEDDVNADDDDFMHS   891 65 79 TEESISKFPDMGSLW 
 846 106 120 VNADDDDFMHSETRE   892 69 83 ISKFPDMGSLWVEFC 
 847 110 124 DDDFMHSETREKELE   893 73 87 PDMGSLWVEFCDEPS 
 848 114 128 MHSETREKELESIDV   894 77 91 SLWVEFCDEPSVGVK 
 849 118 132 TREKELESIDVLLEQ   895 81 95 EFCDEPSVGVKTMKT 
 850 122 136 ELESIDVLLEQTTGG   896 85 99 EPSVGVKTMKTFVIH 
 851 126 140 IDVLLEQTTGGNNKD   897 89 103 GVKTMKTFVIHIQEK 
 852 130 144 LEQTTGGNNKDLKNT   898 93 107 MKTFVIHIQEKNFQT 
 853 134 148 TGGNNKDLKNTMQYL   899 97 111 VIHIQEKNFQTGIFV 
 854 138 152 NKDLKNTMQYLTNFS   900 101 115 QEKNFQTGIFVYQNN 
 855 142 156 KNTMQYLTNFSRFRD   901 105 119 FQTGIFVYQNNITPS 
 856 146 160 QYLTNFSRFRDQETV   902 109 123 IFVYQNNITPSAMKL 
 857 150 164 NFSRFRDQETVGAVI   903 113 127 QNNITPSAMKLVPSI 
 858 154 168 FRDQETVGAVIQLLK   904 117 131 TPSAMKLVPSIPPAT 
 859 158 172 ETVGAVIQLLKSTGL   905 121 135 MKLVPSIPPATIETF 
 860 162 176 AVIQLLKSTGLHPFE   906 125 139 PSIPPATIETFNEAA 
 861 166 180 LLKSTGLHPFEVAQL   907 129 143 PATIETFNEAALVVN 
 862 170 184 TGLHPFEVAQLGSLA   908 133 147 ETFNEAALVVNITHH 
 863 174 188 PFEVAQLGSLACDTA   909 137 151 EAALVVNITHHELVP 
 864 178 192 AQLGSLACDTADEAK   910 141 155 VVNITHHELVPKHIR 
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 911 145 159 THHELVPKHIRLSSD   957 114 128 ETDPLRIAMKELAEK 
 912 149 163 LVPKHIRLSSDEKRE   958 118 132 LRIAMKELAEKKIPL 
 913 153 167 HIRLSSDEKRELLKR   959 122 136 MKELAEKKIPLVIRR 
 914 157 171 SSDEKRELLKRYRLK   960 126 140 AEKKIPLVIRRYLPD 
 915 161 175 KRELLKRYRLKESQL   961 130 144 IPLVIRRYLPDGSFE 
 916 165 179 LKRYRLKESQLPRIQ   962 134 148 IRRYLPDGSFEDWSV 
 917 169 183 RLKESQLPRIQRADP   963 138 152 LPDGSFEDWSVEELI 
 918 173 187 SQLPRIQRADPVALY  Rpb6/7 964   SFEDWSVEELIVDLM 
 919 177 191 RIQRADPVALYLGLK   965   WSVEELIVDLMFFIK 
 920 181 195 ADPVALYLGLKRGEV   966   ELIVDLMFFIKDLSL 
 921 185 199 ALYLGLKRGEVVKII   967   DLMFFIKDLSLNITL 
 922 189 203 GLKRGEVVKIIRKSE  Rpb7 968 3 17 FIKDLSLNITLHPSF 
 923 193 207 GEVVKIIRKSETSGR   969 7 21 LSLNITLHPSFFGPR 
 924 197 211 KIIRKSETSGRYASY   970 11 25 ITLHPSFFGPRMKQY 
 925 201 215 KSETSGRYASYRICM   971 15 29 PSFFGPRMKQYLKTK 
Rpb5/6 926   SGRYASYRICMMSDY   972 19 33 GPRMKQYLKTKLLEE 
 927   ASYRICMMSDYEEAF   973 23 37 KQYLKTKLLEEVEGS 
 928   ICMMSDYEEAFNDGN   974 27 41 KTKLLEEVEGSCTGK 
Rpb6 929 2 16 SDYEEAFNDGNENFE   975 31 45 LEEVEGSCTGKFGYI 
 930 6 20 EAFNDGNENFEDFDV   976 35 49 EGSCTGKFGYILCVL 
 931 10 24 DGNENFEDFDVEHFS   977 39 53 TGKFGYILCVLDYDN 
 932 14 28 NFEDFDVEHFSDEET   978 43 57 GYILCVLDYDNIDIQ 
 933 18 32 FDVEHFSDEETYEEK   979 47 61 CVLDYDNIDIQRGRI 
 934 22 36 HFSDEETYEEKPQFK   980 51 65 YDNIDIQRGRILPTD 
 935 26 40 EETYEEKPQFKDGET   981 55 69 DIQRGRILPTDGSAE 
 936 30 44 EEKPQFKDGETTDAN   982 59 73 GRILPTDGSAEFNVK 
 937 34 48 QFKDGETTDANGKTI   983 63 77 PTDGSAEFNVKYRAV 
 938 38 52 GETTDANGKTIVTGG   984 67 81 SAEFNVKYRAVVFKP 
 939 42 56 DANGKTIVTGGNGPE   985 71 85 NVKYRAVVFKPFKGE 
 940 46 60 KTIVTGGNGPEDFQQ   986 75 89 RAVVFKPFKGEVVDG 
 941 50 64 TGGNGPEDFQQHEQI   987 79 93 FKPFKGEVVDGTVVS 
 942 54 68 GPEDFQQHEQIRRKT   988 83 97 KGEVVDGTVVSCSQH 
 943 58 72 FQQHEQIRRKTLKEK   989 87 101 VDGTVVSCSQHGFEV 
 944 62 76 EQIRRKTLKEKAIPK   990 91 105 VVSCSQHGFEVQVGP 
 945 66 80 RKTLKEKAIPKDQRA   991 95 109 SQHGFEVQVGPMKVF 
 946 70 84 KEKAIPKDQRATTPY   992 99 113 FEVQVGPMKVFVTKH 
 947 74 88 IPKDQRATTPYMTKY   993 103 117 VGPMKVFVTKHLMPQ 
 948 78 92 QRATTPYMTKYERAR   994 107 121 KVFVTKHLMPQDLTF 
 949 82 96 TPYMTKYERARILGT   995 111 125 TKHLMPQDLTFNAGS 
 950 86 100 TKYERARILGTRALQ   996 115 129 MPQDLTFNAGSNPPS 
 951 90 104 RARILGTRALQISMN   997 119 133 LTFNAGSNPPSYQSS 
 952 94 108 LGTRALQISMNAPVF   998 123 137 AGSNPPSYQSSEDVI 
 953 98 112 ALQISMNAPVFVDLE   999 127 141 PPSYQSSEDVITIKS 
 954 102 116 SMNAPVFVDLEGETD   1000 131 145 QSSEDVITIKSRIRV 
 955 106 120 PVFVDLEGETDPLRI   1001 135 149 DVITIKSRIRVKIEG 
 956 110 124 DLEGETDPLRIAMKE   1002 139 153 IKSRIRVKIEGCISQ 
    SUPPLEMENATRY INFORMATION 
82 
 
 
Pol II 
subunit 
Peptide 
No. 
Start 
a.a. 
End 
a.a. 
Sequence  Pol II 
subunit 
Peptide 
No. 
Start 
a.a. 
End 
a.a. 
Sequence 
 1003 143 157 IRVKIEGCISQVSSI   1049 10 24 CNNMLYPREDKENNR 
 1004 147 161 IEGCISQVSSIHAIG   1050 14 28 LYPREDKENNRLLFE 
 1005 151 165 ISQVSSIHAIGSIKE   1051 18 32 EDKENNRLLFECRTC 
 1006 155 169 SSIHAIGSIKEDYLG   1052 22 36 NNRLLFECRTCSYVE 
Rpb7/8 1007   AIGSIKEDYLGAIMS   1053 26 40 LFECRTCSYVEEAGS 
 1008   IKEDYLGAIMSNTLF   1054 30 44 RTCSYVEEAGSPLVY 
 1009   YLGAIMSNTLFDDIF   1055 34 48 YVEEAGSPLVYRHEL 
 1010   IMSNTLFDDIFQVSE   1056 38 52 AGSPLVYRHELITNI 
Rpb8 1011 4 18 TLFDDIFQVSEVDPG   1057 42 56 LVYRHELITNIGETA 
 1012 8 22 DIFQVSEVDPGRYNK   1058 46 60 HELITNIGETAGVVQ 
 1013 12 26 VSEVDPGRYNKVCRI   1059 50 64 TNIGETAGVVQDIGS 
 1014 16 30 DPGRYNKVCRIEAAS   1060 54 68 ETAGVVQDIGSDPTL 
 1015 20 34 YNKVCRIEAASTTQD   1061 58 72 VVQDIGSDPTLPRSD 
 1016 24 38 CRIEAASTTQDQCKL   1062 62 76 IGSDPTLPRSDRECP 
 1017 28 42 AASTTQDQCKLTLDI   1063 66 80 PTLPRSDRECPKCHS 
 1018 32 46 TQDQCKLTLDINVEL   1064 70 84 RSDRECPKCHSRENV 
 1019 36 50 CKLTLDINVELFPVA   1065 74 88 ECPKCHSRENVFFQS 
 1020 40 54 LDINVELFPVAAQDS   1066 78 92 CHSRENVFFQSQQRR 
 1021 44 58 VELFPVAAQDSLTVT   1067 82 96 ENVFFQSQQRRKDTS 
 1022 48 62 PVAAQDSLTVTIASS   1068 86 100 FQSQQRRKDTSMVLF 
 1023 52 66 QDSLTVTIASSLNLE   1069 90 104 QRRKDTSMVLFFVCL 
 1024 56 70 TVTIASSLNLEDTPA   1070 94 108 DTSMVLFFVCLSCSH 
 1025 60 74 ASSLNLEDTPANDSS   1071 98 112 VLFFVCLSCSHIFTS 
 1026 64 78 NLEDTPANDSSATRS   1072 102 116 VCLSCSHIFTSDQKN 
 1027 68 82 TPANDSSATRSWRPP   1073 106 120 CSHIFTSDQKNKRTQ 
 1028 72 86 DSSATRSWRPPQAGD  Rpb9/10 1074   FTSDQKNKRTQFSMI 
 1029 76 90 TRSWRPPQAGDRSLA   1075   QKNKRTQFSMIVPVR 
 1030 80 94 RPPQAGDRSLADDYD   1076   RTQFSMIVPVRCFSC 
 1031 84 98 AGDRSLADDYDYVMY   1077   SMIVPVRCFSCGKVV 
 1032 88 102 SLADDYDYVMYGTAY  Rpb10 1078 4 18 PVRCFSCGKVVGDKW 
 1033 92 106 DYDYVMYGTAYKFEE   1079 8 22 FSCGKVVGDKWESYL 
 1034 96 110 VMYGTAYKFEEVSKD   1080 12 26 KVVGDKWESYLNLLQ 
 1035 100 114 TAYKFEEVSKDLIAV   1081 16 30 DKWESYLNLLQEDEL 
 1036 104 118 FEEVSKDLIAVYYSF   1082 20 34 SYLNLLQEDELDEGT 
 1037 108 122 SKDLIAVYYSFGGLL   1083 24 38 LLQEDELDEGTALSR 
 1038 112 126 IAVYYSFGGLLMRLE   1084 28 42 DELDEGTALSRLGLK 
 1039 116 130 YSFGGLLMRLEGNYR   1085 32 46 EGTALSRLGLKRYCC 
 1040 120 134 GLLMRLEGNYRNLNN   1086 36 50 LSRLGLKRYCCRRMI 
 1041 124 138 RLEGNYRNLNNLKQE   1087 40 54 GLKRYCCRRMILTHV 
 1042 128 142 NYRNLNNLKQENAYL   1088 44 58 YCCRRMILTHVDLIE 
 1043 132 146 LNNLKQENAYLLIRR   1089 48 62 RMILTHVDLIEKFLR 
Rpb8/9 1044   KQENAYLLIRRMTTF   1090 52 66 THVDLIEKFLRYNPL 
 1045   AYLLIRRMTTFRFCR   1091 56 70 LIEKFLRYNPLEKRD 
 1046   IRRMTTFRFCRDCNN  Rpb10/11 1092   FLRYNPLEKRDMNAP 
Rpb9 1047 2 16 TTFRFCRDCNNMLYP   1093   NPLEKRDMNAPDRFE 
 1048 6 20 FCRDCNNMLYPREDK   1094   KRDMNAPDRFELFLL 
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Rpb11 1095 2 16 NAPDRFELFLLGEGE  
 1096 6 20 RFELFLLGEGESKLK  
 1097 10 24 FLLGEGESKLKIDPD  
 1098 14 28 EGESKLKIDPDTKAP  
 1099 18 32 KLKIDPDTKAPNAVV  
 1100 22 36 DPDTKAPNAVVITFE  
 1101 26 40 KAPNAVVITFEKEDH  
 1102 30 44 AVVITFEKEDHTLGN  
 1103 34 48 TFEKEDHTLGNLIRA  
 1104 38 52 EDHTLGNLIRAELLN  
 1105 42 56 LGNLIRAELLNDRKV  
 1106 46 60 IRAELLNDRKVLFAA  
 1107 50 64 LLNDRKVLFAAYKVE  
 1108 54 68 RKVLFAAYKVEHPFF  
 1109 58 72 FAAYKVEHPFFARFK  
 1110 62 76 KVEHPFFARFKLRIQ  
 1111 66 80 PFFARFKLRIQTTEG  
 1112 70 84 RFKLRIQTTEGYDPK  
 1113 74 88 RIQTTEGYDPKDALK  
 1114 78 92 TEGYDPKDALKNACN  
 1115 82 96 DPKDALKNACNSIIN  
 1116 86 100 ALKNACNSIINKLGA  
 1117 90 104 ACNSIINKLGALKTN  
 1118 94 108 IINKLGALKTNFETE  
 1119 98 112 LGALKTNFETEWNLQ  
 1120 102 116 KTNFETEWNLQTLAA  
 1121 106 120 ETEWNLQTLAADDAF  
Rpb11/12 1122   NLQTLAADDAFMSRE  
 1123   LAADDAFMSREGFQI  
 1124   DAFMSREGFQIPTNL  
Rpb12 1125 2 16 SREGFQIPTNLDAAA  
 1126 6 20 FQIPTNLDAAAAGTS  
 1127 10 24 TNLDAAAAGTSQART  
 1128 14 28 AAAAGTSQARTATLK  
 1129 18 32 GTSQARTATLKYICA  
 1130 22 36 ARTATLKYICAECSS  
 1131 26 40 TLKYICAECSSKLSL  
 1132 30 44 ICAECSSKLSLSRTD  
 1133 34 48 CSSKLSLSRTDAVRC  
 1134 38 52 LSLSRTDAVRCKDCG  
 1135 42 56 RTDAVRCKDCGHRIL  
 1136 46 60 VRCKDCGHRILLKAR  
 1137 50 64 DCGHRILLKARTKRL  
  1138 54 68 RILLKARTKRLVQFE  
 1139 56 70 LLKARTKRLVQFEAR  
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Figure 25| Analysis of Npa3 binding to peptides derived from Rpb2, Rpb3, Rpb5, Rpb6, Rpb9, Rpb11 and Rpb12. 
Boxplot representation of the heatmap describing the Npa3 peptide-binding landscape in the presence of GTP, GDP and 
GMPPCP, respectively. Control experiments were performed without Npa3 and nucleotides to test cross-reactivity of the anti-
His antibody. Intensity distribution is shown in logarithmic scale. Peptides with signal intensity <3.5 were defined as unbound 
(grey area). Red boxes indicate false-positive binding of the antibody to the peptides, either directly or in overlapping regions. 
These peptides were not used for further analysis. Peptide numbers are shown for Npa3 binding peptides above the boxplots.  
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Abbreviations 
 
∆ deletion 
°C degree celsius 
Å Ångstrom 
aa amino acid(s) 
AlF aluminium fluoride 
Amp ampicillin 
ATP adenosine 5′-triphosphate 
BICINE 2-(Bis(2-hydroxyethyl)amino)acetic acid 
bp base pair(s) 
BSA bovine serum albumin 
CAM chloramphenicol 
CC correlation coefficient 
cDNA complementary DNA 
CPS counts per second 
CTD Carboxy-terminal domain 
CV column volume 
Da dalton 
DESY Deutsche Elektronen Synchrotron 
DMF N,N-Dimehtlyformamide 
DMSO dimethylsulfoxide 
DNA deoxribonucleic acid 
DTT dithiothreitol 
E. coli Escherichia coli 
EDTA ethylene diamine tetraacetate 
EMBL European Molecular Biology Laboratories 
et al. and others [Latin: et alii] 
EtOH ethanol 
Fig figure 
fl full-length 
g gram or gravitational force 
GDP guanosine 5′-diphosphate 
GTF general transcription factor 
GTP guanosine 5′-triphosphate 
GTPase GTP hydrolase 
GMPPCP βγ-Methyleneguanosine 5′-triphosphate 
GMPPNP 5'-Guanylyl imidodiphosphate 
GPN glycine-proline-asparagine 
h hour(s) 
HCl Hydrochloric acid 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC High-performance liquid chromatography 
Hs Homo sapiens 
Hsp heat-shock protein 
IPTG isopropyl β-D-1-thiogalactopyranoside 
Iwr1 interacting with RNA polymerase II protein 1 
k kilo or thousand 
l liter 
LB lysogeny broth 
M molar (mol/liter) 
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mAu milli absorbance unit 
Min minute(s) 
MOPS 3-(N-morpholino)propanesulfonic acid 
mRNA messanger RNA 
MW molecular weight 
NCBI National Center for Biotechnology Information 
Ni-NTA nickel-nitrilotriacetic acid 
Npa3 nucleolar preribosomal associated protein 3 
nt nucleotide(s) 
OD600 optical density at a wavelength of 600 nm 
Pa Pyrococus abyssi 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDB Protein data bank 
PEG poly(ethylene glycol) 
PI protease inhibitor 
Pi inorganic phosphate 
PIC pre-initiation complex 
PMSF phenylmethylsulfonylfluorid 
Pol  DNA-dependant RNA polymerase 
R-factor residual factor 
RNA ribonucleic acid 
RMSD Root mean square deviation 
RPAP RNA polymerase II-associated proteins 
Rpb RNA polymerase B subunit 
rpm  rounds per minute 
rRNA ribosomal RNA 
RT room temperature 
s or sec second(s) 
S-SAD sulfur-SAD 
SAD single-wavelength anomalous diffraction 
Sc, S. cerevisiae Saccharomyces cerevisiae 
SDS sodium dodecyl sulfate 
SEC size exclusion chormatography 
SLS Swiss Light Source 
TAE tris-acetate-EDTA 
TAP tandem-affinity purification 
TBP TATA-binding protein 
TBS tris buffered saline 
TCA trichloroacetic acid 
TE tris-EDTA 
tet tetracyclin 
TF transcription factor 
Tris tris(hydroxymethyl)aminomethane 
tRNA transfer RNA 
TSS transcription start site  
U unit(s) 
UV ultraviolet 
V volt 
vs versus 
v/v volume per volume 
wt wildtype 
w/v weight per volume 
YPD yeast extract peptone dextrose 
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